Methods and compositions for prognosis and treatment of cancers

ABSTRACT

The invention provides methods of using expression levels of one or more immune cell gene signatures and/or combinations of immune cell gene signatures as selection criteria for selecting a patient having cancer for treatment with an immunotherapy. The invention further provides methods for selecting a patient having cancer who may benefit from a particular immunotherapy, such as an activating immunotherapy or a suppressing immunotherapy and administering to the patient the activating immunotherapy or suppressing immunotherapy to treat the cancer.

FIELD OF INVENTION

The present invention is directed to methods for selecting cancerpatients for treatment with an immunotherapy.

BACKGROUND OF THE INVENTION

Studies in humans with immune checkpoint inhibitors have demonstratedthe promise of harnessing the immune system to control and eradicatetumor growth in difficult to treat indications including melanoma, renalcell carcinoma, lung cancer, breast cancer, ovarian cancer, colorectalcancer, gastric cancer, liver cancer, and bladder cancer.

Tumors arise from normal cells that accumulate mutations leading touncontrolled cellular proliferation and survival under conditions ofstress. In normal circumstances, the immune system, mainly throughcytotoxic CD8 T cells, recognizes these transformed cells and preventsthe invasion into normal tissue. In certain circumstances, tumor cellsescape immune control and progress to disease. The mechanisms of tumorescape may be the product of one or more of the following mechanisms:inability of tumor cells to present neo-antigens on MHC Class Imolecules, down-regulation of MHC Class I molecules on tumor cells,inability of T cells to infiltrate the tumor, increased presence ofimmunosuppressive regulatory T cells or myeloid suppressor cells,enhanced expression of immune checkpoint inhibitors, or increased Th2and Th17 mediators. The relative contributions of these various immunecell subsets across cancer types and their affects on tumor progression,treatment response, and clinical outcomes are poorly studied.

Accordingly, there is a need for methods for selecting patients who arelikely to respond to immuno-based therapies and to develop alternativestrategies for the treatment of cancer.

SUMMARY OF THE INVENTION

In one aspect, the invention features a method of selecting a patienthaving cancer for treatment with an immunotherapy, the method comprisingdetermining the expression level of an immune cell gene signature in abiological sample obtained from the patient, the immune cell genesignature comprising one or more of the following genes (e.g., 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or moreof the following genes): CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5;NCAM1 or NKP46; KLRC3, KLRK1, KLRC2, or KLRD1; ITGAM, ITGAX, CD1C, orCLEC4C; CD68, CD163, ITGAM, ITGAX, or CD14; LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD3D, CD3E, CD2, CD3G,CD6, TRAT1, CD28, or LCK; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CTLA4,BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; CD276, PDL1, PDL2, or IDO1; CD274,PDL2, IDO1, or PVR; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; CD4,IL2RA, or CD69; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; CD40, CD80, CD86,CD70, or GITRL; CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFSF14,or CD226; GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; or FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, or COL8A1,wherein a change in the level of expression of the one or more genes inthe immune cell gene signature relative to a median level identifies apatient for treatment with an immunotherapy.

In some embodiments, the method further comprises the step of informingthe patient that they have an increased likelihood of being responsiveto the immunotherapy. In some embodiments, the method further comprisesthe step of providing a recommendation to the patient for a particularimmunotherapy. In some embodiments, the method further comprises thestep of administering an immunotherapy to the patient if it isdetermined that the patient may benefit from the immunotherapy. In someembodiments, the immunotherapy is an activating immunotherapy or asuppressing immunotherapy.

In some embodiments, the expression level of one or more of CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1 is correlated with the presence of T effector(To) cells in the tumor microenvironment. In some embodiments, anincrease in expression level of one or more of CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1 indicates that the patient is likely to benefit from anactivating immunotherapy. In some embodiments, the activatingimmunotherapy comprises a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM,NKG2D, MICA, or 2B4 agonist.

In some embodiments, the expression level of FOXP3 is correlated to thepresence of T regulatory (T_(reg)) cells in the tumor microenvironment.In some embodiments, an increase in expression level of FOXP3 indicatesthat the patient is likely to benefit from a suppressing immunotherapy.In some embodiments, the suppressing immunotherapy comprises a CTLA-4,PD-1 axis, TIM-3, BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226antagonist.

In some embodiments, the expression level of (a) one or more of MS3A1 orCD48 and/or (b) one or more of CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5 is correlated with the presence of B cells in thetumor microenvironment. In some embodiments, the expression level of (a)one or more of NCAM1 or NKP46 and/or (b) KLRC3, KLRK1, KLRC2, or KLRD1is correlated with the presence of NK cells in the tumormicroenvironment. In some embodiments, the expression level of one ormore of ITGAM, ITGAX, CD1C, or CLEC4C is correlated with the presence ofmyeloid cells in the tumor microenvironment. In some embodiments, theexpression level of one or more of CD68, CD163, ITGAM, ITGAX, or CD14 iscorrelated with the presence of macrophage cells in the tumormicroenvironment. In some embodiments, the expression level of one ormore of LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, or FCGR3A is correlated with the presence of M2macrophage cells in the tumor microenvironment. In some embodiments, theexpression level of one or more of IL17A or IL17F is correlated with thepresence of Th17 cells in the tumor microenvironment. In someembodiments, the expression level of one or more of CCL2, IL1B, IL8,IL6, or PTGS2 is correlated with the presence of inflammatory cells inthe tumor microenvironment. In some embodiments, the expression level of(a) one or more of CTLA4, BTLA, LAG3, HAVCR2, or PDCD1 and/or (b) one ormore of CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT is correlated withthe presence of T cell immune blockers in the tumor microenvironment. Insome embodiments, the expression level of (a) one or more of CD276,PDL1, PDL2, or IDO1 and/or (b) one or more of CD274, PDL2, IDO1, or PVRis correlated to the presence of antigen presenting cell (APC) immuneblockers in the tumor microenvironment. In some embodiments, theexpression level of one or more of CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22 is correlated to T cell chemotaxis. In some embodiments, theexpression level of one or more of CD4, IL2RA, or CD69 is correlatedwith the presence of activated CD4 T cells in the tumormicroenvironment. In some embodiments, the expression level of one ormore of TAPBP, TAP1, TAP2, PSMB9, or PSMB8 is correlated with thepresence of antigen processing in the tumor microenvironment. In someembodiments, the expression level of one or more of CD40, CD80, CD86,CD70, or GITRL is correlated with the presence of costimulatory ligandsin the tumor microenvironment. In some embodiments, the expression levelof one or more of CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFSF14, or CD226 is correlated with the presence of costimulatoryreceptors in the tumor microenvironment. In some embodiments, theexpression level of one or more of GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, or NKG7 is correlated with cytolytic activity and/or the presenceof cytolytic cells in the tumor microenvironment. In some embodiments,the expression level of one or more of FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, or COL8A1 is correlated with thepresence of active fibroblasts in the tumor microenvironment. In someembodiments, the expression level of one or more of CD3D, CD3E, CD2,CD3G, CD6, TRAT1, CD28, or LCK is correlated with the presence of Tcells in the tumor microenvironment.

In other embodiments of any of the above methods, the expression levelis one or more (e.g., 1, 2, 3, 4, 5, or 6) of CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1 is determined. In some embodiments, the expression levelof FOXP3 is determined. In some embodiments, the expression level of oneor more (e.g., 1 or 2) of MS4A1 or CD48 and/or one or more (e.g., 1, 2,3, 4, 5, 6, or 7) of CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, orFCRL5 is determined. In some embodiments, the expression level of one ormore (e.g., 1 or 2) of NCAM1 and NKP46 and/or one or more (e.g., 1, 2,3, or 4) of KLRC3, KLRK1, KLRC2, or KLRD1 is determined. In someembodiments, the expression level of one or more (e.g., 1, 2, 3, or 4)of ITGAM, ITGAX, CD1C, or CLEC4C is determined. In some embodiments, theexpression level of one or more (e.g., 1, 2, 3, 4, or 5) of CD68, CD163,ITGAM, ITGAX, or CD14 is determined. In some embodiments, the expressionlevel of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,or 14) of LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, or FCGR3A is determined. In some embodiments,the expression level of one or more (e.g., 1 or 2) of IL17A or ILB17 isdetermined. In some embodiments, the expression level of one or more(e.g., 1, 2, 3, 4, 5, 6, 7, or 8) of CD3D, CD3E, CD2, CD3G, CD6, TRAT1,CD28, or LCK is determined. In some embodiments, the expression level ofone or more (e.g., 1, 2, 3, 4, or 5) of CCL2, IL1B, IL8, IL6, or PTGS2is determined. In some embodiments, the expression level of one or more(e.g., 1, 2, 3, 4, or 5) of CTLA4, BTLA, LAG3, HAVCR2, or PDCD1 and/orone or more (e.g., 1, 2, 3, 4, 5, or 6) of CTLA4, BTLA, LAG3, HAVCR2,PDCD1, or TIGIT is determined. In some embodiments, the expression levelof one or more (e.g., 1, 2, 3, or 4) of CD276, PDL1, PDL2, or IDO1and/or one or more (e.g., 1, 2, 3, or 4) of CD274, PDL2, IDO1, or PVR isdetermined. In some embodiments, the expression level of one or more(e.g., 1, 2, 3, 4, 5, or 6) of CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22 is determined. In some embodiments, the expression level of one ormore (e.g., 1, 2, or 3) of CD4, IL2RA, or CD69 is determined. In someembodiments, the expression level of one or more (e.g., 1, 2, 3, 4, or5) of TAPBP, TAP1, TAP2, PSMB9, or PSMB8 is determined. In someembodiments, the expression level of one or more (e.g., 1, 2, 3, 4, or5) of CD40, CD80, CD86, CD70, or GITRL is determined. In someembodiments, the expression level of one or more (e.g., 1, 2, 3, 4, 5,6, 7, or 8) of CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFSF14,or CD226 is determined. In some embodiments, the expression level of oneor more (e.g., 1, 2, 3, 4, 5, 6, or 7) of GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, or NKG7 is determined. In some embodiments, the expressionlevel of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11) ofFAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, orCOL8A1 is determined.

In some embodiments of any of the above methods, the expression level ofone or more of the genes in Table 2 are determined.

In some embodiments of any of the above methods, the expression level ofone or more of the genes in Table 3 are determined.

In some embodiments of any of the above methods, the expression level ofone or more of the genes in Table 4 are determined.

In some embodiments of any of the above methods, the expression level ofone or more of the genes in Table 5 are determined.

In some embodiments of any of the above methods, the expression level ofone or more of the genes in Table 6 are determined.

In some embodiments of any of the above methods, the expression level ofone or more of the genes in Table 7 are determined.

In some embodiments of any of the above methods, the expression level ofone or more of the genes in Table 8 are determined.

In some embodiments of any of the above methods, the expression level ofone or more of the genes in Table 9 are determined.

In some embodiments of any of the above methods, the expression level ofone or more of the genes from each of the following gene signaturesCD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; NCAM1 or NKP46; KLRC3,KLRK1, KLRC2, or KLRD1; ITGAM, ITGAX, CD1C, or CLEC4C; CD68, CD163,ITGAM, ITGAX, or CD14; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, orLCK; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CTLA4, BTLA, LAG3, HAVCR2,PDCD1, or TIGIT; CD276, PDL1, PDL2, or IDO1; CD274, PDL2, IDO1, or PVR;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; CD4, IL2RA, or CD69;TAPBP, TAP1, TAP2, PSMB9, or PSMB8; CD40, CD80, CD86, CD70, or GITRL;CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFSF14, or CD226; GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, or COL8A1 are determined.

In some embodiments of any of the above methods, the method furthercomprises determining the ratio of expression level of one or more ofCD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1 to the expression level of FOXP3.In some embodiments, if the ratio of expression level of one or more ofCD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1 to the expression level of FOXP3is high, the patient will likely benefit from an activatingimmunotherapy. In some embodiments, wherein if the ratio of expressionlevel of one or more of CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1 to theexpression level of FOXP3 is low, the patient will likely benefit from asuppressing immunotherapy.

In some embodiments of any of the above methods, the method furthercomprises determining the ratio of T_(eff) to T_(reg) cells. In someembodiments, if the ratio of T_(eff) to T_(reg) is high, the patientwill likely benefit from an activating immunotherapy. In someembodiments, if the ratio of T_(eff) to T_(reg) is low, the patient willlikely benefit from a suppressing immunotherapy. In some embodiments,the activating immunotherapy comprises a CD28, OX40, GITR, CD137, CD27,ICOS, HVEM, NKG2D, MICA, or 2B4 agonist. In some embodiments, thesuppressing immunotherapy comprises a CTLA-4, PD-1 axis, TIM-3, BTLA,VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist.

In some embodiments of any of the above methods, the method is carriedout prior to administering an immunotherapy in order to provide apatient with a pre-administration prognosis for response.

In some embodiments of any of the above methods, the cancer is a breastcancer, melanoma, non-small cell lung cancer (NSCLC), bladder cancer,renal cell carcinoma, colorectal cancer, ovarian cancer, gastric cancer,or liver cancer. In some embodiments, the cancer is primary, advanced,refractory, or recurrent. In some embodiments, the breast cancer ishormone receptor+(HR+), HER2+, or triple negative (TN) breast cancer. Insome embodiments, the NSCLC is non-squamous NSCLC or squamous NSCLC.

In some embodiments of any of the above methods, expression of theimmune cell gene signature in the biological sample obtained from thepatient is detected by measuring mRNA.

In some embodiments of any of the above methods, expression of theimmune cell gene signature in the biological sample obtained from thepatient is detected by measuring plasma protein levels.

BRIEF DESCRIPTION OF THE DRAWINGS

The application file contains at least one drawing executed in color.Copies of this patent or patent application with color drawings will beprovided by the Office upon request and payment of the necessary fee.

FIG. 1A is a Scattermatrix plot of T cell signature genes.

FIG. 1B is a Scattermatrix plot of T effector signature genes.

FIG. 1C is a Scattermatrix plot of activated CD4 T cell signature genes.

FIG. 2A is a Scattermatrix plot of B cell Signature 1, NK cell Signature1, and IL17 signature genes.

FIG. 2B is Scattermatrix plot of B cell Signature 2 genes.

FIG. 2C is Scattermatrix plot of NK cell Signature 2 genes.

FIG. 3A is a Scattermatrix plot of myeloid signature genes.

FIG. 3B is a Scattermatrix plot of macrophage signature genes.

FIG. 3C is a Scattermatrix plot of M2 macrophage signature genes.

FIG. 4 is a Scattermatrix plot of inflammatory signature genes.

FIG. 5A is a Scattermatrix plot of T cell immune blocker (IB T cell)Signature 1 genes.

FIG. 5B is a Scattermatrix plot of IB T cell Signature 2 genes.

FIG. 6A is a Scattermatrix plot of APC immune blocker (IB APC) Signature1 genes.

FIG. 6B is a Scattermatrix plot of IB APC Signature 2 genes.

FIG. 7 is a Scattermatrix plot of antigen processing signature genes.

FIG. 8 is a Scattermatrix plot of costimulatory ligand signature genes.

FIG. 9 is a Scattermatrix plot of costimulatory receptor signaturegenes.

FIG. 10 is a Scattermatrix plot of cytolytic signature genes.

FIG. 11 is a Scattermatrix plot of active fibroblast signature genes.

FIGS. 12A-12C are plots of Principal Component Analysis of nine genesets across cancer indications.

FIG. 13 is a plot of gene expression levels of T effector signaturegenes across indications.

FIG. 14 is a plot of gene expression levels of T regulatory signaturegenes across indications.

FIG. 15 is a plot of gene expression ratios of T effector vs. Tregulatory signature genes across indications.

FIG. 16 is a plot of gene expression levels of B cell signature genesacross indications.

FIG. 17 is a plot of gene expression levels of NK cell signature genesacross indications.

FIG. 18 is a plot of gene expression levels of myeloid signature genesacross indications.

FIG. 19 is a plot of gene expression levels of Th17 (IL17) signaturegenes across indications.

FIG. 20 shows multiple plots of IL17A/IL17F prevalence by indications.IL17 presence is determined by raw Ct<25. Sq- and Non-Sq Lung arecollapsed into one group. HER2+ Breast was not evaluated due to smallsample sizes.

FIG. 21 is a plot of gene expression levels of inflammatory signaturegenes across indications.

FIG. 22 is a plot of gene expression levels of immune blockers on Tcells across indications.

FIG. 23 is a plot of gene expression levels of immune blockers on APCsacross indications.

FIG. 24 is a plot of gene expression ratios of T effector vs. immuneblockers on APC across indications.

FIG. 25 shows multiple plots of gene expression ratios of T effector vs.particular genes in the immune blockers on APC signature genes acrossindications.

FIG. 26 is a plot showing gene expression levels of particular genes inthe immune blockers on T cell signature genes across indications.

FIG. 27 is a plot showing gene expression levels of particular genes inthe immune blockers on APC signature genes across indications.

FIG. 28 is a plot showing the hierarchical clustering of immune genesignature expression across indications. Genes were median centeredacross the samples. Euclidean distance and complete linkage were used togenerate the dendrogram. Red and green colors indicate higher and lowerexpression compared to median, respectively. Black indicates medianexpression.

FIG. 29 is a Scattermatrix plot of CD8 IHC by regions and CD8 RNAlevels. log 2 transformation was performed to normalize thedistribution.

FIG. 30 shows Scatterplots of CD8 IHC by regions and by indications.Blue lines are least square regression lines. Shaded areas indicate 95%confidence intervals.

FIG. 31 is a plot showing the empirical distribution function (orEmpirical CDF, a cumulative distribution function associated with theempirical measure of a sample) of CD8 IHC by regions. The Y axis is thefraction of samples ≤that of the associated CD8 IHC percentage indicatedby the X axis.

FIG. 32 shows Boxplots of gene set expression in association withprimary vs. metastatic status.

FIG. 33 is a Volcano plot for immune gene expression in association withCRC primary vs. metastatic status. Y axis is raw signed-rank Wicoxonp-value, and X axis is log 2 based fold change between primary andmetastatic samples. Genes labeled had Bonferroni adjusted P≤0.05: ARG1,IL17A, VTCN1, IL17F, IL1B, HLA.E, HAVCR2, CD70, FOXP3 and PTGS2.

FIG. 34 shows Boxplots of gene set expression in association withetiology.

FIG. 35 shows Boxplots of immune genes having Kruskal Wallis P≤0.05 forassociation with etiology.

FIG. 36 is a hierarchical clustering of immune genes having p≤0.1 foretiology differences. Genes were median centered across the samples.Euclidean distance and complete linkage were used to generate thedendrogram. Red and green colors indicate higher and lower expressioncompared to median, respectively. Black indicates median expression. Thefollowing colors differentiate etiologies: black=history of Alcoholism;red=HBV+; green=HCV+; blue=HBV+HCV+.

DETAILED DESCRIPTION OF THE INVENTION I. Introduction

The tumor immune microenvironment consists of a host ofimmunosuppressive factors that allow the tumor cells to keep theresident T cells in check and to evade anti-tumor immunity. A study ofthe factors in the tumor stroma or secreted by the tumor cells to keepthe T cells from infiltrating the tumor provides a tool forunderstanding how to convert aggressive tumors into immunogenic tumorscapable of responding to immunotherapy. In the present invention, geneexpression was used to evaluate the prevalence of gene signatures thatrepresent immune cell subsets across seven different cancer types. Thisanalysis provides insight into the tumor immune microenvironment of ninedifferent cancer indications and various tumor subtypes to identify thedrivers of tumor immune biology that dictate response to immunotherapy.

Accordingly, the invention provides methods for selecting a patienthaving cancer (e.g., bladder cancer, breast cancer, colorectal cancer,gastric cancer, liver cancer, melanoma, lung cancer (e.g., non-smallcell lung carcinoma), ovarian cancer, or renal cell carcinoma) fortreatment with an immunotherapy by determining the expression level ofone or more immune cell gene signatures, and comparing this level ofexpression to the median level of expression of the one or more immunecell gene signatures. Detection of increased expression of the one ormore immune cell gene signatures relative to a median level (i.e.,higher expression of the one or more immune cell gene signaturesrelative to the median level in the cancer type) identifies the patientfor treatment with an immunotherapy. The invention also provides methodsfor treating a patient having cancer (e.g., bladder cancer, breastcancer, colorectal cancer, gastric cancer, liver cancer, melanoma, lungcancer (e.g., non-small cell lung carcinoma), ovarian cancer, or renalcell carcinoma) who may benefit from immunotherapy by administering anactivating immunotherapy or a suppressing immunotherapy alone or incombination with a chemotherapy regimen and/or other anti-cancer therapyregimen by determining the expression level of one or more immune cellgene signatures in the patient.

II. Definitions

Unless defined otherwise, technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Singleton et al., Dictionary ofMicrobiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York,N.Y. 1994), and March, Advanced Organic Chemistry Reactions, Mechanismsand Structure 4th ed., John Wiley & Sons (New York, N.Y. 1992), provideone skilled in the art with a general guide to many of the terms used inthe present application.

For purposes of interpreting this specification, the followingdefinitions will apply and whenever appropriate, terms used in thesingular will also include the plural and vice versa. In the event thatany definition set forth below conflicts with any document incorporatedherein by reference, the definition set forth below shall control.

The term “antagonist” is used in the broadest sense, and includes anymolecule that partially or fully blocks, inhibits, interferes, orneutralizes a normal biological activity of a native polypeptidedisclosed herein (e.g., an immune cell receptor or ligand, such asCTLA-4, PD-1, TIM-3, BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226),either by decreasing transcription or translation of the nucleic acidencoding the native polypeptide, or by inhibiting or blocking the nativepolypeptide activity, or both. It will be understood by one of ordinaryskill in the art that, in some instances, an antagonist may antagonizeone activity of the native polypeptide without affecting anotheractivity of the native polypeptide. It will also be understood by one ofordinary skill in the art that, in some instances, an antagonist may bea therapeutic agent that is considered an activating or suppressingimmunotherapy depending on the native polypeptide that it binds,interacts, or associates with. Examples of antagonists include, but arenot limited to, antisense polynucleotides, interfering RNAs, catalyticRNAs, RNA-DNA chimeras, native polypeptide-specific aptamers,antibodies, antigen-binding fragments of antibodies, nativepolypeptide-binding small molecules, native polypeptide-bindingpeptides, and other peptides that specifically bind the nativepolypeptide (including, but not limited to native polypeptide-bindingfragments of one or more native polypeptide ligands, optionally fused toone or more additional domains), such that the interaction between theantagonist and the native polypeptide results in a reduction orcessation of native polypeptide activity or expression.

In a similar manner, the term “agonist” is used in the broadest senseand includes any molecule that mimics, promotes, stimulates, or enhancesa normal biological activity of a native polypeptide disclosed herein(e.g., an immune cell receptor or ligand, such as CD28, OX40, GITR,CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4), by increasingtranscription or translation of the nucleic acid encoding the nativepolypeptide, and/or by inhibiting or blocking activity of a moleculethat inhibits the expression or activity of the native polypeptide,and/or by enhancing normal native polypeptide activity (including, butnot limited to, enhancing the stability of the native polypeptide, orenhancing binding of the native polypeptide to one or more targetligands). It will be understood by one of ordinary skill in the artthat, in some instances, an agonist may agonize one activity of thenative polypeptide without affecting another activity of the nativepolypeptide. It will also be understood by one of ordinary skill in theart that, in some instances, an agonist may be a therapeutic agent thatis considered an activating or suppressing immunotherapy depending onthe native polypeptide that it binds, interacts, or associates with. Theagonist can be selected from an antibody, an antigen-binding fragment,an aptamer, an interfering RNA, a small molecule, a peptide, anantisense molecule, and another binding polypeptide. In another example,the agonist can be a polynucleotide selected from an aptamer,interfering RNA, or antisense molecule that interferes with thetranscription and/or translation of a native polypeptide-inhibitorymolecule. Methods for identifying agonists or antagonists of apolypeptide may comprise contacting a polypeptide with a candidateagonist or antagonist molecule and measuring a detectable change in oneor more biological activities normally associated with the polypeptide.

The term “activating immunotherapy” refers to the use of a therapeuticagent that induces, enhances, or promotes an immune response, including,e.g., a T cell response. The term “suppressing immunotherapy” refers tothe use of a therapeutic agent that interferes with, suppresses, orinhibits an immune response, including, e.g., a T cell response.

“Human effector cells” refer to leukocytes that express one or more FcRsand perform effector functions. In certain embodiments, the cellsexpress at least FcγRIII and perform ADCC effector function(s). Examplesof human leukocytes which mediate ADCC include peripheral bloodmononuclear cells (PBMC), natural killer (NK) cells, monocytes,cytotoxic T cells, and neutrophils. The effector cells may be isolatedfrom a native source, e.g., from blood.

“Regulatory T cells (T_(reg))” refer to a subset of helper T cells thatplay a role in inhibition of self-reactive immune responses and areoften found in sites of chronic inflammation such as in tumor tissue. Incertain embodiments, T_(regs) are defined phenotypically by high cellsurface expression of CD25, CLTA4, GITR, and neuropilin-1 and are underthe control of transcription factor FOXP3. In other embodiments,T_(regs) perform their suppressive function on activated T cells throughcontact-dependent mechanisms and cytokine production. In someembodiments, T_(regs) also modulate immune responses by directinteraction with ligands on dendritic cells (DC), such as, e.g., CTLA4interaction with B7 molecules on DC that elicits the induction ofindoleamine 2,3-dioxygenase (IDO).

The term “antibody” herein is used in the broadest sense and encompassesvarious antibody structures, including but not limited to monoclonalantibodies, polyclonal antibodies, multispecific antibodies (e.g.,bispecific antibodies), and antibody fragments so long as they exhibitthe desired antigen-binding activity. An antibody that binds to a targetrefers to an antibody that is capable of binding the target withsufficient affinity such that the antibody is useful as a diagnosticand/or therapeutic agent in targeting the target. In one embodiment, theextent of binding of an anti-target antibody to an unrelated, non-targetprotein is less than about 10% of the binding of the antibody to targetas measured, e.g., by a radioimmunoassay (RIA) or biacore assay. Incertain embodiments, an antibody that binds to a target has adissociation constant (Kd) of <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM,<0.01 nM, or <0.001 nM (e.g. 10⁻⁸ M or less, e.g. from 10⁻⁸ M to 10⁻¹³M, e.g., from 10⁻⁹ M to 10⁻¹³ M). In certain embodiments, an anti-targetantibody binds to an epitope of a target that is conserved amongdifferent species.

A “blocking antibody” or an “antagonist antibody” is one that partiallyor fully blocks, inhibits, interferes, or neutralizes a normalbiological activity of the antigen it binds. For example, an antagonistantibody may block signaling through an immune cell receptor (e.g., a Tcell receptor) so as to restore a functional response by T cells (e.g.,proliferation, cytokine production, target cell killing) from adysfunctional state to antigen stimulation.

An “agonist antibody” or “activating antibody” is one that mimics,promotes, stimulates, or enhances a normal biological activity of theantigen it binds. Agonist antibodies can also enhance or initiatesignaling by the antigen to which it binds. In some embodiments, agonistantibodies cause or activate signaling without the presence of thenatural ligand. For example, an agonist antibody may increase memory Tcell proliferation, increase cytokine production by memory T cells,inhibit regulatory T cell function, and/or inhibit regulatory T cellsuppression of effector T cell function, such as effector T cellproliferation and/or cytokine production.

An “antibody fragment” refers to a molecule other than an intactantibody that comprises a portion of an intact antibody that binds theantigen to which the intact antibody binds. Examples of antibodyfragments include but are not limited to Fv, Fab, Fab′, Fab′-SH,F(ab′)2; diabodies; linear antibodies; single-chain antibody molecules(e.g. scFv); and multispecific antibodies formed from antibodyfragments.

An “antibody that binds to the same epitope” as a reference antibodyrefers to an antibody that blocks binding of the reference antibody toits antigen in a competition assay by 50% or more, and conversely, thereference antibody blocks binding of the antibody to its antigen in acompetition assay by 50% or more.

The term “benefit” is used in the broadest sense and refers to anydesirable effect and specifically includes clinical benefit as definedherein. Clinical benefit can be measured by assessing various endpoints,e.g., inhibition, to some extent, of disease progression, includingslowing down and complete arrest; reduction in the number of diseaseepisodes and/or symptoms; reduction in lesion size; inhibition (i.e.,reduction, slowing down or complete stopping) of disease cellinfiltration into adjacent peripheral organs and/or tissues; inhibition(i.e. reduction, slowing down or complete stopping) of disease spread;decrease of auto-immune response, which may, but does not have to,result in the regression or ablation of the disease lesion; relief, tosome extent, of one or more symptoms associated with the disorder;increase in the length of disease-free presentation following treatment,e.g., progression-free survival; increased overall survival; higherresponse rate; and/or decreased mortality at a given point of timefollowing treatment.

As used herein, the term “binds,” “specifically binds to,” or is“specific for” refers to measurable and reproducible interactions suchas binding between a target and an antibody, which is determinative ofthe presence of the target in the presence of a heterogeneous populationof molecules including biological molecules. For example, an antibodythat specifically binds to a target (which can be an epitope) is anantibody that binds this target with greater affinity, avidity, morereadily, and/or with greater duration than it binds to other targets. Inone embodiment, the extent of binding of an antibody to an unrelatedtarget is less than about 10% of the binding of the antibody to thetarget as measured, for example, by a radioimmunoassay (RIA). In certainembodiments, an antibody that specifically binds to a target has adissociation constant (Kd) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM.In certain embodiments, an antibody specifically binds to an epitope ona protein that is conserved among the protein from different species. Inanother embodiment, specific binding can include, but does not requireexclusive binding.

The term “biological sample” or “sample” as used herein includes, but isnot limited to, blood, serum, plasma, sputum, tissue biopsies, tumortissue, and nasal samples including nasal swabs or nasal polyps.

The terms “cancer” and “cancerous” refer to or describe thephysiological condition in mammals that is typically characterized byunregulated cell growth. Included in this definition are benign andmalignant cancers. Examples of cancer include but are not limited to,carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particularexamples of such cancers include squamous cell cancer, lung cancer(including small-cell lung cancer, non-small cell lung cancer,adenocarcinoma of the lung, and squamous carcinoma of the lung), cancerof the peritoneum, hepatocellular cancer, gastric or stomach cancer(including gastrointestinal cancer), pancreatic cancer, glioblastoma,cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma,breast cancer, colon cancer, colorectal cancer, endometrial or uterinecarcinoma, salivary gland carcinoma, kidney or renal cancer, livercancer, prostate cancer, vulval cancer, thyroid cancer, hepaticcarcinoma and various types of head and neck cancer, as well as B-celllymphoma (including low grade/follicular non-Hodgkin's lymphoma (NHL);small lymphocytic (SL) NHL; intermediate grade/follicular NHL;intermediate grade diffuse NHL; high grade immunoblastic NHL; high gradelymphoblastic NHL; high grade small non-cleaved cell NHL; bulky diseaseNHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom'sMacroglobulinemia); chronic lymphocytic leukemia (CLL); acutelymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblasticleukemia; and post-transplant lymphoproliferative disorder (PTLD), aswell as abnormal vascular proliferation associated with phakomatoses,edema (such as that associated with brain tumors), and Meigs' syndrome.

An “advanced” cancer is one which has spread outside the site or organof origin, either by local invasion or metastasis.

A “refractory” cancer is one which progresses even though an anti-tumoragent, such as a chemotherapeutic agent, is being administered to thecancer patient. An example of a refractory cancer is one which isplatinum refractory.

A “recurrent” cancer is one which has regrown, either at the initialsite or at a distant site, after a response to initial therapy.

By “platinum-resistant” cancer is meant cancer in a patient that hasprogressed while the patient was receiving platinum-based chemotherapyor cancer in a patient that has progressed within, e.g., 12 months (forinstance, within 6 months) after the completion of platinum-basedchemotherapy. Such a cancer can be said to have or exhibit“platinum-resistance.”

By “chemotherapy-resistant” cancer is meant cancer in a patient that hasprogressed while the patient is receiving a chemotherapy regimen orcancer in a patient that has progressed within, e.g., 12 months (forinstance, within 6 months) after the completion of a chemotherapyregimen. Such a cancer can be said to have or exhibit“chemotherapy-resistance.”

The term “tumor” refers to all neoplastic cell growth and proliferation,whether malignant or benign, and all pre-cancerous and cancerous cellsand tissues. The terms “cancer,” “cancerous,” “cell proliferativedisorder,” “proliferative disorder” and “tumor” are not mutuallyexclusive as referred to herein.

As used herein, “metastasis” is meant the spread of cancer from itsprimary site to other places in the body. Cancer cells can break awayfrom a primary tumor, penetrate into lymphatic and blood vessels,circulate through the bloodstream, and grow in a distant focus(metastasize) in normal tissues elsewhere in the body. Metastasis can belocal or distant. Metastasis is a sequential process, contingent ontumor cells breaking off from the primary tumor, traveling through thebloodstream, and stopping at a distant site. At the new site, the cellsestablish a blood supply and can grow to form a life-threatening mass.Both stimulatory and inhibitory molecular pathways within the tumor cellregulate this behavior, and interactions between the tumor cell and hostcells in the distant site are also significant.

The term “chimeric” antibody refers to an antibody in which a portion ofthe heavy and/or light chain is derived from a particular source orspecies, while the remainder of the heavy and/or light chain is derivedfrom a different source or species.

The “class” of an antibody refers to the type of constant domain orconstant region possessed by its heavy chain. There are five majorclasses of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of thesemay be further divided into subclasses (isotypes), e.g., IgG1, IgG2,IgG3, IgG4, IgAI, and IgA2. The heavy chain constant domains thatcorrespond to the different classes of immunoglobulins are called α, δ,ε, γ, and μ, respectively.

A “chemotherapeutic agent” includes chemical compounds useful in thetreatment of cancer. Examples of chemotherapeutic agents includeerlotinib (TARCEVA®, Genentech/OSI Pharm.), bortezomib (VELCADE®,Millennium Pharm.), disulfiram, epigallocatechin gallate,salinosporamide A, carfilzomib, 17-AAG (geldanamycin), radicicol,lactate dehydrogenase A (LDH-A), fulvestrant (FASLODEX®, AstraZeneca),sunitib (SUTENT®, Pfizer/Sugen), letrozole (FEMARA®, Novartis), imatinibmesylate (GLEEVEC®, Novartis), finasunate (VATALANIB®, Novartis),oxaliplatin (ELOXATIN®, Sanofi), 5-FU (5-fluorouracil), leucovorin,Rapamycin (Sirolimus, RAPAMUNE®, Wyeth), Lapatinib (TYKERB®, GSK572016,Glaxo Smith Kline), Lonafamib (SCH 66336), sorafenib (NEXAVAR®, BayerLabs), gefitinib (IRESSA®, AstraZeneca), AG1478, alkylating agents suchas thiotepa and CYTOXAN® cyclosphosphamide; alkyl sulfonates such asbusulfan, improsulfan and piposulfan; aziridines such as benzodopa,carboquone, meturedopa, and uredopa; ethylenimines and methylamelaminesincluding altretamine, triethylenemelamine, triethylenephosphoramide,triethylenethiophosphoramide and trimethylomelamine; acetogenins(especially bullatacin and bullatacinone); a camptothecin (includingtopotecan and irinotecan); bryostatin; callystatin; CC-1065 (includingits adozelesin, carzelesin and bizelesin synthetic analogs);cryptophycins (particularly cryptophycin 1 and cryptophycin 8);adrenocorticosteroids (including prednisone and prednisolone);cyproterone acetate; 5a-reductases including finasteride anddutasteride); vorinostat, romidepsin, panobinostat, valproic acid,mocetinostat dolastatin; aldesleukin, talc duocarmycin (including thesynthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; asarcodictyin; spongistatin; nitrogen mustards such as chlorambucil,chlomaphazine, chlorophosphamide, estramustine, ifosfamide,mechlorethamine, mechlorethamine oxide hydrochloride, melphalan,novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard;nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine,nimustine, and ranimnustine; antibiotics such as the enediyneantibiotics (e.g., calicheamicin, especially calicheamicin γ1I andcalicheamicin ω1I (Angew Chem. Intl. Ed. Engl. 1994 33:183-186);dynemicin, including dynemicin A; bisphosphonates, such as clodronate;an esperamicin; as well as neocarzinostatin chromophore and relatedchromoprotein enediyne antibiotic chromophores), aclacinomysins,actinomycin, authramycin, azaserine, bleomycins, cactinomycin,carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin,daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN®(doxorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin,2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin,idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolicacid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin,quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexateand 5-fluorouracil (5-FU); folic acid analogs such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine;androgens such as calusterone, dromostanolone propionate, epitiostanol,mepitiostane, testolactone; anti-adrenals such as aminoglutethimide,mitotane, trilostane; folic acid replenisher such as frolinic acid;aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil;amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine;diaziquone; elfomithine; elliptinium acetate; an epothilone; etoglucid;gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids suchas maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamnol;nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharidecomplex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;sizofuran; spirogermanium; tenuazonic acid; triaziquone;2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin,verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL(paclitaxel; Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE®(Cremophor-free), albumin-engineered nanoparticle formulations ofpaclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), andTAXOTERE® (docetaxel, doxetaxel; Sanofi-Aventis); chloranmbucil; GEMZAR®(gemcitabine); 6-thioguanine; mercaptopurine; methotrexate; platinumanalogs such as cisplatin and carboplatin; vinblastine; etoposide(VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE®(vinorelbine); novantrone; teniposide; edatrexate; daunomycin;aminopterin; capecitabine (XELODA®); ibandronate; CPT-11; topoisomeraseinhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such asretinoic acid; and pharmaceutically acceptable salts, acids andderivatives of any of the above.

Chemotherapeutic agent also includes (i) anti-hormonal agents that actto regulate or inhibit hormone action on tumors such as anti-estrogensand selective estrogen receptor modulators (SERMs), including, forexample, tamoxifen (including NOLVADEX®; tamoxifen citrate), raloxifene,droloxifene, iodoxyfene, 4-hydroxytamoxifen, trioxifene, keoxifene,LY117018, onapristone, and FARESTON® (toremifine citrate); (ii)aromatase inhibitors that inhibit the enzyme aromatase, which regulatesestrogen production in the adrenal glands, such as, for example,4(5)-imidazoles, aminoglutethimide, MEGASE® (megestrol acetate),AROMASIN® (exemestane; Pfizer), formestanie, fadrozole, RIVISOR®(vorozole), FEMARA® (letrozole; Novartis), and ARIMIDEX® (anastrozole;AstraZeneca); (iii) anti-androgens such as flutamide, nilutamide,bicalutamide, leuprolide and goserelin; buserelin, tripterelin,medroxyprogesterone acetate, diethylstilbestrol, premarin,fluoxymesterone, all transretionic acid, fenretinide, as well astroxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) proteinkinase inhibitors; (v) lipid kinase inhibitors; (vi) antisenseoligonucleotides, particularly those which inhibit expression of genesin signaling pathways implicated in aberrant cell proliferation, suchas, for example, PKC-alpha, Ralf and H-Ras; (vii) ribozymes such as VEGFexpression inhibitors (e.g., ANGIOZYME®) and HER2 expression inhibitors;(viii) vaccines such as gene therapy vaccines, for example, ALLOVECTIN®,LEUVECTIN®, and VAXID®; PROLEUKIN®, rIL-2; a topoisomerase 1 inhibitorsuch as LURTOTECAN®; ABARELIX® rmRH; and (ix) pharmaceuticallyacceptable salts, acids and derivatives of any of the above.

Chemotherapeutic agent also includes antibodies such as alemtuzumab(Campath), bevacizumab (AVASTIN®, Genentech); cetuximab (ERBITUX®,Imclone); panitumumab (VECTIBIX®, Amgen), rituximab (RITUXAN®,Genentech/Biogen Idec), pertuzumab (OMNITARG®, 2C4, Genentech),trastuzumab (HERCEPTIN®, Genentech), tositumomab (Bexxar, Corixia), andthe antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARG®, Wyeth).Additional humanized monoclonal antibodies with therapeutic potential asagents in combination with the compounds of the invention include:apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab mertansine,cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab,cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab,felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin,ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab,motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab,numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab,pecfusituzumab, pectuzumab, pexelizumab, ralivizumab, ranibizumab,reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab,sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan,tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab,tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab,ustekinumab, visilizumab, and the anti-interleukin-12 (ABT-874/J695,Wyeth Research and Abbott Laboratories) which is a recombinantexclusively human-sequence, full-length IgG1 A antibody geneticallymodified to recognize interleukin-12 p40 protein.

Chemotherapeutic agent also includes “EGFR inhibitors,” which refers tocompounds that bind to or otherwise interact directly with EGFR andprevent or reduce its signaling activity, and is alternatively referredto as an “EGFR antagonist.” Examples of such agents include antibodiesand small molecules that bind to EGFR. Examples of antibodies which bindto EGFR include MAb 579 (ATCC CRL HB 8506), MAb 455 (ATCC CRL HB8507),MAb 225 (ATCC CRL 8508), MAb 528 (ATCC CRL 8509) (see, U.S. Pat. No.4,943,533, Mendelsohn et al.) and variants thereof, such as chimerized225 (C225 or Cetuximab; ERBUTIX®) and reshaped human 225 (H225) (see, WO96/40210, Imclone Systems Inc.); IMC-11F8, a fully human, EGFR-targetedantibody (Imclone); antibodies that bind type II mutant EGFR (U.S. Pat.No. 5,212,290); humanized and chimeric antibodies that bind EGFR asdescribed in U.S. Pat. No. 5,891,996; and human antibodies that bindEGFR, such as ABX-EGF or Panitumumab (see WO98/50433, Abgenix/Amgen);EMD 55900 (Stragliotto et al. Eur. J. Cancer 32A:636-640 (1996));EMD7200 (matuzumab) a humanized EGFR antibody directed against EGFR thatcompetes with both EGF and TGF-alpha for EGFR binding (EMD/Merck); humanEGFR antibody, HuMax-EGFR (GenMab); fully human antibodies known asE1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6. 3 and E7.6. 3 and described inU.S. Pat. No. 6,235,883; MDX-447 (Medarex Inc); and mAb 806 or humanizedmAb 806 (Johns et al., J. Biol. Chem. 279(29):30375-30384 (2004)). Theanti-EGFR antibody may be conjugated with a cytotoxic agent, thusgenerating an immunoconjugate (see, e.g., EP659,439A2, Merck PatentGmbH). EGFR antagonists include small molecules such as compoundsdescribed in U.S. Pat. Nos. 5,616,582, 5,457,105, 5,475,001, 5,654,307,5,679,683, 6,084,095, 6,265,410, 6,455,534, 6,521,620, 6,596,726,6,713,484, 5,770,599, 6,140,332, 5,866,572, 6,399,602, 6,344,459,6,602,863, 6,391,874, 6,344,455, 5,760,041, 6,002,008, and 5,747,498, aswell as the following PCT publications: WO98/14451, WO98/50038,WO99/09016, and WO99/24037. Particular small molecule EGFR antagonistsinclude OSI-774 (CP-358774, erlotinib, TARCEVA® Genentech/OSIPharmaceuticals); PD 183805 (CI 1033, 2-propenamide,N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-,dihydrochloride, Pfizer Inc.); ZD1839, gefitinib (IRESSA®)4-(3′-Chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline,AstraZeneca); ZM 105180 ((6-amino-4-(3-methylphenyl-amino)-quinazoline,Zeneca); BIBX-1382(N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methyl-piperidin-4-yl)-pyrimido[5,4-d]pyrimidine-2,8-diamine,Boehringer Ingelheim); PKI-166((R)-4-[4-[(1-phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenol);(R)-6-(4-hydroxyphenyl)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine);CL-387785 (N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide);EKB-569(N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide)(Wyeth); AG1478 (Pfizer); AG1571 (SU 5271; Pfizer); dual EGFR/HER2tyrosine kinase inhibitors such as lapatinib (TYKERB®, GSK572016 orN-[3-chloro-4-[(3fluorophenyl)methoxy]phenyl]-6[5[[[2methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine).

Chemotherapeutic agents also include “tyrosine kinase inhibitors”including the EGFR-targeted drugs noted in the preceding paragraph;small molecule HER2 tyrosine kinase inhibitor such as TAK165 availablefrom Takeda; CP-724,714, an oral selective inhibitor of the ErbB2receptor tyrosine kinase (Pfizer and OSI); dual-HER inhibitors such asEKB-569 (available from Wyeth) which preferentially binds EGFR butinhibits both HER2 and EGFR-overexpressing cells; lapatinib (GSK572016;available from Glaxo-SmithKline), an oral HER2 and EGFR tyrosine kinaseinhibitor; PKI-166 (available from Novartis); pan-HER inhibitors such ascanertinib (CI-1033; Pharmacia); Raf-1 inhibitors such as antisenseagent ISIS-5132 available from ISIS Pharmaceuticals which inhibit Raf-1signaling; non-HER targeted TK inhibitors such as imatinib mesylate(GLEEVEC®, available from Glaxo SmithKline); multi-targeted tyrosinekinase inhibitors such as sunitinib (SUTENT®, available from Pfizer);VEGF receptor tyrosine kinase inhibitors such as vatalanib(PTK787/ZK222584, available from Novartis/Schering AG); MAPKextracellular regulated kinase I inhibitor CI-1040 (available fromPharmacia); quinazolines, such as PD 153035,4-(3-chloroanilino)quinazoline; pyridopyrimidines; pyrimidopyrimidines; pyrrolopyrimidines,such as CGP 59326, CGP 60261 and CGP 62706; pyrazolopyrimidines,4-(phenylamino)-7H-pyrrolo[2,3-d] pyrimidines; curcumin (diferuloylmethane, 4,5-bis (4-fluoroanilino)phthalimide); tyrphostines containingnitrothiophene moieties; PD-0183805 (Warner-Lamber); antisense molecules(e.g. those that bind to HER-encoding nucleic acid); quinoxalines (U.S.Pat. No. 5,804,396); tryphostins (U.S. Pat. No. 5,804,396); ZD6474(Astra Zeneca); PTK-787 (Novartis/Schering AG); pan-HER inhibitors suchas CI-1033 (Pfizer); Affinitac (ISIS 3521; Isis/Lilly); imatinibmesylate (GLEEVEC®); PKI 166 (Novartis); GW2016 (Glaxo SmithKline);CI-1033 (Pfizer); EKB-569 (Wyeth); Semaxinib (Pfizer); ZD6474(AstraZeneca); PTK-787 (Novartis/Schering AG); INC-1C11 (Imclone),rapamycin (sirolimus, RAPAMUNE®); or as described in any of thefollowing patent publications: U.S. Pat. No. 5,804,396; WO 1999/09016(American Cyanamid); WO 1998/43960 (American Cyanamid); WO 1997/38983(Warner Lambert); WO 1999/06378 (Warner Lambert); WO 1999/06396 (WarnerLambert); WO 1996/30347 (Pfizer, Inc); WO 1996/33978 (Zeneca); WO1996/3397 (Zeneca) and WO 1996/33980 (Zeneca).

Chemotherapeutic agents also include dexamethasone, interferons,colchicine, metoprine, cyclosporine, amphotericin, metronidazole,alemtuzumab, alitretinoin, allopurinol, amifostine, arsenic trioxide,asparaginase, BCG live, bevacuzimab, bexarotene, cladribine,clofarabine, darbepoetin alfa, denileukin, dexrazoxane, epoetin alfa,elotinib, filgrastim, histrelin acetate, ibritumomab, interferonalfa-2a, interferon alfa-2b, lenalidomide, levamisole, mesna,methoxsalen, nandrolone, nelarabine, nofetumomab, oprelvekin,palifermin, pamidronate, pegademase, pegaspargase, pegfilgrastim,pemetrexed disodium, plicamycin, porfimer sodium, quinacrine,rasburicase, sargramostim, temozolomide, VM-26, 6-TG, toremifene,tretinoin, ATRA, valrubicin, zoledronate, and zoledronic acid, andpharmaceutically acceptable salts thereof.

By “platinum-based chemotherapeutic agent” or “platin” is meant anantineoplastic drug that is a coordination complex of platinum. Examplesof platinum-based chemotherapeutic agents include carboplatin,cisplatin, satraplatin, picoplatin, nedaplatin, triplatin, lipoplatin,and oxaliplatinum.

By “platinum-based chemotherapy” is meant therapy with one or moreplatinum-based chemotherapeutic agent, optionally in combination withone or more other chemotherapeutic agents.

By “correlate” or “correlation” is meant comparing, in any way, theperformance and/or results of a first analysis or protocol with theperformance and/or results of a second analysis or protocol. Forexample, one may use the results of a first analysis or protocol todetermine the outcome or result of a second analysis or protocol. Or onemay use the results of a first analysis or protocol to determine whethera second analysis or protocol should be performed. For example, withrespect to the embodiment of gene expression analysis or protocol, onemay use the results of the gene expression analysis or protocol todetermine whether a specific immune cell type or subset is present.

“Effector functions” refer to those biological activities attributableto the Fc region of an antibody, which vary with the antibody isotype.Examples of antibody effector functions include: Clq binding andcomplement dependent cytotoxicity (CDC); Fc receptor binding;antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g. B cell receptor); and B cellactivation.

“Enhancing T cell function” means to induce, cause or stimulate aneffector or memory T cell to have a renewed, sustained or amplifiedbiological function. Examples of enhancing T cell function include:increased secretion of y-interferon from CD8 effector T cells, increasedsecretion of y-interferon from CD4+ memory and/or effector T cells,increased proliferation of CD4+ effector and/or memory T cells,increased proliferation of CD8 effector T cells, increased antigenresponsiveness (e.g., clearance), relative to such levels before theintervention. In one embodiment, the level of enhancement is at least50%, alternatively 60%, 70%, 80%, 90%, 100%, 120%, 150%, 200%. Themanner of measuring this enhancement is known to one of ordinary skillin the art.

A sample, cell, tumor, or cancer which “expresses” one or more immunecell gene signatures at an increased expression level relative to amedian level of expression (e.g., the median level of expression of theone or more immune cell gene signatures in the type of cancer (or in acancer type, wherein the “cancer type” is meant to include cancerouscells (e.g., tumor cells, tumor tissues) as well as non-cancerous cells(e.g., stromal cells, stromal tissues) that surround the cancerous/tumorenvironment) is one in which the expression level of one or more immunecell gene signatures is considered to be a “high immune cell genesignature expression level” to a skilled person for that type of cancer.Generally, such a level will be in the range from about 50% up to about100% or more (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,100%, or more) relative to immune cell gene signature levels in apopulation of samples, cells, tumors, or cancers of the same cancertype. For instance, the population that is used to arrive at the medianexpression level may be particular cancer samples (e.g., bladder cancer,breast cancer, colorectal cancer, gastric cancer, liver cancer,melanoma, lung cancer (e.g., non-small cell lung carcinoma), ovariancancer, or renal cell carcinoma) generally, or subgroupings thereof,such as chemotherapy-resistant cancer, platinum-resistant cancer, aswell as advanced, refractory, or recurrent cancer samples.

By “determining the expression level” used in reference to a particularbiomarker (e.g., one or more immune cell gene signatures), meansexpression of the biomarker(s) (e.g., one or more immune cell genesignatures) in a cancer-associated biological environment (e.g.,expression of the biomarker(s) in the tumor cells), tumor-associatedcells (e.g., tumor-associated stromal cells), as determined using adiagnostic test, any of the detection methods described herein, or thesimilar.

The term “Fc region” herein is used to define a C-terminal region of animmunoglobulin heavy chain that contains at least a portion of theconstant region. The term includes native sequence Fc regions andvariant Fc regions. In one embodiment, a human IgG heavy chain Fc regionextends from Cys226, or from Pro230, to the carboxyl-terminus of theheavy chain. However, the C-terminal lysine (Lys447) of the Fc regionmay or may not be present. Unless otherwise specified herein, numberingof amino acid residues in the Fc region or constant region is accordingto the EU numbering system, also called the EU index, as described inKabat et al, Sequences of Proteins of Immunological Interest, 5th Ed.Public Health Service, National Institutes of Health, Bethesda, Md.,1991.

“Framework” or “FR” refers to variable domain residues other thanhypervariable region (HVR) residues. The FR of a variable domaingenerally consists of four FR domains: FR1, FR2, FR3, and FR4.Accordingly, the HVR and FR sequences generally appear in the followingsequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

The terms “full length antibody,” “intact antibody,” and “wholeantibody” are used herein interchangeably to refer to an antibody havinga structure substantially similar to a native antibody structure orhaving heavy chains that contain an Fc region as defined herein.

A “human antibody” is one which possesses an amino acid sequence whichcorresponds to that of an antibody produced by a human or a human cellor derived from a non-human source that utilizes human antibodyrepertoires or other human antibody-encoding sequences. This definitionof a human antibody specifically excludes a humanized antibodycomprising non-human antigen-binding residues.

A “human consensus framework” is a framework which represents the mostcommonly occurring amino acid residues in a selection of humanimmunoglobulin VL or VH framework sequences. Generally, the selection ofhuman immunoglobulin VL or VH sequences is from a subgroup of variabledomain sequences. Generally, the subgroup of sequences is a subgroup asin Kabat et al, Sequences of Proteins of Immunological Interest, FifthEdition, NIH Publication 91-3242, Bethesda Md. (1991), vols. 1-3. In oneembodiment, for the VL, the subgroup is subgroup kappa I as in Kabat etal, supra. In one embodiment, for the VH, the subgroup is subgroup IIIas in Kabat et al, supra.

A “humanized” antibody refers to a chimeric antibody comprising aminoacid residues from non-human HVRs and amino acid residues from humanFRs. In certain embodiments, a humanized antibody will comprisesubstantially all of at least one, and typically two, variable domains,in which all or substantially all of the HVRs (e.g., CDRs) correspond tothose of a non-human antibody, and all or substantially all of the FRscorrespond to those of a human antibody. A humanized antibody optionallymay comprise at least a portion of an antibody constant region derivedfrom a human antibody. A “humanized form” of an antibody, e.g., anon-human antibody, refers to an antibody that has undergonehumanization.

The term “hypervariable region” or “HVR,” as used herein, refers to eachof the regions of an antibody variable domain which are hypervariable insequence and/or form structurally defined loops (“hypervariable loops”).Generally, native four-chain antibodies comprise six HVRs; three in theVH (HI, H2, H3), and three in the VL (LI, L2, L3). HVRs generallycomprise amino acid residues from the hypervariable loops and/or fromthe “complementarity determining regions” (CDRs), the latter typicallybeing of highest sequence variability and/or involved in antigenrecognition. An HVR region as used herein comprise any number ofresidues located within positions 24-36 (for HVRL1), 46-56 (for HVRL2),89-97 (for HVRL3), 26-35B (for HVRH1), 47-65 (for HVRH2), and 93-102(for HVRH3).

“Tumor immunity” refers to the process in which tumors evade immunerecognition and clearance. Thus, as a therapeutic concept, tumorimmunity is “treated” when such evasion is attenuated, and the tumorsare recognized and attacked by the immune system. Examples of tumorrecognition include tumor binding, tumor shrinkage, and tumor clearance.“Immunogenicity” refers to the ability of a particular substance toprovoke an immune response. Tumors are immunogenic and enhancing tumorimmunogenicity aids in the clearance of the tumor cells by the immuneresponse. Examples of enhancing tumor immunogenicity include but are notlimited to treatment with a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM,NKG2D, MICA, or 2B4 agonist or treatment with a CTLA-4, PD-1 axis,TIM-3, BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist.

An “immunoconjugate” is an antibody conjugated to one or moreheterologous molecule(s), including but not limited to a cytotoxicagent.

An “individual” or “subject” is a mammal. Mammals include, but are notlimited to, domesticated animals (e.g., cows, sheep, cats, dogs, andhorses), primates (e.g., humans and non-human primates such as monkeys),rabbits, and rodents (e.g., mice and rats). In certain embodiments, theindividual or subject is a human.

An “isolated” antibody is one which has been separated from a componentof its natural environment. In some embodiments, an antibody is purifiedto greater than 95% or 99% purity as determined by, for example,electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillaryelectrophoresis) or chromatographic (e.g., ion exchange or reverse phaseHPLC). F or review of methods for assessment of antibody purity, see,e.g., Flatman et al, J. Chromatogr. B 848:79-87 (2007).

An “isolated” nucleic acid refers to a nucleic acid molecule that hasbeen separated from a component of its natural environment. An isolatednucleic acid includes a nucleic acid molecule contained in cells thatordinarily contain the nucleic acid molecule, but the nucleic acidmolecule is present extrachromosomally or at a chromosomal location thatis different from its natural chromosomal location.

“Isolated nucleic acid encoding an anti-target antibody” refers to oneor more nucleic acid molecules encoding antibody heavy and light chains(or fragments thereof), including such nucleic acid molecule(s) in asingle vector or separate vectors, and such nucleic acid molecule(s)present at one or more locations in a host cell.

A “loading” dose herein generally comprises an initial dose of atherapeutic agent administered to a patient, and is followed by one ormore maintenance dose(s) thereof. Generally, a single loading dose isadministered, but multiple loading doses are contemplated herein.Usually, the amount of loading dose(s) administered exceeds the amountof the maintenance dose(s) administered and/or the loading dose(s) areadministered more frequently than the maintenance dose(s), so as toachieve the desired steady-state concentration of the therapeutic agentearlier than can be achieved with the maintenance dose(s).

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a population of substantially homogeneous antibodies,i.e., the individual antibodies comprising the population are identicaland/or bind the same epitope, except for possible variant antibodies,e.g., containing naturally occurring mutations or arising duringproduction of a monoclonal antibody preparation, such variants generallybeing present in minor amounts. In contrast to polyclonal antibodypreparations, which typically include different antibodies directedagainst different determinants (epitopes), each monoclonal antibody of amonoclonal antibody preparation is directed against a single determinanton an antigen. Thus, the modifier “monoclonal” indicates the characterof the antibody as being obtained from a substantially homogeneouspopulation of antibodies, and is not to be construed as requiringproduction of the antibody by any particular method. For example, themonoclonal antibodies to be used according to the methods providedherein may be made by a variety of techniques, including but not limitedto the hybridoma method, recombinant DNA methods, phage-display methods,and methods utilizing transgenic animals containing all or part of thehuman immunoglobulin loci, such methods and other exemplary methods formaking monoclonal antibodies being described herein.

A “naked antibody” refers to an antibody that is not conjugated to aheterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The nakedantibody may be present in a pharmaceutical formulation.

“Native antibodies” refer to naturally occurring immunoglobulinmolecules with varying structures. For example, native IgG antibodiesare heterotetrameric glycoproteins of about 150,000 daltons, composed oftwo identical light chains and two identical heavy chains that aredisulfide-bonded. From N- to C-terminus, each heavy chain has a variableregion (VH), also called a variable heavy domain or a heavy chainvariable domain, followed by three constant domains (CHI, CH2, and CH3).Similarly, from N- to C-terminus, each light chain has a variable region(VL), also called a variable light domain or a light chain variabledomain, followed by a constant light (CL) domain. The light chain of anantibody may be assigned to one of two types, called kappa (κ) andlambda (λ), based on the amino acid sequence of its constant domain.

“Patient response” or “response” (and grammatical variations thereof)can be assessed using any endpoint indicating a benefit to the patient,including, without limitation, (1) inhibition, to some extent, ofdisease progression, including slowing down and complete arrest; (2)reduction in the number of disease episodes and/or symptoms; (3)reduction in lesional size; (4) inhibition (i.e., reduction, slowingdown or complete stopping) of disease cell infiltration into adjacentperipheral organs and/or tissues; (5) inhibition (i.e. reduction,slowing down or complete stopping) of disease spread; (6) decrease ofauto-immune response, which may, but does not have to, result in theregression or ablation of the disease lesion; (7) relief, to someextent, of one or more symptoms associated with the disorder; (8)increase in the length of disease-free presentation following treatment;and/or (9) decreased mortality at a given point of time followingtreatment.

By “radiation therapy” is meant the use of directed gamma rays or betarays to induce sufficient damage to a cell so as to limit its ability tofunction normally or to destroy the cell altogether. It will beappreciated that there will be many ways known in the art to determinethe dosage and duration of treatment. Typical treatments are given as aone-time administration and typical dosages range from 10 to 200 units(Grays) per day.

The term “small molecule” refers to an organic molecule having amolecular weight between 50 Daltons to 2500 Daltons.

The terms “immune cell gene signature” and “immune cell signature” referto any one or a combination or sub-combination of the 31 genes set forthin Table 1. Such sub-combinations of these 31 genes are sometimesreferred to as “gene sets,” and exemplary “gene sets” are set forth inTables 2-8. The gene expression pattern of an immune cell gene signaturein a patient correlates with the presence of an immune cell subtype(e.g., T effector cells, T regulatory cells, B cells, NK cells, myeloidcells, Th17 cells, inflammatory cells, T cell immune blockers, andantigen presenting cell (APC) immune blockers). Each individual gene ormember of an immune cell gene signature is an “immune cell signaturegene.” These genes include, without limitation: CD8A, GZMA, GZMB, IFNy,EOMES, PRF1, FOXP3, MS4A1, CD48, NCAM1, NKP46, ITGAM, ITGAX, CD1C,CLEC4C, IL17A, IL17F, CCL2, IL1B, IL8, IL6, PTGS2, CTLA4, BTLA, LAG3,HAVCR2, PDCD1, CD276, PDL1, PDL2, and IDO1.

The term “PD1-axis antagonist” refers to a molecule that inhibits theinteraction of a PD-1 axis binding partner with either one or more ofits binding partner, so as to remove T cell dysfunction resulting fromsignaling on the PD-1 signaling axis-with a result being to restore orenhance T cell function (e.g., proliferation, cytokine production,target cell killing). As used herein, a PD-1 axis antagonist includes aPD-1 binding antagonist, a PD-L1 binding antagonist, and a PD-L2 bindingantagonist.

“Survival” refers to the patient remaining alive, and includes overallsurvival as well as progression free survival.

“Overall survival” refers to the patient remaining alive for a definedperiod of time, such as 1 year, 5 years, etc. from the time of diagnosisor treatment.

The phrase “progression-free survival” in the context of the presentinvention refers to the length of time during and after treatment duringwhich, according to the assessment of the treating physician orinvestigator, a patient's disease does not become worse, i.e., does notprogress. As the skilled person will appreciate, a patient'sprogression-free survival is improved or enhanced if the patientexperiences a longer length of time during which the disease does notprogress as compared to the average or mean progression free survivaltime of a control group of similarly situated patients.

By “standard of care” herein is intended the anti-tumor/anti-canceragent or agents that are routinely used to treat a particular form ofcancer.

The terms “therapeutically effective amount” or “effective amount” referto an amount of a drug effective to treat cancer in the patient. Theeffective amount of the drug may reduce the number of cancer cells;reduce the tumor size; inhibit (i.e., slow to some extent and preferablystop) cancer cell infiltration into peripheral organs; inhibit (i.e.,slow to some extent and preferably stop) tumor metastasis; inhibit, tosome extent, tumor growth; and/or relieve to some extent one or more ofthe symptoms associated with the cancer. To the extent the drug mayprevent growth and/or kill existing cancer cells, it may be cytostaticand/or cytotoxic. The effective amount may extend progression freesurvival (e.g. as measured by Response Evaluation Criteria for SolidTumors, RECIST, or CA-125 changes), result in an objective response(including a partial response, PR, or complete response, CR), improvesurvival (including overall survival and progression free survival)and/or improve one or more symptoms of cancer (e.g. as assessed byFOSI). Most preferably, the therapeutically effective amount of the drugis effective to improve progression free survival (PFS) and/or overallsurvival (OS).

As used herein, “treatment” refers to clinical intervention in anattempt to alter the natural course of the individual or cell beingtreated, and can be performed either for prophylaxis or during thecourse of clinical pathology. Desirable effects of treatment includepreventing occurrence or recurrence of disease, alleviation of symptoms,diminishment of any direct or indirect pathological consequences of thedisease, decreasing the rate of disease progression, amelioration orpalliation of the disease state, and remission or improved prognosis. Insome embodiments, methods and compositions of the invention are usefulin attempts to delay development of a disease or disorder.

The term “variable region” or “variable domain” refers to the domain ofan antibody heavy or light chain that is involved in binding theantibody to antigen. The variable domains of the heavy chain and lightchain (VH and VL, respectively) of a native antibody generally havesimilar structures, with each domain comprising four conserved frameworkregions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindtet al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007).)A single VH or VL domain may be sufficient to confer antigen-bindingspecificity. Furthermore, antibodies that bind a particular antigen maybe isolated using a VH or VL domain from an antibody that binds theantigen to screen a library of complementary VL or VH domains,respectively. See, e.g., Portolano et al, J. Immunol. 150:880-887(1993); Clarkson et al, Nature 352:624-628 (1991).

III. Methods of Prognosis and Detection

The present invention relates to the identification, selection, and useof biomarkers of cancer (e.g., bladder cancer, breast cancer, colorectalcancer, gastric cancer, liver cancer, melanoma, lung cancer (e.g.,non-small cell lung carcinoma), ovarian cancer, or renal cell carcinoma)that are correlated with an immune cell subtype (e.g., T effector cells,T regulatory cells, B cells, NK cells, myeloid cells, Th17 cells,inflammatory cells, T cell immune blockers, antigen presenting cell(APC) immune blockers). In this respect, the invention relates toanalysis of expression profile(s) in samples from patients with cancer(e.g., bladder cancer, breast cancer, colorectal cancer, gastric cancer,liver cancer, melanoma, lung cancer (e.g., non-small cell lungcarcinoma), ovarian cancer, or renal cell carcinoma), to identifybiomarkers correlated with an immune cell subtype (e.g., T effectorcells, T regulatory cells, B cells, NK cells, myeloid cells, Th17 cells,inflammatory cells, T cell immune blockers, and antigen presenting cell(APC) immune blockers) involved in tumor immunity and the use of thesebiomarkers in selecting patients for treatment with immunotherapy. Thebiomarkers of the invention are listed herein, e.g., in Table 1.

TABLE 1 Gene signature sets and immune cell gene signature set membersGene signature sets Gene signature set members T effector (T_(eff))CD8A, GZMA, GZMB, IFNγ, EOMES, PRF1 T regulatory (T_(reg)) FOXP3 B cellSignature 1 MS4A1, CD48 B cell Signature 2^(#) CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, FCRL5 NK cell Signature 1 NCAM1, NKP46 NK cellSignature 2^(#) KLRC3, KLRK1, KLRC2, KLRD1 Myeloid cell ITGAM, ITGAX,CD1C, CLEC4C Macrophage^(#) CD68, CD163, ITGAM, ITGAX, CD14 M2Macrophage^(#) LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A Th17* IL17A, IL17FInflammatory^(#) CCL2, IL1B, IL8 (CXCL8), IL6, PTGS2 T cell^(#) CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK T cell immune blockers CTLA4,BTLA, LAG3, HAVCR2, PDCD1 (IB T cell) Signature 1 IB T cell Signature2^(#) CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT Antigen presenting cellCD276, PDL1, PDL2, IDO1 immune blockers (IB APC) Signature 1 IB APCSignature 2^(#) CD274, PDL2, IDO1, PVR T cell chemotaxis CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22 Activated CD4 T cell** CD4, IL2RA, CD69Antigen processing** TAPBP, TAP1, TAP2, PSMB9, PSMB8 Costimulatoryligand^(#) CD40, CD80, CD86, CD70, GITRL Costimulatory receptor^(#)CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFSF14, CD226Cytolytic^(#) GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 Activefibroblast^(##) FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 All unmarked gene signature sets were derivedfrom analysis of data using a 90-gene PCR based FLUIDIGM ™ panel. *TheTh17 gene signature set is also described herein as the IL17 gene setand was derived from analysis of data using a 90-gene PCR basedFLUIDIGM ™ panel.. Th17 gene set and IL17 gene set are usedinterchangeably throughout the application and refer to the same geneset. **Gene signature sets that were derived from analysis of data usingan 800-gene custom Nanostring panel (instead of the 90-gene PCR basedFLUIDIGM ™ panel) in urothelial bladder cancer (UBC) samples. ^(#)Genesignature sets that were derived from analysis of data using an 800-genecustom Nanostring panel (instead of the 90-gene PCR based FLUIDIGM ™panel) in non-small cell lung carcinoma (NSCLC) samples. ^(##)Genesignature set that was derived from a targeted RNA-Seq Access in UBCsamples.

The invention provides methods for selecting patients with cancer (e.g.,bladder cancer, breast cancer, colorectal cancer, gastric cancer, livercancer, melanoma, lung cancer (e.g., non-small cell lung carcinoma),ovarian cancer, or renal cell carcinoma) for treatment withimmunotherapy by determining the expression level of one or more immunecell gene signatures (e.g., one or more of the genes listed in Table 1or combinations thereof, e.g., as listed in Tables 2-8), and comparingthe expression level of the immune cell gene signature to a median levelfor expression of the immune cell gene signature (e.g., the median levelfor expression of the immune cell gene signature in the cancer type),where a change in the level of expression of the immune cell genesignature identifies patients for treatment with an immunotherapy.Optionally, the methods include the step of informing the patient thatthey have an increased likelihood of being responsive to animmunotherapy and/or proving a recommendation to the patient for aparticular immunotherapy based on the expression level of one or moreimmune cell gene signatures (e.g., one or more of the genes listed inTable 1 or combinations thereof, e.g., as listed in Tables 2-8).

In some embodiments, the patient is identified for treatment with anactivating immunotherapy or selected as having the likelihood ofbenefiting from an activating immunotherapy regimen if there is anincrease in expression level of one or more immune cell gene signaturesin the T_(eff) gene set (i.e., one or more of CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1) or a decrease in expression level of one or more immunecell gene signatures in the T_(reg) gene set. In other embodiments, thepatient is identified for treatment with a suppressing immunotherapy orselected as having the likelihood of benefiting from a suppressingimmunotherapy if there is an increase in expression level of one or moreimmune cell gene signatures in the T_(reg) gene set (i.e., FOXP3) or adecrease in expression level of one or more immune cell gene signaturesin the T_(eff) gene set (i.e., one or more of CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1). In other embodiments, in addition to determining theexpression levels of one or more immune cell gene signatures in theT_(eff) and/or T_(reg) gene sets, expression levels of one or moreimmune cell gene signatures in combinations of any one of the gene setsas set forth in Tables 2-8 can be determined in order to identify apatient for a particular immunotherapy regimen (e.g., an activatingimmunotherapy regimen or a suppressing immunotherapy regimen).Optionally, these methods are carried out prior to administering animmunotherapy regimen in order to provide the patient with apre-administration prognosis for response to immunotherapy.

In certain embodiments, the expression level of one or more of the genesin an immune cell gene signature in any one particular gene signatureset is determined. For example:

CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; or

FOXP3; or

MS4A1 or CD48; or

CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; or

NCAM1 or NKP46; or

KLRC3, KLRK1, KLRC2, or KLRD1; or

ITGAM, ITGAX, CD1C, or CLEC4C; or

CD68, CD163, ITGAM, ITGAX, or CD14; or

LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, or FCGR3A; or

IL17A or IL17F; or

CCL2, IL1B, IL8, IL6, or PTGS2; or

CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; or

CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; or

CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; or

CD276, PDL1, PDL2, or IDO1; or

CD274, PDL2, IDO1, or PVR; or

CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; or

CD4, IL2RA, or CD69; or

TAPBP, TAP1, TAP2, PSMB9, or PSMB8; or

CD40, CD80, CD86, CD70, or GITRL; or

CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFSF14, or CD226; or

GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; or

FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, orCOL8A1 is determined. In another embodiment, the expression levels ofone or more of the genes in an immune cell gene signature in twoparticular gene signature sets are determined. For example, combinationsof two particular gene signature sets are set forth in Table 2 below.

TABLE 2 Combinations of two gene signature sets CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; and MS4A1 or CD48. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; and NCAM1 or NKP46. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; andFOXP3. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and ITGAM, ITGAX, CD1C,or CLEC4C. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and IL17A or IL17F.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and CCL2, IL1B, IL8, IL6, orPTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and CD276,PDL1, PDL2, or IDO1. FOXP3; and MS4A1 or CD48. FOXP3; and NCAM1 orNKP46. FOXP3; and ITGAM, ITGAX, CD1C, or CLEC4C. FOXP3; and IL17A orIL17F. FOXP3; and CCL2, IL1B, IL8, IL6, or PTGS2. FOXP3; and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; and CD276, PDL1, PDL2, or IDO1.MS4A1 or CD48; and NCAM1 or NKP46. MS4A1 or CD48; and ITGAM, ITGAX,CD1C, or CLEC4C. MS4A1 or CD48; and IL17A or IL17F. MS4A1 or CD48; andCCL2, IL1B, IL8, IL6, or PTGS2. MS4A1 or CD48; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. MS4A1 or CD48; and CD276, PDL1, PDL2, or IDO1. NCAM1or NKP46; and ITGAM, ITGAX, CD1C, or CLEC4C. NCAM1 or NKP46; and IL17Aor IL17F. NCAM1 or NKP46; and CCL2, IL1B, IL8, IL6, or PTGS2. NCAM1 orNKP46; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. NCAM1 or NKP46; andCD276, PDL1, PDL2, or IDO1. ITGAM, ITGAX, CD1C, or CLEC4C; and IL17A orIL17F. ITGAM, ITGAX, CD1C, or CLEC4C; and CCL2, IL1B, IL8, IL6, orPTGS2. ITGAM, ITGAX, CD1C, or CLEC4C; and CTLA4, BTLA, LAG3, HAVCR2, orPDCD1. ITGAM, ITGAX, CD1C, or CLEC4C; and CD276, PDL1, PDL2, or IDO1.IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. IL17A or IL17F; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. IL17A or IL17F; and CD276, PDL1,PDL2, or IDO1. CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2,or IDO1. CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. FOXP3; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. MS4A1 or CD48; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.NCAM1 or NKP46; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. ITGAM,ITGAX, CD1C, or CLEC4C; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CCL2,IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; andCD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; and KLRC3, KLRK1, KLRC2, KLRD1 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; and CD68, CD163, ITGAM, ITGAX, CD14 CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCKCD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and CD274, PDL2,IDO1, PVR CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and CD4, IL2RA, CD69CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and TAPBP, TAP1, TAP2, PSMB9,PSMB8 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and CD40, CD80, CD86,CD70, GITRL CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 FOXP3; and CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 FOXP3; and KLRC3, KLRK1,KLRC2, KLRD1 FOXP3; and CD68, CD163, ITGAM, ITGAX, CD14 FOXP3; andLAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, FCGR3A FOXP3; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28,LCK FOXP3; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT FOXP3; and CD274,PDL2, IDO1, PVR FOXP3; and CD4, IL2RA, CD69 FOXP3; and TAPBP, TAP1,TAP2, PSMB9, PSMB8 FOXP3; and CD40, CD80, CD86, CD70, GITRL FOXP3; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226FOXP3; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 FOXP3; and FAP,FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1MS4A1 or CD48; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5MS4A1 or CD48; and KLRC3, KLRK1, KLRC2, KLRD1 MS4A1 or CD48; and CD68,CD163, ITGAM, ITGAX, CD14 MS4A1 or CD48; and LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A MS4A1or CD48; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK MS4A1 or CD48;and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT MS4A1 or CD48; and CD274,PDL2, IDO1, PVR MS4A1 or CD48; and CD4, IL2RA, CD69 MS4A1 or CD48; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 MS4A1 or CD48; and CD40, CD80, CD86,CD70, GITRL MS4A1 or CD48; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 MS4A1 or CD48; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 MS4A1 or CD48; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 NCAM1 or NKP46; andCD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 NCAM1 or NKP46; andKLRC3, KLRK1, KLRC2, KLRD1 NCAM1 or NKP46; and CD68, CD163, ITGAM,ITGAX, CD14 NCAM1 or NKP46; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A NCAM1 or NKP46; andCD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK NCAM1 or NKP46; and CTLA4,BTLA, LAG3, HAVCR2, PDCD1, TIGIT NCAM1 or NKP46; and CD274, PDL2, IDO1,PVR NCAM1 or NKP46; and CD4, IL2RA, CD69 NCAM1 or NKP46; and TAPBP,TAP1, TAP2, PSMB9, PSMB8 NCAM1 or NKP46; and CD40, CD80, CD86, CD70,GITRL NCAM1 or NKP46; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 NCAM1 or NKP46; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 NCAM1 or NKP46; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 ITGAM, ITGAX, CD1C, or CLEC4C;and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 ITGAM, ITGAX,CD1C, or CLEC4C; and KLRC3, KLRK1, KLRC2, KLRD1 ITGAM, ITGAX, CD1C, orCLEC4C; and CD68, CD163, ITGAM, ITGAX, CD14 ITGAM, ITGAX, CD1C, orCLEC4C; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A ITGAM, ITGAX, CD1C, or CLEC4C; and CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK ITGAM, ITGAX, CD1C, or CLEC4C;and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT ITGAM, ITGAX, CD1C, orCLEC4C; and CD274, PDL2, IDO1, PVR ITGAM, ITGAX, CD1C, or CLEC4C; andCD4, IL2RA, CD69 ITGAM, ITGAX, CD1C, or CLEC4C; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 ITGAM, ITGAX, CD1C, or CLEC4C; and CD40, CD80, CD86, CD70,GITRL ITGAM, ITGAX, CD1C, or CLEC4C; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 ITGAM, ITGAX, CD1C, orCLEC4C; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 ITGAM, ITGAX,CD1C, or CLEC4C; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 IL17A or IL17F; and CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, FCRL5 IL17A or IL17F; and KLRC3, KLRK1, KLRC2, KLRD1IL17A or IL17F; and CD68, CD163, ITGAM, ITGAX, CD14 IL17A or IL17F; andLAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, FCGR3A IL17A or IL17F; and CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1,TIGIT IL17A or IL17F; and CD274, PDL2, IDO1, PVR IL17A or IL17F; andCD4, IL2RA, CD69 IL17A or IL17F; and TAPBP, TAP1, TAP2, PSMB9, PSMB8IL17A or IL17F; and CD40, CD80, CD86, CD70, GITRL IL17A or IL17F; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226IL17A or IL17F; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 IL17A orIL17F; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and KLRC3, KLRK1, KLRC2, KLRD1 CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and CD68, CD163, ITGAM, ITGAX, CD14 CCL2, IL1B, IL8 (CXCL8), IL6,or PTGS2; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGITCCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD274, PDL2, IDO1, PVR CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD4, IL2RA, CD69 CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CCL2, IL1B,IL8 (CXCL8), IL6, or PTGS2; and CD40, CD80, CD86, CD70, GITRL CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and KLRC3, KLRK1, KLRC2, KLRD1 CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD68, CD163, ITGAM, ITGAX, CD14 CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCKCTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD274, PDL2, IDO1,PVR CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD4, IL2RA, CD69 CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD40, CD80, CD86, CD70, GITRL CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 CD276, PDL1, PDL2, or IDO1; and CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CD276, PDL1, PDL2, or IDO1; andKLRC3, KLRK1, KLRC2, KLRD1 CD276, PDL1, PDL2, or IDO1; and CD68, CD163,ITGAM, ITGAX, CD14 CD276, PDL1, PDL2, or IDO1; and LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3ACD276, PDL1, PDL2, or IDO1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28,LCK CD276, PDL1, PDL2, or IDO1; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1,TIGIT CD276, PDL1, PDL2, or IDO1; and CD274, PDL2, IDO1, PVR CD276,PDL1, PDL2, or IDO1; and CD4, IL2RA, CD69 CD276, PDL1, PDL2, or IDO1;and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD276, PDL1, PDL2, or IDO1; andCD40, CD80, CD86, CD70, GITRL CD276, PDL1, PDL2, or IDO1; and CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD276,PDL1, PDL2, or IDO1; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7CD276, PDL1, PDL2, or IDO1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and KLRC3, KLRK1, KLRC2,KLRD1 CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD68, CD163,ITGAM, ITGAX, CD14 CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andLAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, FCGR3A CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andCD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGITCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD274, PDL2, IDO1,PVR CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD4, IL2RA, CD69CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD40,CD80, CD86, CD70, GITRL CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22;and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,CD226 CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5;and KLRC3, KLRK1, KLRC2, KLRD1 CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; and CD68, CD163, ITGAM, ITGAX, CD14 CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; and LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; and CD3D, CD3E, CD2,CD3G, CD6, TRAT1, CD28, LCK CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; and CD274, PDL2, IDO1,PVR CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; and CD4,IL2RA, CD69 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; and CD40, CD80, CD86, CD70, GITRL CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, or FCRL5; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; and FAP,FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1KLRC3, KLRK1, KLRC2, or KLRD1; and CD68, CD163, ITGAM, ITGAX, CD14KLRC3, KLRK1, KLRC2, or KLRD1; and LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A KLRC3, KLRK1,KLRC2, or KLRD1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK KLRC3,KLRK1, KLRC2, or KLRD1; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGITKLRC3, KLRK1, KLRC2, or KLRD1; and CD274, PDL2, IDO1, PVR KLRC3, KLRK1,KLRC2, or KLRD1; and CD4, IL2RA, CD69 KLRC3, KLRK1, KLRC2, or KLRD1; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 KLRC3, KLRK1, KLRC2, or KLRD1; and CD40,CD80, CD86, CD70, GITRL KLRC3, KLRK1, KLRC2, or KLRD1; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 KLRC3,KLRK1, KLRC2, or KLRD1; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7KLRC3, KLRK1, KLRC2, or KLRD1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD68, CD163, ITGAM, ITGAX, orCD14; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A CD68, CD163, ITGAM, ITGAX, or CD14; andCD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CD68, CD163, ITGAM, ITGAX,or CD14; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD68, CD163, ITGAM,ITGAX, or CD14; and CD274, PDL2, IDO1, PVR CD68, CD163, ITGAM, ITGAX, orCD14; and CD4, IL2RA, CD69 CD68, CD163, ITGAM, ITGAX, or CD14; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 CD68, CD163, ITGAM, ITGAX, or CD14; andCD40, CD80, CD86, CD70, GITRL CD68, CD163, ITGAM, ITGAX, or CD14; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226CD68, CD163, ITGAM, ITGAX, or CD14; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CD68, CD163, ITGAM, ITGAX, or CD14; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, orFCGR3A; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,or FCGR3A; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,or FCGR3A; and CD274, PDL2, IDO1, PVR LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and CD4,IL2RA, CD69 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and TAPBP, TAP1, TAP2, PSMB9, PSMB8LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, or FCGR3A; and CD40, CD80, CD86, CD70, GITRL LAPTM5,LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3,FCGR2A, or FCGR3A; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and CTLA4, BTLA, LAG3,HAVCR2, PDCD1, TIGIT CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK;and CD274, PDL2, IDO1, PVR CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, orLCK; and CD4, IL2RA, CD69 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, orLCK; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, or LCK; and CD40, CD80, CD86, CD70, GITRL CD3D, CD3E, CD2,CD3G, CD6, TRAT1, CD28, or LCK; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CD3D, CD3E, CD2, CD3G, CD6, TRAT1,CD28, or LCK; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CTLA4, BTLA, LAG3,HAVCR2, PDCD1, or TIGIT; and CD274, PDL2, IDO1, PVR CTLA4, BTLA, LAG3,HAVCR2, PDCD1, or TIGIT; and CD4, IL2RA, CD69 CTLA4, BTLA, LAG3, HAVCR2,PDCD1, or TIGIT; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CTLA4, BTLA, LAG3,HAVCR2, PDCD1, or TIGIT; and CD40, CD80, CD86, CD70, GITRL CTLA4, BTLA,LAG3, HAVCR2, PDCD1, or TIGIT; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CTLA4, BTLA, LAG3, HAVCR2, PDCD1, orTIGIT; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CTLA4, BTLA,LAG3, HAVCR2, PDCD1, or TIGIT; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD274, PDL2, IDO1, or PVR; andCD4, IL2RA, CD69 CD274, PDL2, IDO1, or PVR; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 CD274, PDL2, IDO1, or PVR; and CD40, CD80, CD86, CD70,GITRL CD274, PDL2, IDO1, or PVR; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD274, PDL2, IDO1, or PVR;and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD274, PDL2, IDO1, orPVR; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD4, IL2RA, or CD69; and TAPBP, TAP1, TAP2, PSMB9, PSMB8CD4, IL2RA, or CD69; and CD40, CD80, CD86, CD70, GITRL CD4, IL2RA, orCD69; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 CD4, IL2RA, or CD69; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CD4, IL2RA, or CD69; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 TAPBP, TAP1, TAP2, PSMB9, orPSMB8; and CD40, CD80, CD86, CD70, GITRL TAPBP, TAP1, TAP2, PSMB9, orPSMB8; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 TAPBP, TAP1, TAP2, PSMB9, or PSMB8; andFAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1CD40, CD80, CD86, CD70, or GITRL; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD40, CD80, CD86, CD70, orGITRL; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD40, CD80, CD86,CD70, or GITRL; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, or CD226; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7 CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,or CD226; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; and FAP,FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1

In another embodiment, the expression levels of one or more of the genesin an immune cell gene signature in three particular gene signature setsare determined. For example, combinations of three particular genesignature sets are set forth in Table 3 below.

TABLE 3 Combinations of three gene signature sets CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; and MS4A1 or CD48. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; and NCAM1 or NKP46. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; and ITGAM, ITGAX, CD1C, or CLEC4C. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; and IL17A or IL17F. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; and CTLA4, BTLA, LAG3, HAVCR2,or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; and CD276,PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 orCD48; and NCAM1 or NKP46. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1or CD48; and ITGAM, ITGAX, CD1C, or CLEC4C. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; and IL17A or IL17F. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; and CCL2, IL1B, IL8, IL6, or PTGS2.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 orCD48; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; NCAM1 or NKP46; and ITGAM, ITGAX, CD1C, or CLEC4C. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; and IL17A or IL17F. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; and CCL2, IL1B, IL8,IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; NCAM1 or NKP46; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; and IL17A orIL17F. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, orCLEC4C; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX,CD1C, or CLEC4C; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A orIL17F; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, orPDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8, IL6, orPTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1. FOXP3; MS4A1 or CD48; and NCAM1 or NKP46. FOXP3; MS4A1 or CD48;and ITGAM, ITGAX, CD1C, or CLEC4C. FOXP3; MS4A1 or CD48; and IL17A orIL17F. FOXP3; MS4A1 or CD48; and CCL2, IL1B, IL8, IL6, or PTGS2. FOXP3;MS4A1 or CD48; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 orCD48; and CD276, PDL1, PDL2, or IDO1. FOXP3; NCAM1 or NKP46; and ITGAM,ITGAX, CD1C, or CLEC4C. FOXP3; NCAM1 or NKP46; and IL17A or IL17F.FOXP3; NCAM1 or NKP46; and CCL2, IL1B, IL8, IL6, or PTGS2. FOXP3; NCAM1or NKP46; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; NCAM1 orNKP46; and CD276, PDL1, PDL2, or IDO1. FOXP3; ITGAM, ITGAX, CD1C, orCLEC4C; and IL17A or IL17F. FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; andCCL2, IL1B, IL8, IL6, or PTGS2. FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; ITGAM, ITGAX, CD1C, orCLEC4C; and CD276, PDL1, PDL2, or IDO1. FOXP3; IL17A or IL17F; and CCL2,IL1B, IL8, IL6, or PTGS2. FOXP3; IL17A or IL17F; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. FOXP3; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1.FOXP3; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, orPDCD1. FOXP3; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, orIDO1. FOXP3; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2,or IDO1. MS4A1 or CD48; NCAM1 or NKP46; and ITGAM, ITGAX, CD1C, orCLEC4C. MS4A1 or CD48; NCAM1 or NKP46; and IL17A or IL17F. MS4A1 orCD48; NCAM1 or NKP46; and CCL2, IL1B, IL8, IL6, or PTGS2. MS4A1 or CD48;NCAM1 or NKP46; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. MS4A1 or CD48;NCAM1 or NKP46; and CD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; and IL17A or IL17F. MS4A1 or CD48; ITGAM, ITGAX,CD1C, or CLEC4C; and CCL2, IL1B, IL8, IL6, or PTGS2. MS4A1 or CD48;ITGAM, ITGAX, CD1C, or CLEC4C; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; and CD276, PDL1, PDL2, orIDO1. MS4A1 or CD48; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2.MS4A1 or CD48; IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.MS4A1 or CD48; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. MS4A1 orCD48; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, orPDCD1. MS4A1 or CD48; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1,PDL2, or IDO1. MS4A1 or CD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; and IL17A or IL17F. NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; and CCL2, IL1B, IL8, IL6, or PTGS2. NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. NCAM1or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CD276, PDL1, PDL2, or IDO1.NCAM1 or NKP46; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2.NCAM1 or NKP46; IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.NCAM1 or NKP46; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. NCAM1 orNKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, orPDCD1. NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1,PDL2, or IDO1. NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1.ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. ITGAM,ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276,PDL1, PDL2, or IDO1. IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. IL17A or IL17F; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; MS4A1 or CD48; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; NCAM1 or NKP46; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. FOXP3; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. FOXP3; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.MS4A1 or CD48; NCAM1 or NKP46; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; IL17A or IL17F; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; CCL2, IL1B, IL8, IL6,or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. MS4A1 or CD48; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 orNKP46; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 orNKP46; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. ITGAM, ITGAX, CD1C, or CLEC4C; CCL2,IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. ITGAM, ITGAX,CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. IL17A or IL17F; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; and CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, FCRL5 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; and CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; and CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, FCRL5 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;IL17A or IL17F; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; CD276, PDL1, PDL2, or IDO1; and CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andCD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; and KLRC3, KLRK1, KLRC2, KLRD1 CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; and KLRC3, KLRK1, KLRC2,KLRD1 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; and KLRC3,KLRK1, KLRC2, KLRD1 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM,ITGAX, CD1C, or CLEC4C; and KLRC3, KLRK1, KLRC2, KLRD1 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; IL17A or IL17F; and KLRC3, KLRK1, KLRC2, KLRD1CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and KLRC3, KLRK1, KLRC2, KLRD1 CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and KLRC3, KLRK1, KLRC2,KLRD1 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CD276, PDL1, PDL2, orIDO1; and KLRC3, KLRK1, KLRC2, KLRD1 CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and KLRC3, KLRK1,KLRC2, KLRD1 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; and CD68,CD163, ITGAM, ITGAX, CD14 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1or CD48; and CD68, CD163, ITGAM, ITGAX, CD14 CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; NCAM1 or NKP46; and CD68, CD163, ITGAM, ITGAX, CD14CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C;and CD68, CD163, ITGAM, ITGAX, CD14 CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; IL17A or IL17F; and CD68, CD163, ITGAM, ITGAX, CD14 CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; andCD68, CD163, ITGAM, ITGAX, CD14 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD68, CD163, ITGAM, ITGAX, CD14CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CD276, PDL1, PDL2, or IDO1; andCD68, CD163, ITGAM, ITGAX, CD14 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD68, CD163, ITGAM,ITGAX, CD14 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; and LAPTM5,LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3,FCGR2A, FCGR3A CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA,MSR1, FPR3, FCGR2A, FCGR3A CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1or NKP46; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; and LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; and LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,FCGR3A CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3ACD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CD276, PDL1, PDL2, or IDO1; andLAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, FCGR3A CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; and CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; NCAM1 or NKP46; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1,CD28, LCK CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, orCLEC4C; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; and CD3D, CD3E, CD2, CD3G,CD6, TRAT1, CD28, LCK CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1,CD28, LCK CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; CD276, PDL1, PDL2, or IDO1; and CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD3D, CD3E,CD2, CD3G, CD6, TRAT1, CD28, LCK CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; and CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; andCTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; and CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; andCTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CTLA4, BTLA, LAG3,HAVCR2, PDCD1, TIGIT CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1,TIGIT CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CD276, PDL1, PDL2, orIDO1; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andCTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; and CD274, PDL2, IDO1, PVR CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; and CD274, PDL2, IDO1, PVR CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; and CD274, PDL2, IDO1, PVRCD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C;and CD274, PDL2, IDO1, PVR CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17Aor IL17F; and CD274, PDL2, IDO1, PVR CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD274, PDL2, IDO1, PVRCD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD274, PDL2, IDO1, PVR CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; CD276, PDL1, PDL2, or IDO1; and CD274, PDL2, IDO1, PVR CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22; and CD274, PDL2, IDO1, PVR CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; and CD4, IL2RA, CD69 CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; and CD4, IL2RA, CD69 CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; NCAM1 or NKP46; and CD4, IL2RA, CD69 CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; and CD4, IL2RA, CD69CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; and CD4, IL2RA,CD69 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and CD4, IL2RA, CD69 CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD4, IL2RA, CD69 CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; CD276, PDL1, PDL2, or IDO1; and CD4,IL2RA, CD69 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and CD4, IL2RA, CD69 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;ITGAM, ITGAX, CD1C, or CLEC4C; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;CD276, PDL1, PDL2, or IDO1; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; and CD40, CD80, CD86, CD70, GITRL CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; and CD40, CD80, CD86, CD70,GITRL CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; and CD40,CD80, CD86, CD70, GITRL CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM,ITGAX, CD1C, or CLEC4C; and CD40, CD80, CD86, CD70, GITRL CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; and CD40, CD80, CD86, CD70,GITRL CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and CD40, CD80, CD86, CD70, GITRL CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD40, CD80,CD86, CD70, GITRL CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CD276, PDL1,PDL2, or IDO1; and CD40, CD80, CD86, CD70, GITRL CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD40,CD80, CD86, CD70, GITRL CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,CD226 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; and CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,CD226 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CD276, PDL1, PDL2, orIDO1; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 orNKP46; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;IL17A or IL17F; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; CD276, PDL1, PDL2, or IDO1; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; and FAP, FN1, MMP2,BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; and FAP, FN1, MMP2,BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and FAP,FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CD276, PDL1,PDL2, or IDO1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 FOXP3; MS4A1 or CD48; andCD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 FOXP3; NCAM1 orNKP46; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 FOXP3;ITGAM, ITGAX, CD1C, or CLEC4C; and CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, FCRL5 FOXP3; IL17A or IL17F; and CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, FCRL5 FOXP3; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2;and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 FOXP3; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, FCRL5 FOXP3; CD276, PDL1, PDL2, or IDO1; and CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, FCRL5 FOXP3; CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22; and CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, FCRL5 FOXP3; MS4A1 or CD48; and KLRC3, KLRK1, KLRC2, KLRD1FOXP3; NCAM1 or NKP46; and KLRC3, KLRK1, KLRC2, KLRD1 FOXP3; ITGAM,ITGAX, CD1C, or CLEC4C; and KLRC3, KLRK1, KLRC2, KLRD1 FOXP3; IL17A orIL17F; and KLRC3, KLRK1, KLRC2, KLRD1 FOXP3; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and KLRC3, KLRK1, KLRC2, KLRD1 FOXP3; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and KLRC3, KLRK1, KLRC2, KLRD1 FOXP3; CD276, PDL1,PDL2, or IDO1; and KLRC3, KLRK1, KLRC2, KLRD1 FOXP3; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and KLRC3, KLRK1, KLRC2, KLRD1 FOXP3;MS4A1 or CD48; and CD68, CD163, ITGAM, ITGAX, CD14 FOXP3; NCAM1 orNKP46; and CD68, CD163, ITGAM, ITGAX, CD14 FOXP3; ITGAM, ITGAX, CD1C, orCLEC4C; and CD68, CD163, ITGAM, ITGAX, CD14 FOXP3; IL17A or IL17F; andCD68, CD163, ITGAM, ITGAX, CD14 FOXP3; CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and CD68, CD163, ITGAM, ITGAX, CD14 FOXP3; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD68, CD163, ITGAM, ITGAX, CD14 FOXP3; CD276,PDL1, PDL2, or IDO1; and CD68, CD163, ITGAM, ITGAX, CD14 FOXP3; CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD68, CD163, ITGAM, ITGAX,CD14 FOXP3; MS4A1 or CD48; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A FOXP3; NCAM1 orNKP46; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C;and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA,MSR1, FPR3, FCGR2A, FCGR3A FOXP3; IL17A or IL17F; and LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,FCGR3A FOXP3; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,FCGR3A FOXP3; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,FCGR3A FOXP3; CD276, PDL1, PDL2, or IDO1; and LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A FOXP3;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3AFOXP3; MS4A1 or CD48; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCKFOXP3; NCAM1 or NKP46; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCKFOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; and CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK FOXP3; IL17A or IL17F; and CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK FOXP3; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; andCD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK FOXP3; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCKFOXP3; CD276, PDL1, PDL2, or IDO1; and CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK FOXP3; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22;and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK FOXP3; MS4A1 or CD48;and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT FOXP3; NCAM1 or NKP46; andCTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT FOXP3; ITGAM, ITGAX, CD1C, orCLEC4C; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT FOXP3; IL17A orIL17F; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT FOXP3; CCL2, IL1B,IL8 (CXCL8), IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGITFOXP3; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CTLA4, BTLA, LAG3,HAVCR2, PDCD1, TIGIT FOXP3; CD276, PDL1, PDL2, or IDO1; and CTLA4, BTLA,LAG3, HAVCR2, PDCD1, TIGIT FOXP3; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT FOXP3; MS4A1 orCD48; and CD274, PDL2, IDO1, PVR FOXP3; NCAM1 or NKP46; and CD274, PDL2,IDO1, PVR FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; and CD274, PDL2, IDO1,PVR FOXP3; IL17A or IL17F; and CD274, PDL2, IDO1, PVR FOXP3; CCL2, IL1B,IL8 (CXCL8), IL6, or PTGS2; and CD274, PDL2, IDO1, PVR FOXP3; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD274, PDL2, IDO1, PVR FOXP3; CD276,PDL1, PDL2, or IDO1; and CD274, PDL2, IDO1, PVR FOXP3; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and CD274, PDL2, IDO1, PVR FOXP3; MS4A1or CD48; and CD4, IL2RA, CD69 FOXP3; NCAM1 or NKP46; and CD4, IL2RA,CD69 FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; and CD4, IL2RA, CD69 FOXP3;IL17A or IL17F; and CD4, IL2RA, CD69 FOXP3; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and CD4, IL2RA, CD69 FOXP3; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD4, IL2RA, CD69 FOXP3; CD276, PDL1, PDL2, or IDO1; and CD4,IL2RA, CD69 FOXP3; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andCD4, IL2RA, CD69 FOXP3; MS4A1 or CD48; and TAPBP, TAP1, TAP2, PSMB9,PSMB8 FOXP3; NCAM1 or NKP46; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 FOXP3;ITGAM, ITGAX, CD1C, or CLEC4C; and TAPBP, TAP1, TAP2, PSMB9, PSMB8FOXP3; IL17A or IL17F; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 FOXP3; CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; and TAPBP, TAP1, TAP2, PSMB9, PSMB8FOXP3; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 FOXP3; CD276, PDL1, PDL2, or IDO1; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 FOXP3; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 FOXP3; MS4A1 or CD48; and CD40, CD80,CD86, CD70, GITRL FOXP3; NCAM1 or NKP46; and CD40, CD80, CD86, CD70,GITRL FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; and CD40, CD80, CD86, CD70,GITRL FOXP3; IL17A or IL17F; and CD40, CD80, CD86, CD70, GITRL FOXP3;CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD40, CD80, CD86, CD70,GITRL FOXP3; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD40, CD80, CD86,CD70, GITRL FOXP3; CD276, PDL1, PDL2, or IDO1; and CD40, CD80, CD86,CD70, GITRL FOXP3; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andCD40, CD80, CD86, CD70, GITRL FOXP3; MS4A1 or CD48; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 FOXP3; NCAM1or NKP46; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 FOXP3; IL17Aor IL17F; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 FOXP3; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 FOXP3;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 FOXP3; CD276, PDL1, PDL2,or IDO1; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 FOXP3; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226FOXP3; MS4A1 or CD48; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7FOXP3; NCAM1 or NKP46; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 FOXP3; IL17A or IL17F; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 FOXP3; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; andGNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 FOXP3; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 FOXP3;CD276, PDL1, PDL2, or IDO1; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7 FOXP3; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 FOXP3; MS4A1 or CD48; and FAP,FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1FOXP3; NCAM1 or NKP46; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; andFAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1FOXP3; IL17A or IL17F; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 FOXP3; CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 FOXP3; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 FOXP3;CD276, PDL1, PDL2, or IDO1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 FOXP3; CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 MS4A1 OR CD48; NCAM1 or NKP46; and CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 MS4A1 OR CD48; ITGAM,ITGAX, CD1C, or CLEC4C; and CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, FCRL5 MS4A1 OR CD48; IL17A or IL17F; and CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, FCRL5 MS4A1 OR CD48; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5MS4A1 OR CD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, FCRL5 MS4A1 OR CD48; CD276, PDL1, PDL2,or IDO1; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 MS4A1OR CD48; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 MS4A1 OR CD48; NCAM1 orNKP46; and KLRC3, KLRK1, KLRC2, KLRD1 MS4A1 OR CD48; ITGAM, ITGAX, CD1C,or CLEC4C; and KLRC3, KLRK1, KLRC2, KLRD1 MS4A1 OR CD48; IL17A or IL17F;and KLRC3, KLRK1, KLRC2, KLRD1 MS4A1 OR CD48; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and KLRC3, KLRK1, KLRC2, KLRD1 MS4A1 OR CD48; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and KLRC3, KLRK1, KLRC2, KLRD1 MS4A1 ORCD48; CD276, PDL1, PDL2, or IDO1; and KLRC3, KLRK1, KLRC2, KLRD1 MS4A1OR CD48; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and KLRC3,KLRK1, KLRC2, KLRD1 MS4A1 OR CD48; NCAM1 or NKP46; and CD68, CD163,ITGAM, ITGAX, CD14 MS4A1 OR CD48; ITGAM, ITGAX, CD1C, or CLEC4C; andCD68, CD163, ITGAM, ITGAX, CD14 MS4A1 OR CD48; IL17A or IL17F; and CD68,CD163, ITGAM, ITGAX, CD14 MS4A1 OR CD48; CCL2, IL1B, IL8 (CXCL8), IL6,or PTGS2; and CD68, CD163, ITGAM, ITGAX, CD14 MS4A1 OR CD48; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD68, CD163, ITGAM, ITGAX, CD14 MS4A1OR CD48; CD276, PDL1, PDL2, or IDO1; and CD68, CD163, ITGAM, ITGAX, CD14MS4A1 OR CD48; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD68,CD163, ITGAM, ITGAX, CD14 MS4A1 OR CD48; NCAM1 or NKP46; and LAPTM5,LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3,FCGR2A, FCGR3A MS4A1 OR CD48; ITGAM, ITGAX, CD1C, or CLEC4C; and LAPTM5,LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3,FCGR2A, FCGR3A MS4A1 OR CD48; IL17A or IL17F; and LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3AMS4A1 OR CD48; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and LAPTM5,LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3,FCGR2A, FCGR3A MS4A1 OR CD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andLAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, FCGR3A MS4A1 OR CD48; CD276, PDL1, PDL2, or IDO1; andLAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, FCGR3A MS4A1 OR CD48; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A MS4A1 OR CD48; NCAM1 or NKP46;and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK MS4A1 OR CD48; ITGAM,ITGAX, CD1C, or CLEC4C; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCKMS4A1 OR CD48; IL17A or IL17F; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1,CD28, LCK MS4A1 OR CD48; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; andCD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK MS4A1 OR CD48; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCKMS4A1 OR CD48; CD276, PDL1, PDL2, or IDO1; and CD3D, CD3E, CD2, CD3G,CD6, TRAT1, CD28, LCK MS4A1 OR CD48; CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK MS4A1OR CD48; NCAM1 or NKP46; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGITMS4A1 OR CD48; ITGAM, ITGAX, CD1C, or CLEC4C; and CTLA4, BTLA, LAG3,HAVCR2, PDCD1, TIGIT MS4A1 OR CD48; IL17A or IL17F; and CTLA4, BTLA,LAG3, HAVCR2, PDCD1, TIGIT MS4A1 OR CD48; CCL2, IL1B, IL8 (CXCL8), IL6,or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT MS4A1 OR CD48;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT MS4A1 OR CD48; CD276, PDL1, PDL2, or IDO1; and CTLA4, BTLA,LAG3, HAVCR2, PDCD1, TIGIT MS4A1 OR CD48; CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT MS4A1 ORCD48; NCAM1 or NKP46; and CD274, PDL2, IDO1, PVR MS4A1 OR CD48; ITGAM,ITGAX, CD1C, or CLEC4C; and CD274, PDL2, IDO1, PVR MS4A1 OR CD48; IL17Aor IL17F; and CD274, PDL2, IDO1, PVR MS4A1 OR CD48; CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; and CD274, PDL2, IDO1, PVR MS4A1 OR CD48; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD274, PDL2, IDO1, PVR MS4A1 OR CD48;CD276, PDL1, PDL2, or IDO1; and CD274, PDL2, IDO1, PVR MS4A1 OR CD48;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD274, PDL2, IDO1,PVR MS4A1 OR CD48; NCAM1 or NKP46; and CD4, IL2RA, CD69 MS4A1 OR CD48;ITGAM, ITGAX, CD1C, or CLEC4C; and CD4, IL2RA, CD69 MS4A1 OR CD48; IL17Aor IL17F; and CD4, IL2RA, CD69 MS4A1 OR CD48; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and CD4, IL2RA, CD69 MS4A1 OR CD48; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD4, IL2RA, CD69 MS4A1 OR CD48; CD276, PDL1, PDL2,or IDO1; and CD4, IL2RA, CD69 MS4A1 OR CD48; CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22; and CD4, IL2RA, CD69 MS4A1 OR CD48; NCAM1 orNKP46; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 MS4A1 OR CD48; ITGAM, ITGAX,CD1C, or CLEC4C; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 MS4A1 OR CD48;IL17A or IL17F; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 MS4A1 OR CD48; CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; and TAPBP, TAP1, TAP2, PSMB9, PSMB8MS4A1 OR CD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and TAPBP, TAP1,TAP2, PSMB9, PSMB8 MS4A1 OR CD48; CD276, PDL1, PDL2, or IDO1; and TAPBP,TAP1, TAP2, PSMB9, PSMB8 MS4A1 OR CD48; CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 MS4A1 OR CD48;NCAM1 or NKP46; and CD40, CD80, CD86, CD70, GITRL MS4A1 OR CD48; ITGAM,ITGAX, CD1C, or CLEC4C; and CD40, CD80, CD86, CD70, GITRL MS4A1 OR CD48;IL17A or IL17F; and CD40, CD80, CD86, CD70, GITRL MS4A1 OR CD48; CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD40, CD80, CD86, CD70, GITRLMS4A1 OR CD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD40, CD80,CD86, CD70, GITRL MS4A1 OR CD48; CD276, PDL1, PDL2, or IDO1; and CD40,CD80, CD86, CD70, GITRL MS4A1 OR CD48; CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22; and CD40, CD80, CD86, CD70, GITRL MS4A1 OR CD48; NCAM1or NKP46; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 MS4A1 OR CD48; ITGAM, ITGAX, CD1C, or CLEC4C; and CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 MS4A1OR CD48; IL17A or IL17F; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 MS4A1 OR CD48; CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 MS4A1 OR CD48; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 MS4A1 OR CD48; CD276, PDL1, PDL2, or IDO1; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226MS4A1 OR CD48; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 MS4A1OR CD48; NCAM1 or NKP46; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7MS4A1 OR CD48; ITGAM, ITGAX, CD1C, or CLEC4C; and GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, NKG7 MS4A1 OR CD48; IL17A or IL17F; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 MS4A1 OR CD48; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 MS4A1 ORCD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 MS4A1 OR CD48; CD276, PDL1, PDL2, or IDO1; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 MS4A1 OR CD48; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 MS4A1 OR CD48; NCAM1 or NKP46; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 MS4A1 OR CD48;ITGAM, ITGAX, CD1C, or CLEC4C; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 MS4A1 OR CD48; IL17A or IL17F;and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1,COL8A1 MS4A1 OR CD48; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and FAP,FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1MS4A1 OR CD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and FAP, FN1, MMP2,BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 MS4A1 OR CD48;CD276, PDL1, PDL2, or IDO1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 MS4A1 OR CD48; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5NCAM1 or NKP46; IL17A or IL17F; and CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, FCRL5 NCAM1 or NKP46; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2;and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 NCAM1 or NKP46;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, FCRL5 NCAM1 or NKP46; CD276, PDL1, PDL2, or IDO1; andCD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 NCAM1 or NKP46;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, FCRL5 NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; and KLRC3, KLRK1, KLRC2, KLRD1 NCAM1 or NKP46; IL17A or IL17F;and KLRC3, KLRK1, KLRC2, KLRD1 NCAM1 or NKP46; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and KLRC3, KLRK1, KLRC2, KLRD1 NCAM1 or NKP46; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and KLRC3, KLRK1, KLRC2, KLRD1 NCAM1 orNKP46; CD276, PDL1, PDL2, or IDO1; and KLRC3, KLRK1, KLRC2, KLRD1 NCAM1or NKP46; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and KLRC3,KLRK1, KLRC2, KLRD1 NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; andCD68, CD163, ITGAM, ITGAX, CD14 NCAM1 or NKP46; IL17A or IL17F; andCD68, CD163, ITGAM, ITGAX, CD14 NCAM1 or NKP46; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and CD68, CD163, ITGAM, ITGAX, CD14 NCAM1 or NKP46;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD68, CD163, ITGAM, ITGAX, CD14NCAM1 or NKP46; CD276, PDL1, PDL2, or IDO1; and CD68, CD163, ITGAM,ITGAX, CD14 NCAM1 or NKP46; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22; and CD68, CD163, ITGAM, ITGAX, CD14 NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A NCAM1 or NKP46; IL17A orIL17F; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A NCAM1 or NKP46; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A NCAM1 or NKP46; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A NCAM1 or NKP46;CD276, PDL1, PDL2, or IDO1; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A NCAM1 or NKP46;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3ANCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CD3D, CD3E, CD2,CD3G, CD6, TRAT1, CD28, LCK NCAM1 or NKP46; IL17A or IL17F; and CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK NCAM1 or NKP46; CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCKNCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD3D, CD3E,CD2, CD3G, CD6, TRAT1, CD28, LCK NCAM1 or NKP46; CD276, PDL1, PDL2, orIDO1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK NCAM1 or NKP46;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD3D, CD3E, CD2,CD3G, CD6, TRAT1, CD28, LCK NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT NCAM1 or NKP46;IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT NCAM1 orNKP46; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CTLA4, BTLA, LAG3,HAVCR2, PDCD1, TIGIT NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT NCAM1 or NKP46;CD276, PDL1, PDL2, or IDO1; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGITNCAM1 or NKP46; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andCTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; and CD274, PDL2, IDO1, PVR NCAM1 or NKP46; IL17A orIL17F; and CD274, PDL2, IDO1, PVR NCAM1 or NKP46; CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; and CD274, PDL2, IDO1, PVR NCAM1 or NKP46;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD274, PDL2, IDO1, PVR NCAM1 orNKP46; CD276, PDL1, PDL2, or IDO1; and CD274, PDL2, IDO1, PVR NCAM1 orNKP46; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD274, PDL2,IDO1, PVR NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CD4, IL2RA,CD69 NCAM1 or NKP46; IL17A or IL17F; and CD4, IL2RA, CD69 NCAM1 orNKP46; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD4, IL2RA, CD69NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD4, IL2RA,CD69 NCAM1 or NKP46; CD276, PDL1, PDL2, or IDO1; and CD4, IL2RA, CD69NCAM1 or NKP46; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD4,IL2RA, CD69 NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and TAPBP,TAP1, TAP2, PSMB9, PSMB8 NCAM1 or NKP46; IL17A or IL17F; and TAPBP,TAP1, TAP2, PSMB9, PSMB8 NCAM1 or NKP46; CCL2, IL1B, IL8 (CXCL8), IL6,or PTGS2; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 NCAM1 or NKP46; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 NCAM1or NKP46; CD276, PDL1, PDL2, or IDO1; and TAPBP, TAP1, TAP2, PSMB9,PSMB8 NCAM1 or NKP46; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; and CD40, CD80, CD86, CD70, GITRL NCAM1 or NKP46; IL17A orIL17F; and CD40, CD80, CD86, CD70, GITRL NCAM1 or NKP46; CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; and CD40, CD80, CD86, CD70, GITRL NCAM1 orNKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD40, CD80, CD86, CD70,GITRL NCAM1 or NKP46; CD276, PDL1, PDL2, or IDO1; and CD40, CD80, CD86,CD70, GITRL NCAM1 or NKP46; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22; and CD40, CD80, CD86, CD70, GITRL NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 NCAM1 or NKP46; IL17A or IL17F; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 NCAM1 orNKP46; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 NCAM1 or NKP46;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 NCAM1 or NKP46; CD276,PDL1, PDL2, or IDO1; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 NCAM1 or NKP46; CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 NCAM1 or NKP46; IL17A orIL17F; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 NCAM1 or NKP46;CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 NCAM1 or NKP46; CD276,PDL1, PDL2, or IDO1; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7NCAM1 or NKP46; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 NCAM1 or NKP46; IL17A or IL17F; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 NCAM1 orNKP46; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 NCAM1 or NKP46;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 NCAM1 or NKP46; CD276,PDL1, PDL2, or IDO1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 NCAM1 or NKP46; CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; andCD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 ITGAM, ITGAX, CD1C,or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, FCRL5 ITGAM, ITGAX, CD1C, or CLEC4C; CD276,PDL1, PDL2, or IDO1; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1,FCRL5 ITGAM, ITGAX, CD1C, or CLEC4C; CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and KLRC3, KLRK1, KLRC2,KLRD1 ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and KLRC3, KLRK1, KLRC2, KLRD1 ITGAM, ITGAX, CD1C, or CLEC4C;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and KLRC3, KLRK1, KLRC2, KLRD1ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; and KLRC3,KLRK1, KLRC2, KLRD1 ITGAM, ITGAX, CD1C, or CLEC4C; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and KLRC3, KLRK1, KLRC2, KLRD1 ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CD68, CD163, ITGAM, ITGAX,CD14 ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and CD68, CD163, ITGAM, ITGAX, CD14 ITGAM, ITGAX, CD1C, orCLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD68, CD163, ITGAM,ITGAX, CD14 ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1;and CD68, CD163, ITGAM, ITGAX, CD14 ITGAM, ITGAX, CD1C, or CLEC4C;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD68, CD163, ITGAM,ITGAX, CD14 ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and LAPTM5,LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3,FCGR2A, FCGR3A ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A ITGAM, ITGAX, CD1C, or CLEC4C;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A ITGAM,ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; and LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,FCGR3A ITGAM, ITGAX, CD1C, or CLEC4C; CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCKITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2;and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK ITGAM, ITGAX, CD1C, orCLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD3D, CD3E, CD2, CD3G,CD6, TRAT1, CD28, LCK ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2,or IDO1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK ITGAM, ITGAX,CD1C, or CLEC4C; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; andCD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGITITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2;and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT ITGAM, ITGAX, CD1C, orCLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CTLA4, BTLA, LAG3,HAVCR2, PDCD1, TIGIT ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2,or IDO1; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT ITGAM, ITGAX, CD1C,or CLEC4C; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CTLA4,BTLA, LAG3, HAVCR2, PDCD1, TIGIT ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; and CD274, PDL2, IDO1, PVR ITGAM, ITGAX, CD1C, or CLEC4C; CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD274, PDL2, IDO1, PVR ITGAM,ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD274,PDL2, IDO1, PVR ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, orIDO1; and CD274, PDL2, IDO1, PVR ITGAM, ITGAX, CD1C, or CLEC4C; CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD274, PDL2, IDO1, PVR ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CD4, IL2RA, CD69 ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD4,IL2RA, CD69 ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD4, IL2RA, CD69 ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1,PDL2, or IDO1; and CD4, IL2RA, CD69 ITGAM, ITGAX, CD1C, or CLEC4C;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD4, IL2RA, CD69ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 ITGAM, ITGAX, CD1C,or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1;and TAPBP, TAP1, TAP2, PSMB9, PSMB8 ITGAM, ITGAX, CD1C, or CLEC4C;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CD40,CD80, CD86, CD70, GITRL ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; and CD40, CD80, CD86, CD70, GITRL ITGAM, ITGAX,CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD40, CD80,CD86, CD70, GITRL ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, orIDO1; and CD40, CD80, CD86, CD70, GITRL ITGAM, ITGAX, CD1C, or CLEC4C;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD40, CD80, CD86,CD70, GITRL ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; and CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 ITGAM,ITGAX, CD1C, or CLEC4C; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22;and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,CD226 ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 ITGAM, ITGAX, CD1C, or CLEC4C; CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 ITGAM, ITGAX,CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; and GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, NKG7 ITGAM, ITGAX, CD1C, or CLEC4C; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and FAP,FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andFAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 ITGAM,ITGAX, CD1C, or CLEC4C; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22;and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1,COL8A1 IL17A or IL17F; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; andCD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, FCRL5 IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; andCD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 IL17A or IL17F;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, FCRL5 IL17A or IL17F; CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; and KLRC3, KLRK1, KLRC2, KLRD1 IL17A or IL17F; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and KLRC3, KLRK1, KLRC2, KLRD1 IL17A orIL17F; CD276, PDL1, PDL2, or IDO1; and KLRC3, KLRK1, KLRC2, KLRD1 IL17Aor IL17F; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and KLRC3,KLRK1, KLRC2, KLRD1 IL17A or IL17F; CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and CD68, CD163, ITGAM, ITGAX, CD14 IL17A or IL17F; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD68, CD163, ITGAM, ITGAX, CD14 IL17A orIL17F; CD276, PDL1, PDL2, or IDO1; and CD68, CD163, ITGAM, ITGAX, CD14IL17A or IL17F; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD68,CD163, ITGAM, ITGAX, CD14 IL17A or IL17F; CCL2, IL1B, IL8 (CXCL8), IL6,or PTGS2; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A IL17A or IL17F; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A IL17A or IL17F;CD276, PDL1, PDL2, or IDO1; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A IL17A or IL17F;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3AIL17A or IL17F; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD3D, CD3E,CD2, CD3G, CD6, TRAT1, CD28, LCK IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK IL17Aor IL17F; CD276, PDL1, PDL2, or IDO1; and CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK IL17A or IL17F; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK IL17A or IL17F;CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT IL17A or IL17F; CD276, PDL1,PDL2, or IDO1; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT IL17A orIL17F; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CTLA4, BTLA,LAG3, HAVCR2, PDCD1, TIGIT IL17A or IL17F; CCL2, IL1B, IL8 (CXCL8), IL6,or PTGS2; and CD274, PDL2, IDO1, PVR IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD274, PDL2, IDO1, PVR IL17A or IL17F; CD276,PDL1, PDL2, or IDO1; and CD274, PDL2, IDO1, PVR IL17A or IL17F; CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD274, PDL2, IDO1, PVR IL17Aor IL17F; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and CD4, IL2RA, CD69IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD4, IL2RA,CD69 IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CD4, IL2RA, CD69IL17A or IL17F; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD4,IL2RA, CD69 IL17A or IL17F; CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 IL17A or IL17F;CD276, PDL1, PDL2, or IDO1; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 IL17A orIL17F; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and TAPBP, TAP1,TAP2, PSMB9, PSMB8 IL17A or IL17F; CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and CD40, CD80, CD86, CD70, GITRL IL17A or IL17F; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD40, CD80, CD86, CD70, GITRL IL17A orIL17F; CD276, PDL1, PDL2, or IDO1; and CD40, CD80, CD86, CD70, GITRLIL17A or IL17F; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD40,CD80, CD86, CD70, GITRL IL17A or IL17F; CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 IL17A or IL17F;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 IL17A or IL17F;CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 IL17A or IL17F; CD276,PDL1, PDL2, or IDO1; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7IL17A or IL17F; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 IL17A or IL17F; CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; andFAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1IL17A or IL17F; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and FAP,FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and KLRC3, KLRK1,KLRC2, KLRD1 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CD276, PDL1, PDL2,or IDO1; and KLRC3, KLRK1, KLRC2, KLRD1 CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and KLRC3, KLRK1,KLRC2, KLRD1 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD68, CD163, ITGAM, ITGAX, CD14 CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CD68, CD163,ITGAM, ITGAX, CD14 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD68, CD163, ITGAM, ITGAX,CD14 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; CD276, PDL1, PDL2, or IDO1; and LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CCL2, IL1B,IL8 (CXCL8), IL6, or PTGS2; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CD276, PDL1,PDL2, or IDO1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CCL2, IL1B,IL8 (CXCL8), IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; CD276, PDL1, PDL2, or IDO1; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1,TIGIT CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGITCCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD274, PDL2, IDO1, PVR CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; CD276, PDL1, PDL2, or IDO1; and CD274, PDL2, IDO1, PVR CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22; and CD274, PDL2, IDO1, PVR CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD4, IL2RA, CD69 CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CD4,IL2RA, CD69 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and CD4, IL2RA, CD69 CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and TAPBP,TAP1, TAP2, PSMB9, PSMB8 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CD276,PDL1, PDL2, or IDO1; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CCL2, IL1B, IL8(CXCL8), IL6, or PTGS2; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22;and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD40, CD80, CD86, CD70,GITRL CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CD276, PDL1, PDL2, orIDO1; and CD40, CD80, CD86, CD70, GITRL CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD40, CD80,CD86, CD70, GITRL CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CCL2, IL1B, IL8 (CXCL8), IL6, orPTGS2; CD276, PDL1, PDL2, or IDO1; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CCL2,IL1B, IL8 (CXCL8), IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CCL2, IL1B, IL8 (CXCL8),IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2; CD276,PDL1, PDL2, or IDO1; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 CCL2, IL1B, IL8 (CXCL8), IL6, or PTGS2;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, FCRL5 CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, FCRL5 CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and KLRC3, KLRK1, KLRC2, KLRD1 CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22;and KLRC3, KLRK1, KLRC2, KLRD1 CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CD68, CD163, ITGAM, ITGAX, CD14 CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22; and CD68, CD163, ITGAM, ITGAX, CD14 CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; CD276, PDL1, PDL2, or IDO1; and LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22;and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA,MSR1, FPR3, FCGR2A, FCGR3A CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276,PDL1, PDL2, or IDO1; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCKCTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CTLA4,BTLA, LAG3, HAVCR2, PDCD1, TIGIT CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CTLA4, BTLA, LAG3,HAVCR2, PDCD1, TIGIT CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CD274, PDL2, IDO1, PVR CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD274, PDL2,IDO1, PVR CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, orIDO1; and CD4, IL2RA, CD69 CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD4, IL2RA, CD69 CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and TAPBP, TAP1,TAP2, PSMB9, PSMB8 CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and TAPBP, TAP1, TAP2, PSMB9, PSMB8CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCD40, CD80, CD86, CD70, GITRL CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22; and CD40, CD80, CD86,CD70, GITRL CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, orIDO1; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7 CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5;KLRC3, KLRK1, KLRC2, or KLRD1; and CD68, CD163, ITGAM, ITGAX, CD14CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; KLRC3, KLRK1,KLRC2, or KLRD1; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; KLRC3, KLRK1, KLRC2, or KLRD1; and CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; KLRC3, KLRK1, KLRC2, or KLRD1; and CTLA4,BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; KLRC3, KLRK1, KLRC2, or KLRD1; and CD274, PDL2, IDO1,PVR CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; KLRC3,KLRK1, KLRC2, or KLRD1; and CD4, IL2RA, CD69 CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; KLRC3, KLRK1, KLRC2, or KLRD1; and TAPBP,TAP1, TAP2, PSMB9, PSMB8 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1,or FCRL5; KLRC3, KLRK1, KLRC2, or KLRD1; and CD40, CD80, CD86, CD70,GITRL CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; KLRC3,KLRK1, KLRC2, or KLRD1; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; KLRC3, KLRK1, KLRC2, or KLRD1; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; KLRC3, KLRK1, KLRC2, or KLRD1; and FAP, FN1, MMP2,BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD68, CD163, ITGAM, ITGAX, orCD14; and LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; CD68, CD163, ITGAM, ITGAX, or CD14; and CD3D, CD3E,CD2, CD3G, CD6, TRAT1, CD28, LCK CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; CD68, CD163, ITGAM, ITGAX, or CD14; and CTLA4, BTLA,LAG3, HAVCR2, PDCD1, TIGIT CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1,or FCRL5; CD68, CD163, ITGAM, ITGAX, or CD14; and CD274, PDL2, IDO1, PVRCD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD68, CD163,ITGAM, ITGAX, or CD14; and CD4, IL2RA, CD69 CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; CD68, CD163, ITGAM, ITGAX, or CD14; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; CD68, CD163, ITGAM, ITGAX, or CD14; and CD40, CD80,CD86, CD70, GITRL CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, orFCRL5; CD68, CD163, ITGAM, ITGAX, or CD14; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD68, CD163, ITGAM, ITGAX, orCD14; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD68, CD163, ITGAM, ITGAX, orCD14; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5;LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, or FCGR3A; and CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28,LCK CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; LAPTM5,LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3,FCGR2A, or FCGR3A; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, orFCGR3A; and CD274, PDL2, IDO1, PVR CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and CD4, IL2RA, CD69 CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, orFCGR3A; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and CD40, CD80,CD86, CD70, GITRL CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, orFCRL5; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA,MSR1, FPR3, FCGR2A, or FCGR3A; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, NKG7 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, orFCRL5; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA,MSR1, FPR3, FCGR2A, or FCGR3A; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, orLCK; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, or FCRL5; CD3D, CD3E, CD2, CD3G, CD6, TRAT1,CD28, or LCK; and CD274, PDL2, IDO1, PVR CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, orLCK; and CD4, IL2RA, CD69 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1,or FCRL5; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and TAPBP,TAP1, TAP2, PSMB9, PSMB8 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1,or FCRL5; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and CD40,CD80, CD86, CD70, GITRL CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, orFCRL5; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD3D, CD3E, CD2, CD3G,CD6, TRAT1, CD28, or LCK; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD3D, CD3E,CD2, CD3G, CD6, TRAT1, CD28, or LCK; and FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT;and CD274, PDL2, IDO1, PVR CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1,or FCRL5; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and CD4, IL2RA,CD69 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CTLA4,BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and TAPBP, TAP1, TAP2, PSMB9, PSMB8CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CTLA4, BTLA,LAG3, HAVCR2, PDCD1, or TIGIT; and CD40, CD80, CD86, CD70, GITRL CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CTLA4, BTLA, LAG3,HAVCR2, PDCD1, or TIGIT; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT;and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1,COL8A1 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD274,PDL2, IDO1, or PVR; and CD4, IL2RA, CD69 CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; CD274, PDL2, IDO1, or PVR; and TAPBP, TAP1,TAP2, PSMB9, PSMB8 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, orFCRL5; CD274, PDL2, IDO1, or PVR; and CD40, CD80, CD86, CD70, GITRLCD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD274, PDL2,IDO1, or PVR; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1,or FCRL5; CD274, PDL2, IDO1, or PVR; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5;CD274, PDL2, IDO1, or PVR; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 CD79A, MS4A1, CD19, STAP1, KIAA0125,POU2AF1, or FCRL5; CD4, IL2RA, or CD69; and TAPBP, TAP1, TAP2, PSMB9,PSMB8 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD4,IL2RA, or CD69; and CD40, CD80, CD86, CD70, GITRL CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, or FCRL5; CD4, IL2RA, or CD69; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD4, IL2RA, or CD69;and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, or FCRL5; CD4, IL2RA, or CD69; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; TAPBP, TAP1, TAP2,PSMB9, or PSMB8; and CD40, CD80, CD86, CD70, GITRL CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, or FCRL5; TAPBP, TAP1, TAP2, PSMB9, or PSMB8;and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,CD226 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; TAPBP,TAP1, TAP2, PSMB9, or PSMB8; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; TAPBP,TAP1, TAP2, PSMB9, or PSMB8; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, or FCRL5; CD40, CD80, CD86, CD70, or GITRL; and CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD79A,MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD40, CD80, CD86, CD70,or GITRL; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD40, CD80, CD86, CD70, orGITRL; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5;CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, orCD226; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, or CD226; and FAP, FN1, MMP2,BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, or FCRL5; GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, or NKG7; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 KLRC3, KLRK1, KLRC2, or KLRD1; CD68,CD163, ITGAM, ITGAX, or CD14; and LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, FCGR3A KLRC3, KLRK1,KLRC2, or KLRD1; CD68, CD163, ITGAM, ITGAX, or CD14; and CD3D, CD3E,CD2, CD3G, CD6, TRAT1, CD28, LCK KLRC3, KLRK1, KLRC2, or KLRD1; CD68,CD163, ITGAM, ITGAX, or CD14; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1,TIGIT KLRC3, KLRK1, KLRC2, or KLRD1; CD68, CD163, ITGAM, ITGAX, or CD14;and CD274, PDL2, IDO1, PVR KLRC3, KLRK1, KLRC2, or KLRD1; CD68, CD163,ITGAM, ITGAX, or CD14; and CD4, IL2RA, CD69 KLRC3, KLRK1, KLRC2, orKLRD1; CD68, CD163, ITGAM, ITGAX, or CD14; and TAPBP, TAP1, TAP2, PSMB9,PSMB8 KLRC3, KLRK1, KLRC2, or KLRD1; CD68, CD163, ITGAM, ITGAX, or CD14;and CD40, CD80, CD86, CD70, GITRL KLRC3, KLRK1, KLRC2, or KLRD1; CD68,CD163, ITGAM, ITGAX, or CD14; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 KLRC3, KLRK1, KLRC2, or KLRD1; CD68,CD163, ITGAM, ITGAX, or CD14; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7 KLRC3, KLRK1, KLRC2, or KLRD1; CD68, CD163, ITGAM, ITGAX, or CD14;and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1,COL8A1 KLRC3, KLRK1, KLRC2, or KLRD1; LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, LCK KLRC3, KLRK1, KLRC2, or KLRD1;LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, or FCGR3A; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGITKLRC3, KLRK1, KLRC2, or KLRD1; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and CD274, PDL2,IDO1, PVR KLRC3, KLRK1, KLRC2, or KLRD1; LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A;and CD4, IL2RA, CD69 KLRC3, KLRK1, KLRC2, or KLRD1; LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, orFCGR3A; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 KLRC3, KLRK1, KLRC2, orKLRD1; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA,MSR1, FPR3, FCGR2A, or FCGR3A; and CD40, CD80, CD86, CD70, GITRL KLRC3,KLRK1, KLRC2, or KLRD1; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 KLRC3, KLRK1,KLRC2, or KLRD1; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, NKG7 KLRC3, KLRK1, KLRC2, or KLRD1; LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,or FCGR3A; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 KLRC3, KLRK1, KLRC2, or KLRD1; CD3D, CD3E, CD2, CD3G,CD6, TRAT1, CD28, or LCK; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGITKLRC3, KLRK1, KLRC2, or KLRD1; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28,or LCK; and CD274, PDL2, IDO1, PVR KLRC3, KLRK1, KLRC2, or KLRD1; CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and CD4, IL2RA, CD69 KLRC3,KLRK1, KLRC2, or KLRD1; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK;and TAPBP, TAP1, TAP2, PSMB9, PSMB8 KLRC3, KLRK1, KLRC2, or KLRD1; CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and CD40, CD80, CD86, CD70,GITRL KLRC3, KLRK1, KLRC2, or KLRD1; CD3D, CD3E, CD2, CD3G, CD6, TRAT1,CD28, or LCK; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 KLRC3, KLRK1, KLRC2, or KLRD1; CD3D, CD3E, CD2,CD3G, CD6, TRAT1, CD28, or LCK; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 KLRC3, KLRK1, KLRC2, or KLRD1; CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, or LCK; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 KLRC3, KLRK1, KLRC2, or KLRD1; CTLA4,BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and CD274, PDL2, IDO1, PVR KLRC3,KLRK1, KLRC2, or KLRD1; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; andCD4, IL2RA, CD69 KLRC3, KLRK1, KLRC2, or KLRD1; CTLA4, BTLA, LAG3,HAVCR2, PDCD1, or TIGIT; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 KLRC3,KLRK1, KLRC2, or KLRD1; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; andCD40, CD80, CD86, CD70, GITRL KLRC3, KLRK1, KLRC2, or KLRD1; CTLA4,BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 KLRC3, KLRK1, KLRC2, orKLRD1; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 KLRC3, KLRK1, KLRC2, or KLRD1; CTLA4,BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 KLRC3, KLRK1, KLRC2, orKLRD1; CD274, PDL2, IDO1, or PVR; and CD4, IL2RA, CD69 KLRC3, KLRK1,KLRC2, or KLRD1; CD274, PDL2, IDO1, or PVR; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 KLRC3, KLRK1, KLRC2, or KLRD1; CD274, PDL2, IDO1, or PVR;and CD40, CD80, CD86, CD70, GITRL KLRC3, KLRK1, KLRC2, or KLRD1; CD274,PDL2, IDO1, or PVR; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 KLRC3, KLRK1, KLRC2, or KLRD1; CD274, PDL2,IDO1, or PVR; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 KLRC3,KLRK1, KLRC2, or KLRD1; CD274, PDL2, IDO1, or PVR; and FAP, FN1, MMP2,BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 KLRC3, KLRK1,KLRC2, or KLRD1; CD4, IL2RA, or CD69; and TAPBP, TAP1, TAP2, PSMB9,PSMB8 KLRC3, KLRK1, KLRC2, or KLRD1; CD4, IL2RA, or CD69; and CD40,CD80, CD86, CD70, GITRL KLRC3, KLRK1, KLRC2, or KLRD1; CD4, IL2RA, orCD69; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 KLRC3, KLRK1, KLRC2, or KLRD1; CD4, IL2RA, or CD69; andGNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 KLRC3, KLRK1, KLRC2, orKLRD1; CD4, IL2RA, or CD69; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 KLRC3, KLRK1, KLRC2, or KLRD1;TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and CD40, CD80, CD86, CD70, GITRLKLRC3, KLRK1, KLRC2, or KLRD1; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226KLRC3, KLRK1, KLRC2, or KLRD1; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; andGNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 KLRC3, KLRK1, KLRC2, orKLRD1; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 KLRC3, KLRK1, KLRC2,or KLRD1; CD40, CD80, CD86, CD70, or GITRL; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 KLRC3, KLRK1,KLRC2, or KLRD1; CD40, CD80, CD86, CD70, or GITRL; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 KLRC3, KLRK1, KLRC2, or KLRD1; CD40,CD80, CD86, CD70, or GITRL; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 KLRC3, KLRK1, KLRC2, or KLRD1;CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, orCD226; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 KLRC3, KLRK1,KLRC2, or KLRD1; CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, or CD226; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 KLRC3, KLRK1, KLRC2, or KLRD1;GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD68, CD163, ITGAM,ITGAX, or CD14; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and CD3D, CD3E, CD2, CD3G,CD6, TRAT1, CD28, LCK CD68, CD163, ITGAM, ITGAX, or CD14; LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,or FCGR3A; and CTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD68, CD163,ITGAM, ITGAX, or CD14; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and CD274, PDL2, IDO1,PVR CD68, CD163, ITGAM, ITGAX, or CD14; LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A;and CD4, IL2RA, CD69 CD68, CD163, ITGAM, ITGAX, or CD14; LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,or FCGR3A; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD68, CD163, ITGAM,ITGAX, or CD14; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and CD40, CD80, CD86, CD70,GITRL CD68, CD163, ITGAM, ITGAX, or CD14; LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A;and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,CD226 CD68, CD163, ITGAM, ITGAX, or CD14; LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A;and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD68, CD163, ITGAM,ITGAX, or CD14; LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD68, CD163, ITGAM,ITGAX, or CD14; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; andCTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT CD68, CD163, ITGAM, ITGAX, orCD14; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and CD274, PDL2,IDO1, PVR CD68, CD163, ITGAM, ITGAX, or CD14; CD3D, CD3E, CD2, CD3G,CD6, TRAT1, CD28, or LCK; and CD4, IL2RA, CD69 CD68, CD163, ITGAM,ITGAX, or CD14; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; andTAPBP, TAP1, TAP2, PSMB9, PSMB8 CD68, CD163, ITGAM, ITGAX, or CD14;CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and CD40, CD80, CD86,CD70, GITRL CD68, CD163, ITGAM, ITGAX, or CD14; CD3D, CD3E, CD2, CD3G,CD6, TRAT1, CD28, or LCK; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CD68, CD163, ITGAM, ITGAX, or CD14;CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, NKG7 CD68, CD163, ITGAM, ITGAX, or CD14; CD3D, CD3E,CD2, CD3G, CD6, TRAT1, CD28, or LCK; and FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD68, CD163, ITGAM, ITGAX,or CD14; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and CD274, PDL2,IDO1, PVR CD68, CD163, ITGAM, ITGAX, or CD14; CTLA4, BTLA, LAG3, HAVCR2,PDCD1, or TIGIT; and CD4, IL2RA, CD69 CD68, CD163, ITGAM, ITGAX, orCD14; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 CD68, CD163, ITGAM, ITGAX, or CD14; CTLA4, BTLA, LAG3,HAVCR2, PDCD1, or TIGIT; and CD40, CD80, CD86, CD70, GITRL CD68, CD163,ITGAM, ITGAX, or CD14; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226CD68, CD163, ITGAM, ITGAX, or CD14; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, orTIGIT; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD68, CD163,ITGAM, ITGAX, or CD14; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; andFAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1CD68, CD163, ITGAM, ITGAX, or CD14; CD274, PDL2, IDO1, or PVR; and CD4,IL2RA, CD69 CD68, CD163, ITGAM, ITGAX, or CD14; CD274, PDL2, IDO1, orPVR; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD68, CD163, ITGAM, ITGAX, orCD14; CD274, PDL2, IDO1, or PVR; and CD40, CD80, CD86, CD70, GITRL CD68,CD163, ITGAM, ITGAX, or CD14; CD274, PDL2, IDO1, or PVR; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD68, CD163,ITGAM, ITGAX, or CD14; CD274, PDL2, IDO1, or PVR; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 CD68, CD163, ITGAM, ITGAX, or CD14;CD274, PDL2, IDO1, or PVR; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 CD68, CD163, ITGAM, ITGAX, or CD14; CD4,IL2RA, or CD69; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD68, CD163, ITGAM,ITGAX, or CD14; CD4, IL2RA, or CD69; and CD40, CD80, CD86, CD70, GITRLCD68, CD163, ITGAM, ITGAX, or CD14; CD4, IL2RA, or CD69; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD68, CD163,ITGAM, ITGAX, or CD14; CD4, IL2RA, or CD69; and GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, NKG7 CD68, CD163, ITGAM, ITGAX, or CD14; CD4, IL2RA,or CD69; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD68, CD163, ITGAM, ITGAX, or CD14; TAPBP, TAP1, TAP2,PSMB9, or PSMB8; and CD40, CD80, CD86, CD70, GITRL CD68, CD163, ITGAM,ITGAX, or CD14; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD68, CD163,ITGAM, ITGAX, or CD14; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD68, CD163, ITGAM, ITGAX, orCD14; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD68, CD163, ITGAM,ITGAX, or CD14; CD40, CD80, CD86, CD70, or GITRL; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD68, CD163,ITGAM, ITGAX, or CD14; CD40, CD80, CD86, CD70, or GITRL; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD68, CD163, ITGAM, ITGAX, orCD14; CD40, CD80, CD86, CD70, or GITRL; and FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD68, CD163, ITGAM, ITGAX,or CD14; CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, or CD226; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD68,CD163, ITGAM, ITGAX, or CD14; CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, or CD226; and FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD68, CD163, ITGAM, ITGAX,or CD14; GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 LAPTM5,LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3,FCGR2A, or FCGR3A; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; andCTLA4, BTLA, LAG3, HAVCR2, PDCD1, TIGIT LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A;CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and CD274, PDL2, IDO1,PVR LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA,MSR1, FPR3, FCGR2A, or FCGR3A; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28,or LCK; and CD4, IL2RA, CD69 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD3D, CD3E, CD2,CD3G, CD6, TRAT1, CD28, or LCK; and TAPBP, TAP1, TAP2, PSMB9, PSMB8LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, or FCGR3A; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, orLCK; and CD40, CD80, CD86, CD70, GITRL LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,or FCGR3A; CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 LAPTM5, LAIR1, CD4,CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, orFCGR3A; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and CD274, PDL2,IDO1, PVR LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, orTIGIT; and CD4, IL2RA, CD69 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CTLA4, BTLA,LAG3, HAVCR2, PDCD1, or TIGIT; and TAPBP, TAP1, TAP2, PSMB9, PSMB8LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, or FCGR3A; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; andCD40, CD80, CD86, CD70, GITRL LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CTLA4, BTLA,LAG3, HAVCR2, PDCD1, or TIGIT; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CTLA4,BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, orTIGIT; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD274, PDL2, IDO1, or PVR;and CD4, IL2RA, CD69 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD274, PDL2, IDO1, orPVR; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A;CD274, PDL2, IDO1, or PVR; and CD40, CD80, CD86, CD70, GITRL LAPTM5,LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3,FCGR2A, or FCGR3A; CD274, PDL2, IDO1, or PVR; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,or FCGR3A; CD274, PDL2, IDO1, or PVR; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD274, PDL2, IDO1, or PVR;and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1,COL8A1 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA,MSR1, FPR3, FCGR2A, or FCGR3A; CD4, IL2RA, or CD69; and TAPBP, TAP1,TAP2, PSMB9, PSMB8 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD4, IL2RA, or CD69; andCD40, CD80, CD86, CD70, GITRL LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD4, IL2RA, orCD69; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1,CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD4, IL2RA, or CD69; andGNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 LAPTM5, LAIR1, CD4, CSF1R,CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A;CD4, IL2RA, or CD69; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2,CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; TAPBP, TAP1,TAP2, PSMB9, or PSMB8; and CD40, CD80, CD86, CD70, GITRL LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,or FCGR3A; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,or FCGR3A; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, NKG7 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; TAPBP, TAP1, TAP2,PSMB9, or PSMB8; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD40, CD80, CD86,CD70, or GITRL; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; CD40, CD80, CD86,CD70, or GITRL; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 LAPTM5,LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3,FCGR2A, or FCGR3A; CD40, CD80, CD86, CD70, or GITRL; and FAP, FN1, MMP2,BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 LAPTM5, LAIR1,CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A,or FCGR3A; CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, or CD226; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, or FCGR3A; CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, or CD226; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 LAPTM5, LAIR1, CD4, CSF1R, CD163,ADAP2, CD68, MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, or FCGR3A; GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD3D, CD3E, CD2,CD3G, CD6, TRAT1, CD28, or LCK; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, orTIGIT; and CD274, PDL2, IDO1, PVR CD3D, CD3E, CD2, CD3G, CD6, TRAT1,CD28, or LCK; CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and CD4,IL2RA, CD69 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; CTLA4,BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and TAPBP, TAP1, TAP2, PSMB9, PSMB8CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; CTLA4, BTLA, LAG3,HAVCR2, PDCD1, or TIGIT; and CD40, CD80, CD86, CD70, GITRL CD3D, CD3E,CD2, CD3G, CD6, TRAT1, CD28, or LCK; CTLA4, BTLA, LAG3, HAVCR2, PDCD1,or TIGIT; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; CTLA4,BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; CTLA4,BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; and FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, or LCK; CD274, PDL2, IDO1, or PVR; and CD4, IL2RA, CD69CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; CD274, PDL2, IDO1, orPVR; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, or LCK; CD274, PDL2, IDO1, or PVR; and CD40, CD80, CD86,CD70, GITRL CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; CD274,PDL2, IDO1, or PVR; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, orLCK; CD274, PDL2, IDO1, or PVR; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; CD274,PDL2, IDO1, or PVR; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28,or LCK; CD4, IL2RA, or CD69; and TAPBP, TAP1, TAP2, PSMB9, PSMB8 CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; CD4, IL2RA, or CD69; andCD40, CD80, CD86, CD70, GITRL CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28,or LCK; CD4, IL2RA, or CD69; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, CD226 CD3D, CD3E, CD2, CD3G, CD6, TRAT1,CD28, or LCK; CD4, IL2RA, or CD69; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; CD4, IL2RA,or CD69; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; TAPBP,TAP1, TAP2, PSMB9, or PSMB8; and CD40, CD80, CD86, CD70, GITRL CD3D,CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; TAPBP, TAP1, TAP2, PSMB9, orPSMB8; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; TAPBP,TAP1, TAP2, PSMB9, or PSMB8; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; TAPBP, TAP1, TAP2,PSMB9, or PSMB8; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK;CD40, CD80, CD86, CD70, or GITRL; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, or LCK; CD40, CD80, CD86, CD70, or GITRL; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28,or LCK; CD40, CD80, CD86, CD70, or GITRL; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD3D, CD3E, CD2,CD3G, CD6, TRAT1, CD28, or LCK; CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, or CD226; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; CD27,CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, or CD226;and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1,COL8A1 CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK; GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, or NKG7; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CTLA4, BTLA, LAG3, HAVCR2, PDCD1,or TIGIT; CD274, PDL2, IDO1, or PVR; and CD4, IL2RA, CD69 CTLA4, BTLA,LAG3, HAVCR2, PDCD1, or TIGIT; CD274, PDL2, IDO1, or PVR; and TAPBP,TAP1, TAP2, PSMB9, PSMB8 CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT;CD274, PDL2, IDO1, or PVR; and CD40, CD80, CD86, CD70, GITRL CTLA4,BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; CD274, PDL2, IDO1, or PVR; andCD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; CD274, PDL2, IDO1, or PVR;and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CTLA4, BTLA, LAG3,HAVCR2, PDCD1, or TIGIT; CD274, PDL2, IDO1, or PVR; and FAP, FN1, MMP2,BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CTLA4, BTLA,LAG3, HAVCR2, PDCD1, or TIGIT; CD4, IL2RA, or CD69; and TAPBP, TAP1,TAP2, PSMB9, PSMB8 CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; CD4,IL2RA, or CD69; and CD40, CD80, CD86, CD70, GITRL CTLA4, BTLA, LAG3,HAVCR2, PDCD1, or TIGIT; CD4, IL2RA, or CD69; and CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CTLA4, BTLA, LAG3,HAVCR2, PDCD1, or TIGIT; CD4, IL2RA, or CD69; and GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, NKG7 CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; CD4,IL2RA, or CD69; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1,COL4A2, COL5A1, COL8A1 CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT;TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and CD40, CD80, CD86, CD70, GITRLCTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; TAPBP, TAP1, TAP2, PSMB9, orPSMB8; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; TAPBP, TAP1,TAP2, PSMB9, or PSMB8; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; TAPBP, TAP1, TAP2, PSMB9, orPSMB8; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; CD40, CD80,CD86, CD70, or GITRL; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFRSF14, TNFSF14, CD226 CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT;CD40, CD80, CD86, CD70, or GITRL; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT; CD40, CD80,CD86, CD70, or GITRL; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 CTLA4, BTLA, LAG3, HAVCR2, PDCD1, orTIGIT; CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,or CD226; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CTLA4, BTLA,LAG3, HAVCR2, PDCD1, or TIGIT; CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, or CD226; and FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CTLA4, BTLA, LAG3, HAVCR2,PDCD1, or TIGIT; GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; andFAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1CD274, PDL2, IDO1, or PVR; CD4, IL2RA, or CD69; and TAPBP, TAP1, TAP2,PSMB9, PSMB8 CD274, PDL2, IDO1, or PVR; CD4, IL2RA, or CD69; and CD40,CD80, CD86, CD70, GITRL CD274, PDL2, IDO1, or PVR; CD4, IL2RA, or CD69;and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,CD226 CD274, PDL2, IDO1, or PVR; CD4, IL2RA, or CD69; and GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, NKG7 CD274, PDL2, IDO1, or PVR; CD4, IL2RA, orCD69; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD274, PDL2, IDO1, or PVR; TAPBP, TAP1, TAP2, PSMB9, orPSMB8; and CD40, CD80, CD86, CD70, GITRL CD274, PDL2, IDO1, or PVR;TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD274, PDL2, IDO1, or PVR;TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and GNLY, KLRK1, KLRB1, GZMH, GZMA,KLRD1, NKG7 CD274, PDL2, IDO1, or PVR; TAPBP, TAP1, TAP2, PSMB9, orPSMB8; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD274, PDL2, IDO1, or PVR; CD40, CD80, CD86, CD70, orGITRL; and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, CD226 CD274, PDL2, IDO1, or PVR; CD40, CD80, CD86, CD70, orGITRL; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD274, PDL2,IDO1, or PVR; CD40, CD80, CD86, CD70, or GITRL; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD274, PDL2, IDO1,or PVR; CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14,TNFSF14, or CD226; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7CD274, PDL2, IDO1, or PVR; CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, or CD226; and FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD274, PDL2, IDO1, or PVR;GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; and FAP, FN1, MMP2, BGN,LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD4, IL2RA, or CD69;TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and CD40, CD80, CD86, CD70, GITRLCD4, IL2RA, or CD69; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, CD226 CD4, IL2RA,or CD69; TAPBP, TAP1, TAP2, PSMB9, or PSMB8; and GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, NKG7 CD4, IL2RA, or CD69; TAPBP, TAP1, TAP2, PSMB9,or PSMB8; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD4, IL2RA, or CD69; CD40, CD80, CD86, CD70, or GITRL;and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,CD226 CD4, IL2RA, or CD69; CD40, CD80, CD86, CD70, or GITRL; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD4, IL2RA, or CD69; CD40, CD80,CD86, CD70, or GITRL; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, COL8A1 CD4, IL2RA, or CD69; CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, or CD226; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD4, IL2RA, or CD69; CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, or CD226; and FAP,FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD4,IL2RA, or CD69; GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; and FAP,FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1TAPBP, TAP1, TAP2, PSMB9, or PSMB8; CD40, CD80, CD86, CD70, or GITRL;and CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14,CD226 TAPBP, TAP1, TAP2, PSMB9, or PSMB8; CD40, CD80, CD86, CD70, orGITRL; and GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 TAPBP, TAP1,TAP2, PSMB9, or PSMB8; CD40, CD80, CD86, CD70, or GITRL; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 TAPBP,TAP1, TAP2, PSMB9, or PSMB8; CD27, CD28, ICOS, TNFRSF4, TNFRSF14,TNFRSF18, TNFRSF14, TNFSF14, or CD226; and GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, NKG7 TAPBP, TAP1, TAP2, PSMB9, or PSMB8; CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, or CD226; and FAP, FN1,MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 TAPBP,TAP1, TAP2, PSMB9, or PSMB8; GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, orNKG7; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD40, CD80, CD86, CD70, or GITRL; CD27, CD28, ICOS,TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, or CD226; and GNLY,KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 CD40, CD80, CD86, CD70, or GITRL;CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, orCD226; and FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2,COL5A1, COL8A1 CD40, CD80, CD86, CD70, or GITRL; GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, or NKG7; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1 CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFRSF14, TNFSF14, or CD226; GNLY, KLRK1, KLRB1,GZMH, GZMA, KLRD1, or NKG7; and FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1

In another embodiment, the expression levels of one or more of the genesin an immune cell gene signature in four particular gene signature setsare determined. For example, combinations of four particular genesignature sets are set forth in Table 4 below.

TABLE 4 Combinations of four gene signature sets CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; and NCAM1 or NKP46. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; and ITGAM, ITGAX,CD1C, or CLEC4C. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 orCD48; and IL17A or IL17F. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1or CD48; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; NCAM1 or NKP46; and ITGAM, ITGAX, CD1C, or CLEC4C. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; and IL17A orIL17F. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46;and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; NCAM1 or NKP46; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; ITGAM, ITGAX, CD1C, CLEC4C, and IL17A or IL17F. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, CLEC4C, and CCL2, IL1B,IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;ITGAM, ITGAX, CD1C, CLEC4C, and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C,CLEC4C, and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; IL17A or IL17F; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; CCL2, IL1B, IL8, IL6, or PTGS2; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; and ITGAM, ITGAX,CD1C, or CLEC4C. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;NCAM1 or NKP46; and IL17A or IL17F. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; NCAM1 or NKP46; and CCL2, IL1B, IL8, IL6, or PTGS2.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; MS4A1 or CD48; NCAM1 or NKP46; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX,CD1C, CLEC4C, and IL17A or IL17F. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, CLEC4C, and CCL2, IL1B, IL8,IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;ITGAM, ITGAX, CD1C, CLEC4C, and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX,CD1C, CLEC4C, and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; IL17A or IL17F; and CCL2, IL1B, IL8, IL6,or PTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; IL17Aor IL17F; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; IL17A or IL17F; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; CCL2, IL1B, IL8,IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, CLEC4C, and IL17A or IL17F. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,CLEC4C, and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, CLEC4C, and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, CLEC4C, and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; IL17A orIL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; NCAM1 or NKP46; IL17A or IL17F; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 orNKP46; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276,PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 orNKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C,CLEC4C, IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, CLEC4C, IL17A or IL17F;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; ITGAM, ITGAX, CD1C, CLEC4C, IL17A or IL17F; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX,CD1C, CLEC4C, CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX,CD1C, CLEC4C, CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C,CLEC4C, CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; CCL2, IL1B, IL8, IL6,or PTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276,PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B,IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276,PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; and ITGAM,ITGAX, CD1C, or CLEC4C. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; and IL17Aor IL17F. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; and CCL2, IL1B, IL8,IL6, or PTGS2. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; and CD276,PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, CLEC4C,and IL17A or IL17F. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, CLEC4C;and CCL2, IL1B, IL8, IL6, or PTGS2. FOXP3; MS4A1 or CD48; ITGAM, ITGAX,CD1C, CLEC4C; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 orCD48; ITGAM, ITGAX, CD1C, CLEC4C; and CD276, PDL1, PDL2, or IDO1. FOXP3;MS4A1 or CD48; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2.FOXP3; MS4A1 or CD48; IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, orPDCD1. FOXP3; MS4A1 or CD48; IL17A or IL17F; and CD276, PDL1, PDL2, orIDO1. FOXP3; MS4A1 or CD48; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48; CCL2, IL1B, IL8,IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1.FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, CLEC4C; and IL17A or IL17F.FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, CLEC4C; and CCL2, IL1B, IL8,IL6, or PTGS2. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, CLEC4C; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, CLEC4C; and CD276, PDL1, PDL2, or IDO1. FOXP3; NCAM1 orNKP46; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. FOXP3; NCAM1or NKP46; IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.FOXP3; NCAM1 or NKP46; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1.FOXP3; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. FOXP3; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, orPTGS2; and CD276, PDL1, PDL2, or IDO1. FOXP3; NCAM1 or NKP46; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3;ITGAM, ITGAX, CD1C, CLEC4C; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, orPTGS2. FOXP3; ITGAM, ITGAX, CD1C, CLEC4C; IL17A or IL17F; and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; ITGAM, ITGAX, CD1C, CLEC4C; IL17Aor IL17F; and CD276, PDL1, PDL2, or IDO1. FOXP3; ITGAM, ITGAX, CD1C,CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2,or PDCD1. FOXP3; ITGAM, ITGAX, CD1C, CLEC4C; CCL2, IL1B, IL8, IL6, orPTGS2; and CD276, PDL1, PDL2, or IDO1. FOXP3; ITGAM, ITGAX, CD1C,CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1. FOXP3; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; IL17A or IL17F; ITGAM, ITGAX, CD1C,CLEC4C; and CD276, PDL1, PDL2, or IDO1. FOXP3; IL17A or IL17F; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; and IL17A or IL17F. MS4A1 or CD48; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; and CCL2, IL1B, IL8, IL6, or PTGS2. MS4A1or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; and CD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; NCAM1 orNKP46; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. MS4A1 orCD48; NCAM1 or NKP46; IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, orPDCD1. MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; and CD276, PDL1,PDL2, or IDO1. MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, orPTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. MS4A1 or CD48; NCAM1 orNKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1.MS4A1 or CD48; NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. MS4A1 orCD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. MS4A1 orCD48; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; IL17A or IL17F; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. MS4A1 or CD48;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. NCAM1 or NKP46; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCD276, PDL1, PDL2, or IDO1. NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. NCAM1 or NKP46;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, orPDCD1. ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276,PDL1, PDL2, or IDO1. ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1. IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; NCAM1 or NKP46; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX,CD1C, or CLEC4C; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; IL17A or IL17F; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;NCAM1 or NKP46; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; IL17A or IL17F; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46;IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6,or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, orPTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, orCLEC4C; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; CCL2, IL1B,IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; MS4A1 or CD48;NCAM1 or NKP46; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. FOXP3; MS4A1 or CD48; IL17A or IL17F;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; MS4A1 or CD48;CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22. FOXP3; MS4A1 or CD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; MS4A1 or CD48;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; NCAM1 or NKP46; IL17A orIL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; NCAM1or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22. FOXP3; NCAM1 or NKP46; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.FOXP3; NCAM1 or NKP46; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; ITGAM, ITGAX,CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. FOXP3; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, or CCL22. FOXP3; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. FOXP3; CCL2, IL1B, IL8, IL6, or PTGS2;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. FOXP3; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. MS4A1 or CD48;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. MS4A1 or CD48; NCAM1 or NKP46; IL17A orIL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. MS4A1 or CD48;NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. MS4A1 or CD48; NCAM1 or NKP46; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22. MS4A1 or CD48; NCAM1 or NKP46; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. MS4A1 orCD48; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. MS4A1 or CD48; IL17A or IL17F; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,or CCL22. MS4A1 or CD48; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. MS4A1 or CD48; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. MS4A1 or CD48; CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. MS4A1 or CD48; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22. NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. NCAM1or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. NCAM1 or NKP46; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. NCAM1 orNKP46; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22. NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. ITGAM, ITGAX, CD1C, or CLEC4C; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. ITGAM, ITGAX, CD1C, orCLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.

In some embodiments, a combination of four particular gene signaturesets includes, or consists of, a combination including one or more ofthe following gene signature sets: B cell Signature 2 (CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, FCRL5); NK cell Signature 2 (KLRC3,KLRK1, KLRC2, KLRD1); Macrophage (CD68, CD163, ITGAM, ITGAX, CD14); M2Macrophage (LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A); T cell (CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK); IB T cell Signature 2 (CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT); IB APC Signature 2 (CD274, PDL2, IDO1, PVR); ActivatedCD4 T cell (CD4, IL2RA, CD69); Antigen processing (TAPBP, TAP1, TAP2,PSMB9, PSMB8); Costimulatory ligand (CD40, CD80, CD86, CD70, GITRL);Costimulatory receptor (CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFSF14, CD226); Cytolytic (GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7); and/or Active fibroblast (FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1).

In another embodiment, the expression levels of one or more of the genesin an immune cell gene signature in five particular gene signature setsare determined. For example, combinations of five particular genesignature sets are set forth in Table 5 below.

TABLE 5 Combinations of five gene signature sets CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; and ITGAM, ITGAX,CD1C, or CLEC4C. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 orCD48; NCAM1 or NKP46; and IL17A or IL17F. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; and CCL2, IL1B, IL8, IL6,or PTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;NCAM1 or NKP46; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; and IL17A or IL17F.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, orPTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; IL17A or IL17F; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; and IL17A or IL17F. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 orNKP46; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; IL17A or IL17F; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; NCAM1 or NKP46; IL17A or IL17F; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46;CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; CCL2,IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, orPTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276,PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and IL17Aor IL17F. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CCL2, IL1B, IL8, IL6, orPTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CTLA4, BTLA, LAG3, HAVCR2, orPDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46;IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2,or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 orNKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, orPTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2,or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX,CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2,or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2,or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276,PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; and IL17A or IL17F. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; and CCL2, IL1B, IL8, IL6, or PTGS2. FOXP3; MS4A1or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; and CD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 orCD48; NCAM1 or NKP46; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, orPTGS2. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46;IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48;NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B, IL8,IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48;NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. FOXP3; MS4A1 orCD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 orCD48; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48; ITGAM, ITGAX,CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2,or IDO1. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3;MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1.FOXP3; MS4A1 or CD48; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48; CCL2, IL1B,IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276,PDL1, PDL2, or IDO1. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. FOXP3; NCAM1or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. FOXP3; NCAM1or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1,PDL2, or IDO1. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1.FOXP3; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; NCAM1 or NKP46; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1.FOXP3; NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3; NCAM1 or NKP46; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17Aor IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2,or PDCD1. FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. FOXP3; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3; ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2.MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CD276, PDL1,PDL2, or IDO1. MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2,or PDCD1. MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; NCAM1or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. MS4A1 or CD48; NCAM1 or NKP46; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1.MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; NCAM1or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. MS4A1 or CD48; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. MS4A1 or CD48; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276,PDL1, PDL2, or IDO1. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17Aor IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1 . MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1 . MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1 . CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;NCAM1 or NKP46; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX,CD1C, or CLEC4C; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; IL17A or IL17F;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; CCL2, IL1B, IL8, IL6, or PTGS2;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; NCAM1 or NKP46; IL17A or IL17F; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; NCAM1 or NKP46; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8,IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM,ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; CCL2, IL1B, IL8, IL6, orPTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB; IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, orPTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; IL17A or IL17F; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, orPTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; IL17A or IL17F; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; IL17A or IL17F; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1or CD48; NCAM1 or NKP46; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B,IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 orCD48; NCAM1 or NKP46; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B,IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 orCD48; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. FOXP3; MS4A1 or CD48; IL17A or IL17F; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 orCD48; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 orCD48; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.FOXP3; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; NCAM1 or NKP46;IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. FOXP3; NCAM1 or NKP46; IL17A or IL17F;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.FOXP3; NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; ITGAM, ITGAX, CD1C,or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3;ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.FOXP3; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8,IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 orCD48; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 orNKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 or NKP46; IL17Aor IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B, IL8,IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 or NKP46; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17Aor IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17Aor IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. MS4A1 or CD48; IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. MS4A1 or CD48; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8,IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46;IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.

In some embodiments, a combination of five particular gene signaturesets includes, or consists of, a combination including one or more ofthe following gene signature sets: B cell Signature 2 (CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, FCRL5); NK cell Signature 2 (KLRC3,KLRK1, KLRC2, KLRD1); Macrophage (CD68, CD163, ITGAM, ITGAX, CD14); M2Macrophage (LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A); T cell (CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK); IB T cell Signature 2 (CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT); IB APC Signature 2 (CD274, PDL2, IDO1, PVR); ActivatedCD4 T cell (CD4, IL2RA, CD69); Antigen processing (TAPBP, TAP1, TAP2,PSMB9, PSMB8); Costimulatory ligand (CD40, CD80, CD86, CD70, GITRL);Costimulatory receptor (CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFSF14, CD226); Cytolytic (GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7); and/or Active fibroblast (FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1).

In another embodiment, the expression levels of one or more of the genesin an immune cell gene signature in six particular gene signature setsare determined. For example, combinations of six particular genesignature sets are set forth in Table 6 below.

TABLE 6 Combinations of six gene signature sets CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; and IL17A or IL17F. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17Aor IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, orPTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2,or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B,IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; IL17A or IL17F; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CCL2, IL1B,IL8, IL6, or PTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8,IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B,IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276,PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CTLA4, BTLA, LAG3, HAVCR2,or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CD276,PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8,IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2,or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46;IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX,CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, or PTGS2. FOXP3;MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; andCD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1,PDL2, or IDO1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2,or IDO1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1.FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48;NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1,PDL2, or IDO1. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4,BTLA, LAG3, HAVCR2, or PDCD1. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276,PDL1, PDL2, or IDO1. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276,PDL1, PDL2, or IDO1. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3; NCAM1 or NKP46; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. MS4A1 or CD48;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. MS4A1or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 orCD48; NCAM1 or NKP46; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 orCD48; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 orCD48; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 orCD48; ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 orCD48; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; CCL2, IL1B, IL8,IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 orNKP46; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX,CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB; IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, orPTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 orNKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 orCD48; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48;NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1or NKP46; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48;NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 orCD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. FOXP3; MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; NCAM1 or NKP46; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; NCAM1 orNKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3;NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; ITGAM, ITGAX,CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. FOXP3; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 or NKP46; IL17Aor IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48;NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; L17Aor IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B,IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. ITGAM, ITGAX, CD1C orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22.

In some embodiments, a combination of six particular gene signature setsincludes, or consists of, a combination including one or more of thefollowing gene signature sets: B cell Signature 2 (CD79A, MS4A1, CD19,STAP1, KIAA0125, POU2AF1, FCRL5); NK cell Signature 2 (KLRC3, KLRK1,KLRC2, KLRD1); Macrophage (CD68, CD163, ITGAM, ITGAX, CD14); M2Macrophage (LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A); T cell (CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK); IB T cell Signature 2 (CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT); IB APC Signature 2 (CD274, PDL2, IDO1, PVR); ActivatedCD4 T cell (CD4, IL2RA, CD69); Antigen processing (TAPBP, TAP1, TAP2,PSMB9, PSMB8); Costimulatory ligand (CD40, CD80, CD86, CD70, GITRL);Costimulatory receptor (CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFSF14, CD226); Cytolytic (GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7); and/or Active fibroblast (FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1).

In another embodiment, the expression levels of one or more of the genesin an immune cell gene signature in seven particular gene signature setsare determined. For example, combinations of seven particular genesignature sets are set forth in Table 7 below.

TABLE 7 Combinations of seven gene signature sets CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; and CCL2, IL1B, IL8, IL6, orPTGS2. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; andCTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2,IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276,PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46;IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 orCD48; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276,PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA,LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 orNKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17Aor IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3,HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, orIDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3;MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CTLA4, BTLA, LAG3, HAVCR2, orPDCD1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1,PDL2, or IDO1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3; MS4A1 orCD48; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1.FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. MS4A1 or CD48;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 orCD48; NCAM1 or NKP46; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;NCAM1 or NKP46; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX,CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2,or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 orNKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; ITGAM, ITGAX,CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 orCD48; NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 orCD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B,IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17A orIL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48;NCAM1 or NKP46; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22.FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; MS4A1 or CD48; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B,IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3;MS4A1 or CD48; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, CCL22. FOXP3; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. FOXP3; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22. MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22.

In some embodiments, a combination of seven particular gene signaturesets includes, or consists of, a combination including one or more ofthe following gene signature sets: B cell Signature 2 (CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, FCRL5); NK cell Signature 2 (KLRC3,KLRK1, KLRC2, KLRD1); Macrophage (CD68, CD163, ITGAM, ITGAX, CD14); M2Macrophage (LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A); T cell (CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK); IB T cell Signature 2 (CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT); IB APC Signature 2 (CD274, PDL2, IDO1, PVR); ActivatedCD4 T cell (CD4, IL2RA, CD69); Antigen processing (TAPBP, TAP1, TAP2,PSMB9, PSMB8); Costimulatory ligand (CD40, CD80, CD86, CD70, GITRL);Costimulatory receptor (CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFSF14, CD226); Cytolytic (GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7); and/or Active fibroblast (FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1).

In another embodiment, the expression levels of one or more of the genesin an immune cell gene signature in eight particular gene signature setsare determined. For example, combinations of eight particular genesignature sets are set forth in Table 8 below.

TABLE 8 Combinations of eight gene signature sets CD8A, GZMA, GZMB,IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;and CTLA4, BTLA, LAG3, HAVCR2, or PDCD1. CD8A, GZMA, GZMB, IFNγ, EOMES,or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CD276, PDL1,PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 orNKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. FOXP3;MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, orPDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 orNKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 orNKP46; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; ITGAM, ITGAX, CD1C, or CLEC4C;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C,or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM,ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;FOXP3; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, orCCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 orNKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB; IFNγ, EOMES, or PRF1;MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8,IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2,or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1; MS4A1 or CD48; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, or CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2,IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276,PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, orIDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; MS4A1 or CD48;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; MS4A1 or CD48;NCAM1 or NKP46; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1,CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; MS4A1 or CD48; ITGAM,ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2;CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. FOXP3; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22. MS4A1 or CD48; NCAM1or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B,IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1,PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22.

In some embodiments, a combination of eight particular gene signaturesets includes, or consists of, a combination including one or more ofthe following gene signature sets: B cell Signature 2 (CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, FCRL5); NK cell Signature 2 (KLRC3,KLRK1, KLRC2, KLRD1); Macrophage (CD68, CD163, ITGAM, ITGAX, CD14); M2Macrophage (LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A); T cell (CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK); IB T cell Signature 2 (CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT); IB APC Signature 2 (CD274, PDL2, IDO1, PVR); ActivatedCD4 T cell (CD4, IL2RA, CD69); Antigen processing (TAPBP, TAP1, TAP2,PSMB9, PSMB8); Costimulatory ligand (CD40, CD80, CD86, CD70, GITRL);Costimulatory receptor (CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFSF14, CD226); Cytolytic (GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7); and/or Active fibroblast (FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1).

In some embodiment, the expression levels of one or more of the genes inthe immune cell gene signature in nine gene signature sets aredetermined. For example, combinations of nine particular gene signaturesets are set forth in Table 9 below.

TABLE 9 Combinations of nine gene signature sets CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4,BTLA, LAG3, HAVCR2, or PDCD1; and CD276, PDL1, PDL2, or IDO1. CD8A,GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3;MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A orIL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CD276, PDL1, PDL2, or IDO1; andCX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX,CD1C, or CLEC4C; IL17A or IL17F; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; MS4A1 or CD48; NCAM1 or NKP46; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; FOXP3; MS4A1 or CD48;ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, orPTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1;and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ,EOMES, or PRF1; FOXP3; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C;IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3,HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10,CXCR3, CCL21, CCL22. CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1; MS4A1 orCD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, or CLEC4C; IL17A or IL17F;CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9, CXCL10, CXCR3, CCL21,CCL22. FOXP3; MS4A1 or CD48; NCAM1 or NKP46; ITGAM, ITGAX, CD1C, orCLEC4C; IL17A or IL17F; CCL2, IL1B, IL8, IL6, or PTGS2; CTLA4, BTLA,LAG3, HAVCR2, or PDCD1; CD276, PDL1, PDL2, or IDO1; and CX3CL1, CXCL9,CXCL10, CXCR3, CCL21, CCL22.

In some embodiments, a combination of nine particular gene signaturesets includes, or consists of, a combination including one or more ofthe following gene signature sets: B cell Signature 2 (CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, FCRL5); NK cell Signature 2 (KLRC3,KLRK1, KLRC2, KLRD1); Macrophage (CD68, CD163, ITGAM, ITGAX, CD14); M2Macrophage (LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO,SLA, MSR1, FPR3, FCGR2A, FCGR3A); T cell (CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, LCK); IB T cell Signature 2 (CTLA4, BTLA, LAG3, HAVCR2,PDCD1, TIGIT); IB APC Signature 2 (CD274, PDL2, IDO1, PVR); ActivatedCD4 T cell (CD4, IL2RA, CD69); Antigen processing (TAPBP, TAP1, TAP2,PSMB9, PSMB8); Costimulatory ligand (CD40, CD80, CD86, CD70, GITRL);Costimulatory receptor (CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18,TNFSF14, CD226); Cytolytic (GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1,NKG7); and/or Active fibroblast (FAP, FN1, MMP2, BGN, LOXL2, PDPN,PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1).

In other embodiments, the expression level of one or more of the genesin an immune cell gene signature in any 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, or 22 particular gene signature sets set forth in Table1 are determined.

In some embodiments, the expression levels of one or more of the genesin an immune cell gene signature in all 23 gene signature sets aredetermined. For example:

CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1;

FOXP3;

MS4A1 orCD48;

CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, or FCRL5;

NCAM1 or NKP46;

KLRC3, KLRK1, KLRC2, or KLRD1;

ITGAM, ITGAX, CD1C, or CLEC4C;

CD68, CD163, ITGAM, ITGAX, or CD14;

LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA, MSR1,FPR3, FCGR2A, or FCGR3A;

IL17A or IL17F;

CCL2, IL1B, IL8, IL6, or PTGS2;

CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, or LCK;

CTLA4, BTLA, LAG3, HAVCR2, or PDCD1;

CTLA4, BTLA, LAG3, HAVCR2, PDCD1, or TIGIT;

CD276, PDL1, PDL2, or IDO1;

CD274, PDL2, IDO1, or PVR;

CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, or CCL22;

CD4, IL2RA, or CD69;

TAPBP, TAP1, TAP2, PSMB9, or PSMB8;

CD40, CD80, CD86, CD70, or GITRL;

CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFSF14, or CD226;

GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, or NKG7; and

FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, COL8A1is determined. In some embodiments, one or more of the genes in Table 14is further included as an immune cell signature gene in one of the genesets described herein (e.g., T_(eff), B cell, NK cell, T_(reg), myeloid,T cell chemotaxis, etc). In other embodiments, one or more of the genesin Table 14 is further included as an immune cell signature gene in afurther identified gene set (e.g., Th1, Th2, mast cells, antigenpresenting cells (APC), etc).

Optionally, the methods include determining the ratio of expressionlevels of one or more immune cell gene signatures between gene sets tofurther identify a cancer patient for treatment with an immunotherapy orwho may have the likelihood of benefiting from a particularimmunotherapy. For example, the ratio of expression levels of one ormore immune cell gene signatures in the T_(eff) gene set (e.g., one ormore of CD8A, GZMA, GZMB, IFNγ, EOMES, or PRF1) may be compared to theexpression levels of one or more immune cell gene signatures in any ofthe T_(reg) gene set (e.g., FOXP3), an IB APC gene signature set (e.g.,one or more of CD276, PDL1, PDL2, or IDO1), and/or an IB T cell genesignature set (e.g., one or more of CTLA4, BTLA, LAG3, HAVCR2, or PDCD1)to determine whether the patient should be treated with an immunotherapyor would have a likelihood of benefitting from particular immunotherapy.In other embodiments, the methods include determining the ratio of thepresence of the immune cell subtype (e.g., T_(eff) to T_(reg), T_(eff)to B cells, T_(eff) to NK cells, T_(eff) to IB T cell, T_(eff) to IBAPC, T_(eff) to inflammatory cells) in a sample from a patient withcancer (e.g., bladder cancer, breast cancer, colorectal cancer, gastriccancer, liver cancer, melanoma, lung cancer (e.g., non-small cell lungcarcinoma), ovarian cancer, or renal cell carcinoma).

The expression level of an immune cell gene signature may be assessed byany method known in the art suitable for determination of specificprotein levels in a patient sample, and is preferably determined by animmunohistochemical (“IHC”) method employing antibodies specific for animmune cell gene signature. Such methods are well known and routinelyimplemented in the art, and corresponding commercial antibodies and/orkits are readily available. Preferably, the expression levels of themarker/indicator proteins of the invention are assessed using thereagents and/or protocol recommendations of the antibody or kitmanufacturer. The skilled person will also be aware of further means fordetermining the expression level of an immune cell gene signature by IHCmethods. Therefore, the expression level of one or more of themarkers/indicators of the invention can be routinely and reproduciblydetermined by a person skilled in the art without undue burden. However,to ensure accurate and reproducible results, the invention alsoencompasses the testing of patient samples in a specialized laboratorythat can ensure the validation of testing procedures.

Preferably, the expression level of an immune cell gene signature isassessed in a biological sample that contains or is suspected to containcancer cells. The sample may be, for example, a tissue resection, atissue biopsy, or a metastatic lesion obtained from a patient sufferingfrom, suspected to suffer from, or diagnosed with cancer (e.g., bladdercancer, breast cancer, colorectal cancer, gastric cancer, liver cancer,melanoma, lung cancer (e.g., non-small cell lung carcinoma), ovariancancer, or renal cell carcinoma). Preferably, the sample is a sample ofa tissue, a resection or biopsy of a tumor, a known or suspectedmetastatic cancer lesion or section, or a blood sample, e.g., aperipheral blood sample, known or suspected to comprise circulatingcancer cells. The sample may comprise both cancer cells, i.e., tumorcells, and non-cancerous cells, and, in certain embodiments, comprisesboth cancerous and non-cancerous cells. In aspects of the inventioncomprising the determination of gene expression in stroma components,the sample comprises both cancer/tumor cells and non-cancerous cellsthat are, e.g., associated with the cancer/tumor cells (e.g., tumorassociated fibroblasts, endothelial cells, pericytes, the extra-cellularmatrix, and/or various classes of leukocytes). In other aspects, theskilled artisan, e.g., a pathologist, can readily discern cancer cellsfrom non-cancerous (e.g., stromal cells, endothelial cells, etc.).Methods of obtaining biological samples including tissue resections,biopsies, and body fluids, e.g., blood samples comprising cancer/tumorcells, are well known in the art. In some embodiments, the sampleobtained from the patient is collected prior to beginning anyimmunotherapy or other treatment regimen or therapy, e.g., chemotherapyor radiation therapy for the treatment of cancer or the management oramelioration of a symptom thereof. Therefore, in some embodiments, thesample is collected before the administration of immunotherapeuticagents or other agents, or the start of immunotherapy or other treatmentregimen.

In addition to the methods described above, the invention alsoencompasses further immunohistochemical methods for assessing theexpression level of one or more immune cell gene signatures, such as byWestern blotting and ELISA-based detection. As is understood in the art,the expression level of the marker/indicator proteins of the inventionmay also be assessed at the mRNA level by any suitable method known inthe art, such as Northern blotting, real time PCR, and RT PCR.Immunohistochemical- and mRNA-based detection methods and systems arewell known in the art and can be deduced from standard textbooks, suchas Lottspeich (Bioanalytik, Spektrum Akademisher Verlag, 1998) orSambrook and Russell (Molecular Cloning: A Laboratory Manual, CSH Press,Cold Spring Harbor, N.Y., U.S.A., 2001). The described methods are ofparticular use for determining the expression levels of an immune cellgene signature in a patient or group of patients relative to controllevels established in a population diagnosed with advanced stages of acancer (e.g., bladder cancer, breast cancer, colorectal cancer, gastriccancer, liver cancer, melanoma, lung cancer (e.g., non-small cell lungcarcinoma), ovarian cancer, or renal cell carcinoma).

For use in the detection methods described herein, the skilled personhas the ability to label the polypeptides or oligonucleotidesencompassed by the present invention. As routinely practiced in the art,hybridization probes for use in detecting mRNA levels and/or antibodiesor antibody fragments for use in IHC methods can be labeled andvisualized according to standard methods known in the art. Non-limitingexamples of commonly used systems include the use of radiolabels, enzymelabels, fluorescent tags, biotin-avidin complexes, chemiluminescence,and the like.

The expression level of one or more of an immune cell gene signature canalso be determined on the protein level by taking advantage ofimmunoagglutination, immunoprecipitation (e.g., immunodiffusion,immunelectrophoresis, immune fixation), western blotting techniques(e.g., in situ immuno histochemistry, in situ immuno cytochemistry,affinity chromatography, enzyme immunoassays), and the like. Amounts ofpurified polypeptide may also be determined by physical methods, e.g.,photometry. Methods of quantifying a particular polypeptide in a mixtureusually rely on specific binding, e.g., of antibodies.

As mentioned above, the expression level of the marker/indicatorproteins according to the present invention may also be reflected inincreased or decreased expression of the corresponding gene(s) encodingthe immune cell gene signature. Therefore, a quantitative assessment ofthe gene product prior to translation (e.g. spliced, unspliced orpartially spliced mRNA) can be performed in order to evaluate theexpression of the corresponding gene(s). The person skilled in the artis aware of standard methods to be used in this context or may deducethese methods from standard textbooks (e.g. Sambrook, 2001). Forexample, quantitative data on the respective concentration/amounts ofmRNA encoding one or more of an immune cell gene signature as describedherein can be obtained by Northern Blot, Real Time PCR, and the like.

IV. Methods of Treatment

The invention further provides methods for administering an activatingor suppressing immunotherapy to patients with a cancer (e.g., bladdercancer, breast cancer, colorectal cancer, gastric cancer, liver cancer,melanoma, lung cancer (e.g., non-small cell lung carcinoma), ovariancancer, or renal cell carcinoma that is chemotherapy-resistant,chemotherapy-sensitive, refractory, primary, advanced, or recurrent), ifthe patient is determined to have a change in the level of expression ofone or more immune cell gene signatures in any of the gene sets. In oneembodiment, the patient is administered an activating immunotherapy ifthere is an increase in expression level of one or more immune cell genesignatures in the T_(eff) gene set (i.e., one or more of CD8A, GZMA,GZMB, IFNγ, EOMES, or PRF1) or a decrease in expression level of one ormore immune cell gene signatures in the T_(reg) gene set. In otherembodiments, the patient is administered a suppressing immunotherapy ifthere is an increase in expression level of one or more immune cell genesignatures in the T_(reg) gene set (i.e., FOXP3) or a decrease inexpression level of one or more immune cell gene signatures in theT_(eff) gene set (i.e., one or more of CD8A, GZMA, GZMB, IFNγ, EOMES, orPRF1). In other embodiments, in addition to determining the expressionlevels of one or more immune cell gene signatures in the T_(eff) and/orT_(reg) gene sets, expression levels of one or more immune cell genesignatures in combinations of any one of the gene sets as set forth inTables 2-8 can be determined prior to administering a particularimmunotherapy regimen to the patient (e.g., an activating immunotherapyregimen or a suppressing immunotherapy regimen).

In some embodiments, the activating immunotherapy includes a CD28, OX40,GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist. Inparticular embodiments, the agonist (e.g., a CD28, OX40, GITR, CD137,CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist) increases, enhances, orstimulates an immune response or function in a patient having cancer. Insome embodiments, the agonist modulates the expression and/or activityof a ligand (e.g., a T cell receptor ligand), and/or increases orstimulates the interaction of the ligand with its immune receptor,and/or increases or stimulates the intracellular signaling mediated byligand binding to the immune receptor. In other embodiments, thesuppressing immunotherapy includes a CTLA-4, PD-1 axis, TIM-3, BTLA,VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist. In particularembodiments, the antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA,VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist) is an agent thatinhibits and/or blocks the interaction of a ligand (e.g., a T cellreceptor ligand) with its immune receptor or is an antagonist of ligandand/or receptor expression and/or activity, or is an agent that blocksthe intracellular signaling mediated by a ligand (e.g., a T cellreceptor ligand) with its immune receptor.

In some embodiments, the methods of the invention may further compriseadministering the activating immunotherapy (e.g., a CD28, OX40, GITR,CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist) or the suppressingimmunotherapy (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA, VISTA, LAG-3,B7H4, CD96, TIGIT, or CD226 antagonist) with an additional therapy. Theadditional therapy may be radiation therapy, surgery, chemotherapy, genetherapy, DNA therapy, viral therapy, RNA therapy, bone marrowtransplantation, nanotherapy, monoclonal antibody therapy, or acombination of the foregoing. The additional therapy may be in the formof an adjuvant or neoadjuvant therapy. In some embodiments, theadditional therapy is the administration of side-effect limiting agents(e.g., agents intended to lessen the occurrence and/or severity of sideeffects of treatment, such as anti-nausea agents, etc.). In someembodiments, the additional therapy is radiation therapy. In someembodiments, the additional therapy is surgery. In some embodiments, theadditional therapy may be one or more of the chemotherapeutic agentsdescribed hereinabove. For example, these methods involve theco-administration of the activating immunotherapy (e.g., a CD28, OX40,GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist) or thesuppressing immunotherapy (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA,VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist) with one or moreadditional chemotherapeutic agents (e.g., carboplatin and/orpaclitaxel), as described further below. Immunotherapy optionally incombination with one or more chemotherapeutic agents (e.g., carboplatinand/or paclitaxel) preferably extends and/or improves survival,including progression free survival (PFS) and/or overall survival (OS).In one embodiment, immunotherapy extends survival at least about 20%more than survival achieved by administering an approved anti-tumoragent, or standard of care, for the cancer being treated.

For the prevention or treatment of cancer (e.g., bladder cancer, breastcancer, colorectal cancer, gastric cancer, liver cancer, melanoma, lungcancer (e.g., non-small cell lung carcinoma), ovarian cancer, or renalcell carcinoma), the dose of the agonist (e.g., a CD28, OX40, GITR,CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist) or antagonist(e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA, VISTA, LAG-3, B7H4, CD96,TIGIT, or CD226 antagonist) will depend on the type of cancer to betreated, as defined above, the severity and course of the cancer,whether the antibody is administered for preventive or therapeuticpurposes, previous therapy, the patient's clinical history and responseto the drug, and the discretion of the attending physician.

In one embodiment, a fixed dose of the agonist or antagonist isadministered. The fixed dose may suitably be administered to the patientat one time or over a series of treatments. Where a fixed dose isadministered, preferably it is in the range from about 20 mg to about2000 mg. For example, the fixed dose may be approximately 420 mg,approximately 525 mg, approximately 840 mg, or approximately 1050 mg ofthe agonist (e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D,MICA, or 2B4 agonist) or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3,BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist). Where aseries of doses are administered, these may, for example, beadministered approximately every week, approximately every 2 weeks,approximately every 3 weeks, or approximately every 4 weeks, butpreferably approximately every 3 weeks. The fixed doses may, forexample, continue to be administered until disease progression, adverseevent, or other time as determined by the physician. For example, fromabout two, three, or four, up to about 17 or more fixed doses may beadministered.

In one embodiment, one or more loading dose(s) of the agonist (e.g., aCD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist)or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA, VISTA, LAG-3,B7H4, CD96, TIGIT, or CD226 antagonist) are administered, followed byone or more maintenance dose(s). In another embodiment, a plurality ofthe same dose is administered to the patient.

While the agonist (e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM,NKG2D, MICA, or 2B4 agonist) or antagonist (e.g., a CTLA-4, PD-1 axis,TIM-3, BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist) maybe administered as a single anti-tumor agent, the patient is optionallytreated with a combination of agonist (e.g., a CD28, OX40, GITR, CD137,CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist) or antagonist (e.g., aCTLA-4, PD-1 axis, TIM-3, BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, orCD226 antagonist) and one or more (additional) chemotherapeuticagent(s). Exemplary chemotherapeutic agents herein include: gemcitabine,carboplatin, oxaliplatin, irinotecan, fluoropyrimidine (e.g., 5-FU),paclitaxel (e.g., nab-paclitaxel), docetaxel, topotecan, capecitabine,temozolomide, interferon-alpha, and/or liposomal doxorubicin (e.g.,pegylated liposomal doxorubicin). The combined administration includesco-administration or concurrent administration, using separateformulations or a single pharmaceutical formulation, and consecutiveadministration in either order, wherein preferably there is a timeperiod while both (or all) active agents simultaneously exert theirbiological activities. Thus, the chemotherapeutic agent may beadministered prior to, or following, administration of the agonist(e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4agonist) or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA, VISTA,LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist). In this embodiment, thetiming between at least one administration of the chemotherapeutic agentand at least one administration of the agonist (e.g., a CD28, OX40,GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist) orantagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA, VISTA, LAG-3, B7H4,CD96, TIGIT, or CD226 antagonist) is preferably approximately 1 month orless (3 weeks, 2, weeks, 1 week, 6 days, 5, days, 4 days, 3 days, 2days, 1 day). Alternatively, the chemotherapeutic agent and the agonist(e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4agonist) or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA, VISTA,LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist) are administeredconcurrently to the patient, in a single formulation or separateformulations. Treatment with the combination of the chemotherapeuticagent (e.g., carboplatin and/or paclitaxel) and the agonist (e.g., aCD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist)or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA, VISTA, LAG-3,B7H4, CD96, TIGIT, or CD226 antagonist) may result in a synergistic, orgreater than additive, therapeutic benefit to the patient.

Particularly desired chemotherapeutic agents for combining with theagonist (e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA,or 2B4 agonist) or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA,VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist), e.g. for therapyof ovarian cancer, include: a chemotherapeutic agent such as a platinumcompound (e.g., carboplatin), a taxol such as paclitaxel or docetaxel,topotecan, or liposomal doxorubicin.

Particularly desired chemotherapeutic agents for combining with theagonist (e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA,or 2B4 agonist) or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA,VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist), e.g., for therapyof breast cancer, include: chemotherapeutic agents such as capecitabine,and a taxol such as paclitaxel (e.g., nab-paclitaxel) or docetaxel.

Particularly desired chemotherapeutic agents for combining with theagonist (e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA,or 2B4 agonist) or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA,VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist), e.g., for therapyof colorectal cancer, include: chemotherapeutic agents such as afluoropyrimidine (e.g., 5-FU), paclitaxel, cisplatin, topotecan,irinotecan, fluoropyrimidine-oxaliplatin, fluoropyrimidine-irinotecan,FOLFOX4 (5-FU, lecovorin, oxaliplatin), and IFL (ironotecan, 5-FU,leucovorin).

Particularly desired chemotherapeutic agents for combining with theagonist (e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA,or 2B4 agonist) or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA,VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist), e.g., for therapyof renal cell carcinoma, include: chemotherapeutic agents such asinterferon-alpha2a.

A chemotherapeutic agent, if administered, is usually administered atdosages known therefore, or optionally lowered due to combined action ofthe drugs or negative side effects attributable to administration of thechemotherapeutic agent. Preparation and dosing schedules for suchchemotherapeutic agents may be used according to manufacturers'instructions or as determined empirically by the skilled practitioner.Where the chemotherapeutic agent is paclitaxel, preferably, it isadministered at a dose between about 130 mg/m² to 200 mg/m² (for exampleapproximately 175 mg/m²), for instance, over 3 hours, once every 3weeks. Where the chemotherapeutic agent is carboplatin, preferably it isadministered by calculating the dose of carboplatin using the Calvertformula which is based on a patient's preexisting renal function orrenal function and desired platelet nadir. Renal excretion is the majorroute of elimination for carboplatin. The use of this dosing formula, ascompared to empirical dose calculation based on body surface area,allows compensation for patient variations in pretreatment renalfunction that might otherwise result in either underdosing (in patientswith above average renal function) or overdosing (in patients withimpaired renal function). The target AUC of 4-6 mg/mL/min using singleagent carboplatin appears to provide the most appropriate dose range inpreviously treated patients.

Aside from the agonist (e.g., a CD28, OX40, GITR, CD137, CD27, ICOS,HVEM, NKG2D, MICA, or 2B4 agonist) or antagonist (e.g., a CTLA-4, PD-1axis, TIM-3, BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist)and chemotherapeutic agent, other therapeutic regimens may be combinedtherewith. For example, a second (third, fourth, etc.) chemotherapeuticagent(s) may be administered, wherein the second chemotherapeutic agentis an antimetabolite chemotherapeutic agent, or a chemotherapeutic agentthat is not an antimetabolite. For example, the second chemotherapeuticagent may be a taxane (such as paclitaxel or docetaxel), capecitabine,or platinum-based chemotherapeutic agent (such as carboplatin,cisplatin, or oxaliplatin), anthracycline (such as doxorubicin,including, liposomal doxorubicin), topotecan, pemetrexed, vinca alkaloid(such as vinorelbine), and TLK 286. “Cocktails” of differentchemotherapeutic agents may be administered.

Other therapeutic agents that may be combined with the agonist (e.g., aCD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist)or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA, VISTA, LAG-3,B7H4, CD96, TIGIT, or CD226 antagonist), and/or chemotherapeutic agentinclude any one or more of: a HER inhibitor, HER dimerization inhibitor(for example, a growth inhibitory HER2 antibody such as trastuzumab, ora HER2 antibody which induces apoptosis of a HER2-overexpressing cell,such as 7C2, 7F3 or humanized variants thereof); an antibody directedagainst a different tumor associated antigen, such as EGFR, HER3, HE R4;anti-hormonal compound, e.g., an anti-estrogen compound such astamoxifen, or an aromatase inhibitor; a cardioprotectant (to prevent orreduce any myocardial dysfunction associated with the therapy); acytokine; an EGFR-targeted drug (such as TARCEVA® IRESSA® or cetuximab);a tyrosine kinase inhibitor; a COX inhibitor (for instance a COX-1 orCOX-2 inhibitor); non-steroidal anti-inflammatory drug, celecoxib(CELEBREX®); farnesyl transferase inhibitor (for example,Tipifarnib/ZARNESTRA® R115777 available from Johnson and Johnson orLonafarnib SCH66336 available from Schering-Plough); antibody that bindsoncofetal protein CA 125 such as Oregovomab (MoAb B43.13); HER2 vaccine(such as HER2AutoVac vaccine from Pharmexia, or APC8024 protein vaccinefrom Dendreon, or HER2 peptide vaccine from GSK/Corixa); another HERtargeting therapy (e.g. trastuzumab, cetuximab, ABX-EGF, EMD7200,gefitinib, erlotinib, CP724714, CI1033, GW572016, IMC-11F8, TAK165,etc); Raf and/or ras inhibitor (see, for example, WO 2003/86467);doxorubicin HCl liposome injection (DOXIL®); topoisomerase 1 inhibitorsuch as topotecan; taxane; HER2 and EGFR dual tyrosine kinase inhibitorsuch as lapatinib/GW572016; TLK286 (TELCYTA®); EMD-7200; a medicamentthat treats nausea such as a serotonin antagonist, steroid, orbenzodiazepine; a medicament that prevents or treats skin rash orstandard acne therapies, including topical or oral antibiotic; amedicament that treats or prevents diarrhea; a body temperature-reducingmedicament such as acetaminophen, diphenhydramine, or meperidine;hematopoietic growth factor, etc.

Suitable dosages for any of the above-noted co-administered agents arethose presently used and may be lowered due to the combined action(synergy) of the agent and the agonist (e.g., a CD28, OX40, GITR, CD137,CD27, ICOS, HVEM, NKG2D, MICA, or 2B4 agonist) or antagonist (e.g., aCTLA-4, PD-1 axis, TIM-3, BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, orCD226 antagonist). In addition to the above therapeutic regimes, thepatient may be subjected to surgical removal of tumors and/or cancercells, and/or radiation therapy.

Where the agonist (e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM,NKG2D, MICA, or 2B4 agonist) or antagonist (e.g., a CTLA-4, PD-1 axis,TIM-3, BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist) is anantibody, preferably the administered antibody is a naked antibody. Theagonist (e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D, MICA,or 2B4 agonist) or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3, BTLA,VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist) administered maybe conjugated with a cytotoxic agent. Preferably, the conjugate and/orantigen to which it is bound is/are internalized by the cell, resultingin increased therapeutic efficacy of the conjugate in killing the cancercell to which it binds. In a preferred embodiment, the cytotoxic agenttargets or interferes with nucleic acid in the cancer cell. Examples ofsuch cytotoxic agents include maytansinoids, calicheamicins,ribonucleases, and DNA endonucleases.

The agonist (e.g., a CD28, OX40, GITR, CD137, CD27, ICOS, HVEM, NKG2D,MICA, or 2B4 agonist) or antagonist (e.g., a CTLA-4, PD-1 axis, TIM-3,BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist) can beadministered by gene therapy. See, for example, WO 96/07321 publishedMar. 14, 1996 concerning the use of gene therapy to generateintracellular antibodies. There are two major approaches to getting thenucleic acid (optionally contained in a vector) into the patient'scells; in vivo and ex vivo. For in vivo delivery the nucleic acid isinjected directly into the patient, usually at the site where theantibody is required. For ex vivo treatment, the patient's cells areremoved, the nucleic acid is introduced into these isolated cells andthe modified cells are administered to the patient either directly or,for example, encapsulated within porous membranes which are implantedinto the patient (see, e.g. U.S. Pat. Nos. 4,892,538 and 5,283,187).There are a variety of techniques available for introducing nucleicacids into viable cells. The techniques vary depending upon whether thenucleic acid is transferred into cultured cells in vitro or in vivo inthe cells of the intended host. Techniques suitable for the transfer ofnucleic acid into mammalian cells in vitro include the use of liposomes,electroporation, microinjection, cell fusion, DEAE-dextran, the calciumphosphate precipitation method, etc. A commonly used vector for ex vivodelivery of the gene is a retrovirus. The currently preferred in vivonucleic acid transfer techniques include transfection with viral vectors(such as adenovirus, Herpes simplex I virus, or adeno-associated virus)and lipid-based systems (useful lipids for lipid-mediated transfer ofthe gene are DOTMA, DOPE and DC-Chol, for example). In some situationsit is desirable to provide the nucleic acid source with an agent thattargets the target cells, such as an antibody specific for a cellsurface membrane protein or the target cell, a ligand for a receptor onthe target cell, etc. Where liposomes are employed, proteins which bindto a cell surface membrane protein associated with endocytosis may beused for targeting and/or to facilitate uptake, e.g. capsid proteins orfragments thereof tropic for a particular cell type, antibodies forproteins which undergo internalization in cycling, and proteins thattarget intracellular localization and enhance intracellular half-life.The technique of receptor-mediated endocytosis is described, forexample, by Wu et al., J. Biol. Chem. 262:44294432 (1987); and Wagner etal., Proc. Natl. Acad. Sci. USA 87:3410-3414 (1990). For review of thecurrently known gene marking and gene therapy protocols see Anderson etal., Science 256:808-813 (1992). See also WO 93/25673 and the referencescited therein.

EXAMPLES Materials and Experimental Methods Statistical Analysis

Statistical analysis was performed using the R statistical software.FLUIDIGM™ and Nanostring data were normalized using the housekeepinggene approach. Specifically, median gene expression of the fivehousekeeping genes (SP2, GUSB, TMEM55B, VPS33B, and SDHA) was estimatedand subtracted from each sample. Gene set expression was represented bythe median expression of the member genes. To evaluatebetween-indication and within-indication variability for each genesignature, linear mixed effects models were used with indications as therandom effect. ICC (intraclass correlation), the ratio of thebetween-indication variance to the total variance, was computed for eachgene signature. Differential expression analysis between the clinicalresponse groups was carried out using Wilcoxon rank sum tests. P valueswere not adjusted for multiple corrections. Differential expressionbetween primary and metastatic CRC pairs was assessed using Wilcoxonsigned rank tests, and the derived p-values were adjusted for multipletesting errors using the Bonferroni method.

Example 1: A High Degree of Correlation was Observed for Immune CellSignature Genes within a Given Gene Signature Set

To assess the characteristics of the immune landscape in the tumormicroenvironment of different tumors, PCR based gene expressionsignatures were employed to analyze the distribution of immune cellsubsets across seven cancer types including urothelial bladder cancer(UBC), breast cancer (BC), non-small cell lung cancer (NSCLC), melanoma,renal cell cancers (RCC), ovarian cancer (OvCa), gastric cancer, livercancer, and colorectal cancer (CRC). Table 1 depicts the immune genesignatures generated based on exclusive expression of genes in immunecell subsets including effector CD8 T cells (T_(eff)), regulatory Tcells (T_(reg)), T cells (all), activated CD4 T cells, T cellchemotaxis, myeloid cells, macrophages (all), M2 macrophages, B cells,Th17 cells, NK cells, and innate inflammatory signatures. Expression ofimmune blockers present in T cells (IB T cells) and antigen presentingcells or tumor cells (IB APC/tumors) were also analyzed (Table 1). Table1 also depicts the immune gene signature sets of antigen processing,costimulatory ligands, costimulatory receptors, cytolytic, angiogenesis,and active fibroblast signatures. The gene signature sets were analyzedusing a 90-gene FLUIDIGM™ panel or an 800-gene custom Nanostring panel,as indicated in Table 1, using RNA extracted from archival FFPE tumorspecimens. In general, a high degree of correlation was observed forgenes within a given gene set by METHODOLOGY (FIGS. 1-11): T_(eff),0.72; B cell, 0.8; Myeloid, 0.54; Inflammatory, 0.59; T cell IB, 0.49;IB APC/tumors, 0.5. The only exception was IL17 signatures (R=0.3).

Principal component analysis was applied to decompose the variance forthe nine gene signatures. The first two principal components accountedfor the majority of the variability (45% and 14% for the first andsecond components, respectively; FIG. 12A). Inspection of the factorloading of the first component revealed that the first principalcomponent was related to T_(eff), B cell, and IB APC/tumors signatures(FIGS. 12B and 12C).

Principal component analysis further suggested that immune landscapesvaried between tumor types. To examine whether this between-indicationheterogeneity dominates the total variability, linear mixed effectsmodels were used with indications as the random effect to decomposewithin- and between-indication variability. Intraclass correlation (ICC)was calculated for each gene signature. The ICC is calculated as theratio of the between-indication variance to the total variance and has avalue between 0 and 1. As shown in Table 10, ICCs ranged from 0.11 to0.29, indicating that there was a substantial amount ofwithin-indication heterogeneity for all gene signatures considereddespite clear mean differences between indications.

TABLE 10 Between-Indication Total Signature Variance Variance ICC Teff0.65 2.61 0.2 Treg 0.84 2.47 0.25 Bcell 1.02 3.32 0.24 NKcell 1.06 4.180.2 Myeloid 0.32 1.57 0.17 IL17 3.23 11.45 0.22 Inflammatory 1.02 2.510.29 IB. T 0.58 4.91 0.11 IB. APC 0.53 1.89 0.22

Example 2: T_(eff) Signature Genes Represent CD8 T Cell Infiltration

The expression profile of the signature genes within the T_(eff) geneset (see, Table 1 above) across cancer types was determined. A survey ofthe T_(eff) signature across cancer types showed differences in medianexpression not just between cancers but also between subtypes within agiven indication. While most indications exhibited comparable expressionof T_(eff) genes, NSCLC, melanoma, RCC, and Her2⁺ or TN BC had thehighest levels of T_(eff), while CRC and OvCa had the lowest, followedby hormone receptor positive (HR+) BC (FIG. 13). Within a cancer type, awide range of expression patterns was observed suggesting thatsubpopulations within CRC or OvCa may have T_(eff) expression levelssimilar to cancer types like melanoma or RCC.

To determine if the T_(eff) gene set represented the presence of CD8 Tcells, digital pathology was conducted for CD8 IHC to enumerate thenumber of CD8 T cells in the tumor center (CN) and the invasive margin(IM) (FIG. 30).

CD8 IHC were evaluated in three regions, tumor peripheral, invasivemargin (IM) and center (Cn). The relationship between IM and Cn CD8 IHC,as well as between CD8 IHC and RNA, was assessed using scattermatrixplot. Raw values of CD8 IHC readings are right skewed; therefore, log2-transformation was performed to normalize the distribution. CD8 IHCvalues that were zero were imputed to be half of the minimum non-zerovalue for log 2 transformation. A high degree of correlation wasobserved between CD8 IHC and CD8 RNA transcripts across indications(FIG. 29). A high degree of correlation was observed between IM and CNCD8 IHC readings, with a Spearman correlation coefficient equaling 0.76for the log 2 transformed values. CD8 RNA was found to be highlycorrelated with center/IM CD8 IHC positivity, with a Spearmancorrelation coefficient approximately 0.66 (samples from the samepatients were not consolidated for the analyses in this section). Whenbreaking down by indication, high correlation between IM and Cn CD8 IHCpositivity persists, with Spearman correlation ranging from 0.69 to0.82.

In addition, a marked correlation was observed between IM and CNprevalence of CD8 T cells across indications (FIG. 30). A summary of CD8positivity by invasive margin (IM) and tumor center (CN) within eachindication is presented in Table 11. The empirical cumulativedistributions were plotted for both IM and CN in FIG. 31 to detectdistributional differences between these two regions and betweenindications. Among the five indications, melanoma tumors on average hadthe highest CD8 T cell presence and the largest dynamic range. CRC andbladder tumors, on average, had the lowest CD8 T cell infiltrates andalso, the smallest dynamic range. These results were highly correlatedwith the rank order of the T_(eff) signatures.

In addition, CD8 T cells were significantly more abundant at invasivemargin than at tumor center for melanoma and RCC tumors.

TABLE 11 IM. IM. Cn. Cn. N Median 25th%-75th% Median 25th%-75th% MELA-35 3.07 (0.98-5.66) 2.22 (0.57-5.13) NOMA RENAL 56 3.36 (1.11-4.97)1.835 (0.925-3.503) BLADDER 61 1.47 (1.09-3.19) 1.08 (0.33-1.96) LUNG 682.495 (1.245-5.87)  1.66 (0.9275-3.432)  COLO- 22 0.96 (0.785-1.21) 0.34 (0.1275-0.6575) RECTAL

The cancer types that contain a CD8 T cell infiltrate most likelyrepresented tumors that prevent anti-tumor immunity by overexpressingimmunosuppressive cells relative to activated T cells. While the generalprevalence of T_(eff) signatures reflected the abundance of tumorinfiltrating lymphocytes across indications, the ratio of T_(eff)signatures to T_(reg) ranked the cancer types in a manner similar to theones most likely to respond to immunotherapies. NSCLC, RCC, and melanomahad the highest ratio of T_(eff):T_(reg) reflecting “immunogenic” tumortypes. Indications known to have poor responses to immunotherapies likeCRC and OvCa were the cancer types with the lowest ratio ofT_(eff):T_(reg) (FIG. 15). While TN and Her2⁺ breast cancers exhibited ahigher median expression of T_(eff) signatures, their tumormicroenvironment was also shown to be rich in T_(reg) and this isreflected by the low relative ratio of T_(eff) to T_(reg) signatures.Thus, therapies targeting T regulatory cells, such as anti-OX40(abundantly expressed in T_(reg)) in combination with checkpointinhibitors, provide useful therapies for triggering an effectiveanti-tumor immune response.

Example 3: T_(reg) Signature Genes are Abundant in Breast Cancer

Tumors recruit immunosuppressive cells to inhibit antitumoral T_(eff)responses. Regulatory T cells (T_(reg)), characterized by Foxp3expression, antagonize T_(eff) action. To test the potential of in-situimmunosuppression, prevalence of Foxp3 was evaluated among tumorindications. Presence of T_(reg) was highest among BC subtypes (Her2⁺similar to triple negative (TN), both higher than hormone receptorpositive (HR⁺)) followed by NSCLC, UBC, CRC, OvCa, RCC, and melanoma,with significantly reduced counts (FIG. 14). Effective T_(reg)-dependentimmunosuppression requires a certain proportion of T_(eff):T_(reg), thusthe proportion of T_(eff) to T_(reg) was assessed. T_(eff):T_(reg) ratiowas highest in melanoma, followed by RCC, NSCLC, and UBC (FIG. 15).Despite differences in independent T_(eff) and T_(reg) values, BC (HR⁺,Her2⁺ and TN), CRC, and ovarian had similarly reduced T_(eff):T_(reg)ratios (FIG. 15). These results suggest that tumors with lowT_(eff):T_(reg) may benefit from therapies targeting T_(reg).

Example 4: B Cell, NK Cell, and Myeloid Cell Signature Genes Vary AcrossCancer Indications

In preclinical models, B cells were shown to promote intratumoralimmunosuppression by recruiting and enabling anti-inflammatorymacrophages. On the other hand, NK cells were shown to recognize stressmolecules expressed by tumors and direct tumor rejection. The presenceof B cells followed a distribution similar to T_(eff) across indications(FIG. 16), while NK cells were highest in OvCa, followed by all theother indications (FIG. 17). Myeloid signature, which encompasses bothmacrophages and dendritic cells, was similar among indications, exceptfor reduced levels in CRC and OvCa (FIG. 18), likely representing a lowimmune infiltrate in these indications. A further distinction was thatthe median expression of myeloid gene set was higher in non squamousNSCLC compared to squamous NSCLC.

Example 5: Th17 Signature Genes are Distinct in Each Tumor Type

While tumor infiltrating lymphocytes were shown to be associated withbetter prognosis in several cancer indications, production of IL-17A andIL-17F by Th17 cells was linked to worse prognosis in several tumors,such as CRC, TN BC (Couchad, 20123 Scientific Reports), and ovariancancer. In some cases, production of IL-17A and IL-17F was associatedwith better prognosis in indications such as esophageal squamouscarcinoma. Analysis of IL-17A and IL-17F across indications showed acomplex distribution: tumors expressing IL-17A alone, IL-17F alone,IL-17A⁺/IL-17F⁺ and IL-17A⁻/IL-17F⁻ (FIG. 20). The presence of singlepopulations yielded to a gene signature index of 0.3 (FIG. 2A).Colorectal carcinoma is the indication with the highest levels of IL-17genes, followed by squamous NSCLC, bladder and non squamous NSCLC (FIG.19). Her2⁺ BC, HR⁺ BC, and OvCa were the indications with the lowestprevalence of IL-17 genes.

When the prevalence of IL-17A and IL-17F was assessed in eachindication, heterogeneity in the single and double gene distribution wasobserved. For instance, IL-17A and IL-17F were mainly co-expressed inCRC, squamous NSCLC, and bladder cancer, while Her2⁺ BC exhibited noIL-17A expression (FIG. 20). These results suggest that IL-17 biologymay be distinct in each tumor type and that targeted therapies towardthese cytokines may have to consider preponderance of the targetedtissue. For example, IL-17 signature was particularly overrepresented inprimary CRC compared to all other tumor types. Th17 cells have beenknown to be associated with microbial dysbiosis in the colon. To examineif the high expression of Th17 signatures was unique to the primarytumor or if it was translated to distant metastases an analysis ofmatched primary tumors and metastases expression of IL-17 genes wasassessed. Analysis of matched primary tumors and metastases showed thatindeed the prevalence of Th17 signatures in CRC may be driven by thecolon immunobiology rather than by characteristics of the tumor (FIG.32). The liver is abundant in Kuppfer cells, sessile macrophagesimportant in clearing cellular debris and gut derived microbialproducts. Considering that Arg1 and the myeloid markers are higher inCRC liver metastases, this suggested that resident organmicroenvironment is an equally important determinant in contributing tothe immunosuppressive microenvironment.

Example 6: Immune Response in the Tumor Microenvironment Changes BetweenPrimary and Metastatic Sites

The immune landscape in the tumor microenvironment may reflect eitherthe endogenous immune responses characteristic of the organ or thespecific recruitment by the tumor cells. Thus, it remains to bedetermined whether the tumor immune microenvironment is maintained whenthe tumor metastasizes. To test this possibility, the immune genesignatures were compared between 47 pairs of asynchronous matchedprimary and metastastic CRC tumors. Most of the metastases were locatedin the liver and lung (36 and 5, respectively) and the rest in otherorgans.

Differences of gene set expression between primary and metastatic pairswere evaluated using Wilcoxon signed-rank test, and multiplicity of thetests was adjusted using the Bonferroni approach. Table 12 shows log 2fold change of primary over metastatic samples together with Wilcoxonsigned-rank test p values (i.e., Table 12 shows the fold change of thegene signatures using metastases as denominator). A positive fold changeindicates higher expression in the CR/PR group compared to the PD group.Boxplot of gene set expression in association with primary metastaticstatus is shown in FIG. 32.

TABLE 12 Bonferroni Signature log2FoldChange raw p corrected p Teff−0.36 0.13 1 Treg 0.74 0.00028 0.00224 Inflammatory 0.67 0.0085 0.068NKcell 0.5 0.092 0.736 Bcell −0.08 0.55 1 Myeloid −0.49 0.025 0.2 IL17 43.8e−07 3.04e−06 Teff/Treg −0.91 5.4e−08 4.32e−07

The IL-17 gene signature, characteristic of primary CRC tumors, wasstrikingly reduced in CRC metastases, irrespective of location in theliver or lung (−4 fold, p=3.04×10{circumflex over ( )}−6). T_(reg) werealso significantly decreased in metastases (−0.76 fold, p=0.002272).While there were no significant differences in T_(eff) between primaryand metastases, the T_(eff):T_(reg) ratio was significantly increased inthe metastases (+0.91 fold, p=4.344×10{circumflex over ( )}−7). Finally,myeloid gene sets tend to be increased in the metastasis while theinflammatory signature is reduced (+0.49 and −67, p=0.1992 and 0.068,respectively).

Differences of immune gene expression between primary and metastaticpairs were evaluated using Wilcoxon signed-rank test for each of the 96immune genes, and multiplicity of the tests were adjusted using theBonferroni approach. Genes that were identified as significantlydifferentially expressed between primary and metastatic samples(Bonferroni corrected p≤0.05) were ARG1, IL17A, VTCN1, IL17F, IL1B,HLA.E, HAVCR2, CD70, FOXP3 and PTGS2.

At the level of individual genes, Arg1, expressed in hepatocytes andanti-inflammatory macrophages, was the single highest upregulated genebetween colon primary and liver metastases (FIG. 33). Taken together,these results suggest that the immune responses in the tumormicroenvironment changes between primary and metastatic sites, mirroringthe subjacent immune landscape of the organ rather than specificrecruitment by tumor cells.

Example 7: Hormone Driven Tumors Display Reduced Inflammation

Tumor-associated inflammation may promote tumor growth, angiogenesis,and recruitment of myeloid suppressor cells, which in turn switch off Tcell mediated antitumoral response. Inflammasome products (IL-1β andIL-18), chemokines (CCL2, CCL22) and cytokines (IL-6, IL-8) weredescribed to be part of this process in different indications. By usingan inflammatory gene signature, it was observed that the overallinflammation varied across indications (FIG. 21). The most inflamedtumors were NSCLC, UBC, and RCC, while the least inflamed indicationswere HR⁺ BC, liver, Her2⁺ BC, and OvCa. These results suggest thathormone driven tumors display reduced local inflammation.

Example 8: The Presence of T Cell Immune Blockers Trails T_(eff)Distribution Across Cancer Indications

To prevent uncontrolled T_(eff) activation, inhibitory receptors (IB)are upregulated on immune cells and/or tumor cells upon T cellactivation. A mechanism of tumor escape is induction of the ligands forT cell IB, therefore turning off effective anti-tumor responses. Todetermine the possible impact of these receptor:ligand interactions,prevalence of IB T cell signatures and IB APC/tumor signatures wereanalyzed. Presence of T cell immune blockers trailed T_(eff)distribution across indications (FIG. 22). In all indications, CTLA4presented the lowest prevalence of IB T cell, while Tim3 (HVACR2) hadthe highest (FIG. 26). PD-1 and Lag3 were second in abundance in the IBT cell signature. Expression of BTLA was either reduced in OvCa and CRCor expressed similarly to PD1 and Lag3 in melanoma, RCC, UBC, BC, andNSCLC. These data suggest that, regardless of the tumor type,infiltrating T_(eff) were similarly equipped with inhibitory receptors.

Intratumoral antigen presenting cells (APC) and tumors express theinhibitory ligands for IB T cells as well as enzymes that producecatabolytes that inhibit T cell activation. To analyze the presence ofIB APC/tumor, a gene signature was generated and analyzed acrossindications. Prevalence of APC-IB signature was similar amongindications, except for a marked reduction in HR⁺ BC and CRC (FIG. 23).A granular analysis of genes was conducted to assess the relativeexpression patterns of individual APC-IB genes across cancer types (FIG.27). Expression of CD276 was highest and differentiated from the othergenes. PD-L1, PD-L2, and IDO1 were highly correlated (0.7). Of thesegenes, the highest expressed was IDO1 (FIG. 27). In addition, the ratioof gene expression of T_(eff) gene signatures to APC-IB gene signatureswas also determined across indications (FIG. 24). The ratio of geneexpression of T_(eff) gene signatures to each individual gene in theAPC-IB gene signature was also determined across indications (FIG. 25).Of these, OvCa and HR⁺ BC had the lowest ratios of Teff/CD276 andTeff/PDL2, while OvCa alone had the lowest T_(eff)/IDO1 ratio,suggesting that immunotherapy in OvCa may require the blockade ofseveral immune inhibitors to trigger a treatment response.

Example 9: A High Degree of Heterogeneity is Present in the ImmuneSignature Gene Sets Across Cancer Indications

A hierarchical clustering of the immune gene sets across indications wasperformed to analyze the immune landscape among tumor type. A highdegree of heterogeneity was observed in the immune gene sets acrossindications, where some tumors showed a remarkable immune presence,while others were “immune deserts” (FIG. 28).

The unsupervised analysis clustered together the three types of breastcancer and the two types of lung tumors, suggesting that immunologicalsimilarities may arise from the tissue where the tumors grow. On theother hand, CRC and OvCa showed an immune desert cluster, devoid ofimmune gene signatures, except for IL17 and NK, respectively. Overall,the tumors with highest T_(eff) infiltration were melanoma, RCC,NSCLC(Sq) and Her2+ and TN BC. However, the latter two cancers (i.e.,Her2+ and TN BC) also exhibited a high incidence of T_(reg), suggestingthat the intratumoral immune responses in these tumors may be negated bythe effects of T_(reg). The most inflamed tumor was NSCLC-non squamouscarcinoma, followed by NSCLC-squamous cell carcinoma, and UBC. Thetumors with the highest incidence of IB APC/tumors were NSCLC, RCC, UBC,followed by melanoma, and TN BC. On the other hand, CRC, OvCa, HR⁺, andHer2⁺ BC had no signs of inflammation.

Considering the factors mentioned above, it is predicted that no singlefactor across indications contributes to responses to checkpointinhibition but rather the complexity of the tumor immunemicroenvironment dictates the drivers of resistance or response toimmunotherapy. Therefore, analyzing the differences in one or moreimmune cell gene signatures from multiple gene sets likely provides amore complete prognosis for resistance or response to immunotherapy.

Example 10: Gene Set Expression is not Significantly Associated withHepatocellular Carcinoma (HCC) Etiology

Differences in gene set expression between the four etiology groups inHCC were evaluated using Kruskal Wallis tests, and multiplicity of thetests was adjusted using the Bonferroni approach. Table 13 shows medianexpression for each etiology group together with Kruskal-Wallis test pvalues. No immune subset was found to be significantly associated withHCC etiology although T_(eff) subset was numerically higher in the virusdouble positive group (FIGS. 34 and 35). Differences of immune geneexpression were evaluated using Kruskal-Wallis test for each of the 96immune genes shown in Table 14 and no multiplicity correction wasapplied. These data suggest that despite disparate tumor etiologies,liver tumors share similar immune microenvironments.

Hierarchical clustering of immune genes having P≤0:1 for etiologydifferences is shown in FIG. 36. Genes were median centered across thesamples. Euclidean distance and complete linkage were used to generatethe dendrogram. Red and green colors indicate higher and lowerexpression than median, respectively. Black indicates median expression.The following colors differentiate etiologies: black/History ofAlcoholism; red/HBV+; green/HCV+; blue/HBV+HCV+. A high degree ofintraclass heterogeneity was present in HCC, with roughly half of tumorswith high immune genes, but this difference could not be explained byHCC etiologic subtypes.

TABLE 13 Alcohol- HBV+ Bonferroni Signature ism HBV+ HCV+ HCV+ raw pcorrected p Teff −2.22 −1.8 −2.33 −1.36 0.14 1 Treg −1.36 −1.6 −1.64−1.68 0.882 1 Inflam- −0.16 −0.04 −1.46 −0.08 0.245 1 matory NKcell−3.18 −2.23 −2.69 −1.7 0.142 1 Bcell −0.67 0.88 −0.22 0.35 0.151 1Myeloid −2 −1.02 −1.96 −1.53 0.158 1 IL17 −12.4 −14.77 −12.7 −14.61 0.581 Teff/Treg −0.56 −0.1 −0.32 0.41 0.201 1

TABLE 14 ARG1 BTLA CCL2 CCL22 CCL28 CCL5 CCR5 CCR7 CD1C CD244 CD27 CD274CD274_IvG CD276 CD28 CD3E CD4 CD40 CD40LG CD48 CD69 CD70 CD80 CD8A CD8BCLEC4C CSF2 CTLA4 CX3CL1 CXCL10 CXCL9 CXCR3 EOMES EPCAM FCRL5 FOXP3 GUSBGZMA GZMB HAVCR2 HLA_A HLA_B HLA_C HLA_E ICAM1 ICOS IDO1 IFNγ IL10 IL12AIL13 IL17A IL17F IL1B IL2 IL2RA IL4 IL6 IL7 IL7R IL8 ITGAM ITGAX KLRK1LAG3 LGALS9 MAP4K1 MICA MICB MS4A1 NCAM1 PDCD1 PDCD1LG2 PRF1 PTGER2PTGER4 PTGS2 PTPRC PTPRC_2 RORC SDHA SP2 TBX21 TFRC TGFB1 TMEM55B TNFTNFRSF14 TNFRSF4 TNFSF9 VCAM1 VEGFA VPS33B VTCN1 CD86 TNFSF4

1-67. (canceled)
 68. A method of treating a human patient having acancer with an immunotherapy, the method comprising: (i) determining theexpression level of an immune cell gene signature in a tumor sampleobtained from the patient, the immune cell gene signature comprising oneor more of the following gene signature sets: (a) CD8A, GZMA, GZMB,IFNγ, EOMES, and PRF1; (b) FOXP3; (c) MS4A1 and CD48; (d) CD79A, MS4A1,CD19, STAP1, KIAA0125, POU2AF1, and FCRL5; (e) NCAM1 and NKP46; (f)KLRC3, KLRK1, KLRC2, and KLRD1; (g) CD68, CD163, ITGAM, ITGAX, and CD14;(h) LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, CD45RO, SLA,MSR1, FPR3, FCGR2A, and FCGR3A; (i) IL17A and IL17F; (j) CCL2, IL1B,IL8, IL6, and PTGS2; (k) CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, andLCK; (l) CTLA4, BTLA, LAG3, HAVCR2, and PDCD1; (m) CTLA4, BTLA, LAG3,HAVCR2, PDCD1, and TIGIT; (n) CD276, PDL1, PDL2, and IDO1; (o) CD274,PDL2, IDO1, and PVR: (p) CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, and CCL22:(q) CD4, IL2RA, and CD69; (r) TAPBP, TAP1, TAP2, PSMB9, and PSMB8; (s)CD40, CD80, CD86, CD70, and GITRL: (t) CD27, CD28, ICOS, TNFRSF4,TNFRSF14, TNFRSF18, TNFSF14, and CD226; (u) GNLY, KLRK1, KLRB1, GZMH,GZMA, KLRD1, and NKG7; or (v) FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB,COL4A1, COL4A2, COL5A1, and COL8A1, wherein a change in the level ofexpression of each member of the immune cell gene signature relative toa median level identifies a patient for treatment with an immunotherapy;and (ii) administering the immunotherapy to the patient.
 69. The methodof claim 68, wherein the expression level of: (a) CD8A, GZMA, GZMB,IFNγ, EOMES, and PRF1 are correlated with the presence of T effector(T_(eff)) cells in the tumor microenvironment; (b) FOXP3 is correlatedto the presence of T regulatory (T_(reg)) cells in the tumormicroenvironment; (c) MS3A1 and CD48 and/or CD79A, MS4A1, CD19, STAP1,KIAA0125, POU2AF1, and FCRL5 are correlated with the presence of B cellsin the tumor microenvironment; (d) NCAM1 and NKP46 and/or KLRC3, KLRK1,KLRC2, and KLRD1 are correlated with the presence of NK cells in thetumor microenvironment: (e) CD68, CD163, ITGAM, ITGAX, and CD14 arecorrelated with the presence of macrophage cells in the tumormicroenvironment; (f) LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, and FCGR3A are correlated withthe presence of M2 macrophage cells in the tumor microenvironment; (g)IL17A and IL17F are correlated with the presence of Th17 cells in thetumor microenvironment; (h) CCL2, IL1B, IL8, IL6, and PTGS2 arecorrelated with the presence of inflammatory cells in the tumormicroenvironment; (i) CTLA4, BTLA, LAG3, HAVCR2, and PDCD1 and/or CTLA4,BTLA, LAG3, HAVCR2, PDCD1, and TIGIT are correlated with the presence ofT cell immune blockers in the tumor microenvironment: (j) CD276, PDL1,PDL2, and IDO1 and/or CD274, PDL2, IDO1, and PVR are correlated to thepresence of antigen presenting cell (APC) immune blockers in the tumormicroenvironment; (k) CX3CL1, CXCL9, CXCL10, CXCR3, CCL21, and CCL22 arecorrelated to T cell chemotaxis; (l) CD4, IL2RA, and CD69 are correlatedwith the presence of activated CD4 T cells in the tumormicroenvironment; (m) TAPBP, TAP1, TAP2, PSMB9, and PSMB8 is correlatedwith the presence of antigen processing in the tumor microenvironment:(n) CD40, CD80, CD86, CD70, and GITRL is correlated with the presence ofcostimulatory ligands in the tumor microenvironment (o) CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFSF14, and CD226 are correlatedwith the presence of costimulatory receptors in the tumormicroenvironment; (p) GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, and NKG7are correlated with cytolytic activity and/or the presence of cytolyticcells in the tumor microenvironment; (q) FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, and COL8A1 are correlated with thepresence of active fibroblasts in the tumor microenvironment; and/or (r)CD3D, CD3E, CD2, CD3G, CD6, TRAT1, CD28, and LCK are correlated with thepresence of T cells in the tumor microenvironment.
 70. The method ofclaim 68, further comprising determining the ratio of T_(eff) to T_(reg)cells.
 71. The method of claim 70, wherein if the ratio of T_(eff) toT_(reg) is high, the patient will likely benefit from an immunotherapy.72. The method of claim 70, wherein if the ratio of T_(eff) to T_(reg)is low, the patient will likely benefit from an immunotherapy.
 73. Themethod of claim 68, wherein the determining is carried out prior toadministering the immunotherapy in order to provide a patient with apre-administration prognosis for response.
 74. The method of claim 68,wherein the cancer is a breast cancer, melanoma, non-small cell lungcancer (NSCLC), bladder cancer, renal cell carcinoma, colorectal cancer,ovarian cancer, gastric cancer, or liver cancer.
 75. The method of claim74, wherein the cancer is primary, advanced, refractory, or recurrent.76. The method of claim 74, wherein the breast cancer is hormonereceptor+ (HR+), HER2+, or triple negative (TN) breast cancer.
 77. Themethod of claim 74, wherein the NSCLC is non-squamous NSCLC or squamousNSCLC.
 78. The method of claim 68, wherein expression of the immune cellgene signature in the tumor sample obtained from the patient is detectedby measuring mRNA.
 79. The method of claim 68, wherein the immunotherapyenhances tumor immunogenicity.
 80. The method of claim 68, wherein theimmunotherapy comprises treatment with a CD28, OX40, GITR, CD137, CD27,ICOS, HVEM, NKG2D, MICA, or 2B4 agonist or treatment with a CTLA-4, PD-1axis, TIM-3, BTLA, VISTA, LAG-3, B7H4, CD96, TIGIT, or CD226 antagonist.81. The method of claim 80, wherein the immunotherapy comprisestreatment with a PD-1 axis binding antagonist.
 82. The method of claim81, wherein the PD-1 axis binding antagonist is a PD-L1 bindingantagonist, a PD-1 binding antagonist, or a PD-L2 binding antagonist.83. The method of claim 68, wherein the change in the level ofexpression of each member of the immune cell gene signature is anincrease relative to the median level.
 84. The method of claim 68,wherein the change in the level of expression of each member of theimmune cell gene signature is a decrease relative to the median level.85. A method of treating a human patient having a cancer, the methodcomprising administering an immunotherapy to the patient, wherein atumor sample obtained from the patient has been determined to have achange in the level of expression of each member of an immune cell genesignature relative to a median level, the immune cell gene signaturecomprising one or more of the following gene signature sets: (a) CD8A,GZMA, GZMB, IFNγ, EOMES, and PRF1; (b) FOXP3; (c) MS4A1 and CD48; (d)CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, and FCRL5: (e) NCAM1 andNKP46; (f) KLRC3, KLRK1, KLRC2, and KLRD1; (g) CD68, CD163, ITGAM,ITGAX, and CD14; (h) LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68,MRC1, CD45RO, SLA, MSR1, FPR3, FCGR2A, and FCGR3A; (i) IL17A and IL17F;(j) COL2, IL1B, IL8, IL6, and PTGS2; (k) CD3D, CD3E, CD2, CD3G, CD6,TRAT1, CD28, and LCK; (l) CTLA4, BTLA, LAG3, HAVCR2, and PDCD1; (m)CTLA4, BTLA, LAG3, HAVCR2, PDCD1, and TIGIT; (n) CD276, PDL1, PDL2, andIDO1; (o) CD274, PDL2, IDO1, and PVR; (p) CX3CL1, CXCL9, CXCL10, CXCR3,CCL21, and CCL22; (q) CD4, IL2RA, and CD69; (r) TAPBP, TAP1, TAP2,PSMB9, and PSMB8; (s) CD40, CD80, CD86, CD70, and GITRL; (t) CD27, CD28,ICOS, TNFRSF4, TNFRSF14, TNFRSF18, TNFSF14, and CD226; (u) GNLY, KLRK1,KLRB1, GZMH, GZMA, KLRD1, and NKG7; or (v) FAP, FN1, MMP2, BGN, LOXL2,PDPN, PDGFRB, COL4A1, COL4A2, COL5A1, and COL8A1.